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ABSTRACT OF THE DISSERTATION

Comparative Studies of TSLP and IL-7 in Normal Early Human Neonatal and Adult
B Cell Development
by
Terry-Ann Milford
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, June 2016
Dr. Kimberly J. Payne, Chairperson

Defining the role of cytokines in promoting human B cell development is
important for understanding B cell leukemia and for developing strategies to restore B
cell production that is lost during some therapies. The purpose of this study was to
investigate the roles of the IL-7R ligands, thymic stromal lymphopoietin (TSLP) and IL7, in the early stages of normal postnatal and adult human B cell development. Using
novel in vitro and in vivo model systems, we show that TSLP and IL-7 are able to expand
B cell precursors individually and in combination from CB hematopoietic stem cells. In
this model TSLP increases were seen in the CD34+ pro-B subset and maintained through
subsequent stages of development. Adult B lymphopoiesis unlike CB B lymphopoiesis is
IL-7– but may not be TSLP–dependent. We also used the expression of IL-7R, to
identify a lymphoid progenitor that lacks myeloid potential. This information will be
important in developing strategies for restoring B cell development after therapy and
supports our ongoing leukemia studies by providing a rationale for targeting the TSLP
signaling pathway in developing therapies for high-risk B cell acute lymphoblastic
leukemia.

xvi

CHAPTER ONE
INTRODUCTION
Sites of B Lymphopoiesis
The sites of B lymphopoiesis change during ontogeny. During early to midgestation, B cells can be found in the yolk sac, placenta, fetal liver and bone marrow of
the fetus. From mid-gestation onward, the bone marrow becomes the primary organ for
early B cell development (Magnon & Frenette, 2008). In the BM, hematopoietic stem
cells (HSC) interact with stromal cells in specialized microenvironments described as
niches (Tokoyoda, Egawa, Sugiyama, Choi, & Nagasawa, 2004). Here, the stromal cells
secrete growth factors that direct lineage restriction of developing blood cells. They also
express adhesion molecules that maintain cellular contact between the developing cells
and the cytokine-secreting stromal cells (Ryan, Nuccie, Abboud, & Winslow, 1991;
Tokoyoda et al., 2004). Some of the cytokines that regulate the nascent steps in early B
cell differentiation include, Flt-3 ligand, IL-7 and TSLP.

Stages of B Lymphopoiesis
To produce competent, non-self reacting, antibody-producing B cells, HSCs
undergo multiple stages of specification, commitment and differentiation, beginning in
the bone marrow. Mouse models of B cell development have been essential in
understanding the complex network of cytokine-receptor signaling-transcription factor
interactions that direct these processes early on. Flow cytometry and PCR are some of the
techniques used to characterize the discreet stages of B lymphopoiesis – including pro-B,
pre-B, immature B and mature B cells– by the expression of surface antigens and
receptors as shown in Figure 1 (Parrish et al., 2009; Pribyl & LeBien, 1996; Rawlings,
1

Quan, Kato, & Witte, 1995; Scheeren et al., 2010). In mice, surface antigens including
B220, AA4.1, CD43, CD19, CD24, Flt3, IL-7R and IgM are used to identify six stages
(Hardy’s Fractions A-F) of developing B cells (Hardy, Carmack, Shinton, Kemp, &
Hayakawa, 1991; Hardy & Hayakawa, 2001). Analogous populations are present in
humans but some of the surface antigens used to identify them differ (Ichii, Oritani, &
Kanakura, 2014). This review will focus primarily on the surface markers used to identify
these subsets in human B cell development.

Figure 1. A model of human B cell development based on the mouse. For simplicity, B
cell differentiation is viewed as a linear process. As cells differentiate down the B lineage,
they express combinations of surface markers and intracellular proteins that aid their
identification. A summary of selected antigens and enzymes expressed at different stages
of human B lymphopoiesis is shown above. Horizontal triangles indicate decreasing
expression of the antigen and lines indicate sustained expression of the antigen.

2

Mouse HSCs are enriched in the Kit+Lin–Sca-1+ (KLS) fraction of the BM and
account for 0.01% – 0.05% of total nucleated cells found there (Challen, Boles, Lin, &
Goodell, 2009; Okada et al., 1992; Spangrude, Heimfeld, & Weissman, 1988). They
undergo several rounds of restriction to generate progenitors from which erythroid and
myeloid populations differentiate, and a common lymphoid progenitor (CLP), from
which B, T and natural killer (NK) cells arise (Kondo, Weissman, & Akashi, 1997). The
mouse CLP was initially identified as Lin−IL-7R+Thy-1.1− Sca-1loc-Kitlo (Kondo,
Weissman, et al., 1997). This phenotype was later refined to include Flk2+ (Karsunky,
Inlay, Serwold, Bhattacharya, & Weissman, 2008). Unlike the mouse, the human HSC
was identified in the fetal bone marrow by the expression of a single marker, CD34, and
absence of other lineage markers (Baum, Weissman, Tsukamoto, Buckle, & Peault,
1992). While there is some consensus in the field about the phenotype of the mouse CLP,
the phenotype of the human counterpart remains debatable.
The combinations of markers used to identify these lymphoid-restricted
progenitors in humans, vary according to the tissue being evaluated. In fetal and adult
BM, Galy et al. used the phenotype CD34+Lin–CD38+CD10+ to identify lymphoidprimed cells (Galy, Travis, Cen, & Chen, 1995). Other groups identified these cells by
IL-7Rα (Ryan et al., 1997), CXCR4 and TdT expression together with CD34 (Ishii et al.,
1999). Like adult BM, CB cultures of CD34+CD10–CD19–IL-7Rα+ cells generated
lymphoid cells– NK, B and T cells– in addition to macrophages, suggesting that these
cells are permissive depending on the cytokines supplementing the cultures (Reynaud,
Lefort, Manie, Coulombel, & Levy, 2003). An alternative phenotype, CD34+CD38–
CD7+ also describes a putative CLP in CB cultures (Hao et al., 2001). These lymphoid-
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restricted cells also express PU.1 and EBF, transcription factors that direct lymphocyte
development along with TdT and RAG-1, -2, proteins that regulate immunoglobulin
heavy chain rearrangement (Hystad et al., 2007; Reynaud et al., 2003; Rossi et al., 2003).
In Chapter 6, we demonstrate that expression of IL-7R can be used to identify
progenitors from CB that are biased toward lymphoid lineages.
Between the CLP and committed progenitor B cell stages, a few B cell
intermediates have been proposed based on expression of surface markers and B cell
specific intracellular proteins. Hystad et al. defined the phenotype of the earliest B cell
intermediate as CD34+CD38+CD10+CD19– (Hystad et al., 2007). These intermediates
share the surface phenotype of the CLP thus making the two populations
indistinguishable only by surface marker expression (Galy et al., 1995; LeBien, 2000).
Whether these two populations are the same or different at the genetic level remains to be
determined. The development of the immunoglobulin heavy chain begins in the early B
cell with rearrangement of the D-to-J segments (Davi et al., 1997) and expression of
associated genes and proteins including RAG-1,-2, TdT, and the pre-BCR components
CD79a (also known as mb-1) and CD179a (also known as VpreB) (Dworzak, Fritsch,
Froschl, Printz, & Gadner, 1998; Hystad et al., 2007; LeBien, 2000). The early B cell
intermediate also expresses myeloid, T cell and NK cell associated genes (Hystad et al.,
2007). Another intermediate, the pre/pro-B cell with the phenotype, CD34+CD10–CD19+,
is found in the fetal liver, fetal bone marrow and CB (Sanz, Alvarez-Mon, Martinez, & de
la Hera, 2003; Sanz et al., 2010). Sanz et al. showed that the pre/pro-B cell is an alternate
pathway to generate pro-B cells from CB HSCs (Sanz et al., 2010). Whether this alternate
pathway for generating pro-B is active in adult BM remains undetermined.

4

The next stage of B cell development is the pro-B cell, conventionally described
as CD19+CD34+CD10+ cells (Loken, Shah, Dattilio, & Civin, 1987; Rossi et al., 2003).
TdT, RAG-1, and RAG-2 are expressed as V-to-DJ heavy chain rearrangement is
completed (Ghia et al., 1996). Nonproductive VDJ rearrangement in the pro-B cell,
results in death by apoptosis (LeBien, 2000). The pro-B to pre-B cell transition is
marked by cytoplasmic IgM (μHC) expression, cell surface expression of the pre-BCR
and loss of CD34 and TdT (Ghia et al., 1996; LeBien, 2000). The pre-BCR complex is
composed of μHC, CD179a, CD179b (surrogate light chains), and CD79a, CD79b (signal
transduction heterodimers) (LeBien, 2000). Pre-BCR expression is a critical checkpoint
in B cell development. It involves inhibition of further heavy chain rearrangement by
suppressing RAG-1, and RAG-2; initiation of light chain rearrangement with reexpression RAG-1, RAG-2 and increased proliferation of pre-BCR expressing cells
(LeBien, 2000). The pre-B cell progresses to the immature B cell stage after successful
light chain rearrangement, producing IgM on the B cell surface. At this stage, immature
B cells migrate from the bone marrow into the periphery where they undergo further
maturation.

Transcription Factors Involved in Early B Cell Commitment
To successfully generate B cells, transcription factors act in an inter-dependent
regulatory framework to, suppress non-B lineage genes, increase expression of cytokine
receptors and surface markers and regulate immunoglobulin gene rearrangement. Based
on mouse studies, Ikaros, PU.1, E2A, EBF and PAX-5 are major transcription factors
involved in the differentiation of B cells from HSCs (Figure 2). The roles of these
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transcription factors in murine B cell differentiation are largely extrapolated to human. A
proposed interplay between the transcription factors is illustrated in Figure 2.

Ikaros and PU.1
Ikaros and PU.1 are expressed in HSCs and multipotent progenitors (MPP)
(Akashi, Traver, Miyamoto, & Weissman, 2000; Klug et al., 1998). Together, they
repress non-B lineage fate and facilitate expression of lymphocyte-associated genes.
Ikaros is required for the expression of the transcription factors E2A, EBF and PAX5,
necessary for B cell specification and commitment (Bain et al., 1994; Kee & Murre,
1998; Lin & Grosschedl, 1995; Nutt, Urbanek, Rolink, & Busslinger, 1997). In
hematopoietic progenitors including the CLP, Ikaros and PU.1 activate lymphoid specific
genes (Fuxa & Skok, 2007; Hagman & Lukin, 2006) including Flt-3 (Carotta et al., 2010)
and IL-7Rα (DeKoter, Lee, & Singh, 2002). In the absence of Ikaros or PU.1,
hematopoietic progenitors show reduced expression of Flt3 (Nichogiannopoulou,
Trevisan, Neben, Friedrich, & Georgopoulos, 1999) and IL-7R (DeKoter et al., 2002). B
cells are also absent in the fetal liver and bone marrows of these mice (Wang et al.,
1996), possibly due to failure to increase expression of these receptors.

E2A and EBF
The E2A gene produces two spliced variants, E12 and E47. Together they
regulate the expression of IL-7Rα, RAG-1/-2, EBF and pre-BCR components, CD79a,
CD79b, CD179a and CD179b (Beck, Peak, Ota, Nemazee, & Murre, 2009; Kee & Murre,
1998; Ye & Graf, 2007). B cell development is perturbed at the pro-B stage in the
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absence of either E12 or E47 (Bain et al., 1994; Bain et al., 1997). EBF is required for B
cell specification and is regulated by E2A (Smith, Gisler, & Sigvardsson, 2002), PU.1
and IL-7R (Medina et al., 2004). EBF directly activates PAX-5 (O'Riordan &
Grosschedl, 1999); regulates RAG-1 and RAG-2 (Lin & Grosschedl, 1995), the pre-BCR
components CD79a (Sigvardsson et al., 2002), CD79b (B29) (Akerblad, Rosberg,
Leanderson, & Sigvardsson, 1999), CD179a (Sigvardsson, O'Riordan, & Grosschedl,
1997) and CD179b (Gisler & Sigvardsson, 2002). B cell generation is blocked at an early
stage, in the absence of EBF, similar to the E2A absence (Lin & Grosschedl, 1995). Loss
of both EBF and E2A produce a more severe deficiency in B cell development than loss
of the individual transcription factors (O'Riordan & Grosschedl, 1999).

PAX-5
PAX-5 induction is the first step in B cell commitment (Busslinger, 2004) as it
induces the expression B cell specific genes CD19, increases CD79a, CD179a and
CD179b (Ichii et al., 2014; Nutt, Heavey, Rolink, & Busslinger, 1999) and blocks the
expression of the T cell gene, Notch1 (Monroe & Dorshkind, 2007; Souabni, Cobaleda,
Schebesta, & Busslinger, 2002). B cells maintain PAX-5 expression until the mature B
cell stage (Adams et al., 1992). In pro-B cells, inactivation of PAX-5 allows macrophage
and T cell differentiation in vitro and in vivo, respectively (Mikkola, Heavey, Horcher, &
Busslinger, 2002).
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Figure 2. Transcription factors responsible for early B cell differentiation and commitment. Early B cell differentiation generally
occurs in the bone marrow, where HSCs advance along the B lineage under the influence of transcription factors. Within the
multi-lineage committed progenitor (MLP), PU.1 and Ikaros (black) are involved in lymphoid commitment. In the pre-pro-B and
pro-B cells, E2A and EBF (maroon) are expressed. They regulate genes involved in immunoglobulin rearrangement (red triangle)
was well as the transcription factor PAX-5 (blue), which is vital for commitment to the B lineage. PAX5 further facilitates
expression of CD19 as well as additional genes (blue triangle), required for expression of pre-B cell receptor (pre-BCR) at the
pre-B cell stage. Pre-B cells with productive expression of pre-BCR can proliferate, bind antigens a further differentiate into
immature B cells with a mature immunoglobulin on the cell’s surface. At this stage they migrate from the bone marrow into the
periphery where they mature further.

Cytokines in Early B Cell Development
Flt-3 ligand (FL)
Mouse and human FL are cross-reactive, sharing 72% amino acid identity (Lyman
& Jacobsen, 1998). Several isoforms of FL exist. Humans express biologically active FL
as both transmembrane and soluble forms (Lyman & Jacobsen, 1998; Lyman et al.,
1995). Using Northern blot, Lyman et al. found that FL expression was ubiquitous as it
was detected in a variety of cells and tissues including PB leukocytes, spleen, thymus,
liver, heart and skeletal muscle (Lyman et al., 1994). On the other hand, Flt-3 was
primarily detected on hematopoietic stem and progenitor cells (Lyman & Jacobsen, 1998;
Zeigler et al., 1994), thus constraining the activities of its ligand. The roles of FL–Flt-3
signaling in B cell development include upregulation of the IL-7R (Borge, Adolfsson,
Martensson, Martensson, & Jacobsen, 1999), and synergizing with IL-7 to expand and
increase proliferation of primitive hematopoietic progenitors and pro-B cells (Ahsberg et
al., 2010; Namikawa, Muench, & Roncarolo, 1996). In accordance with these functions,
Flt-3 mutant mice exhibited reduced numbers of progenitors (Mackarehtschian et al.,
1995).

Interleukin-7 (IL-7)
IL-7, a 25 kDa protein, originally isolated from the supernatant of the IxN/A6
murine bone marrow stromal cell line was able to stimulate proliferation and on its own
support maintenance of B lymphoid progenitors in vitro (Namen, Lupton, et al., 1988;
Namen, Schmierer, et al., 1988). Human IL-7 was cloned shortly afterward and it
stimulated proliferation of both mouse and human B lineage progenitors (Goodwin et al.,
1989). Mouse IL-7 and human IL-7 share 81% homology in the coding region of the
9

nucleotide (Goodwin et al., 1989; Lupton et al., 1990) and 60% at the protein level
(Goodwin et al., 1989). Stromal cells of the bone marrow and thymus are the primary
producers of IL-7 (Hara et al., 2012). Other cells that produce IL-7 include keratinocytes,
intestinal epithelial cells, fetal and follicular DCs (Fry & Mackall, 2002). On the cells’
surface, IL-7 binds to a heterodimeric receptor complex of IL-7Ralso called CD127)
and IL-2RG chains (also known as common gamma chain, C, CD132) (Noguchi et al.,
1993). The IL-7R chain is shared only by one other cytokine receptor – discussed in the
following section–unlike IL-2RG that is shared by other cytokine receptors, including IL2, IL-4, IL-9 and IL-15. Alternative splicing of the human IL-7R gene, produces a
secreted form that binds IL-7 (Goodwin et al., 1990) but not TSLP (Lundstrom et al.,
2013). In vitro, soluble IL-7R (sIL-7R) inhibited the effects of IL-7 (Crawley,
Faucher, & Angel, 2010), while in vivo, sIL-7R enhanced IL-7’s activity (Lundstrom et
al., 2013). Increased soluble IL-7R concentrations have been associated autoimmune
conditions such as multiple sclerosis (MS) (Gregory et al., 2007; Lundstrom et al., 2013)
and systemic lupus erythematosous (SLE) (Badot et al., 2013).
While mouse and human IL-7 are homologous, their biological functions related
to B cells are thought to differ. IL-7 stimulation increased the growth and proliferation of
murine pro-B and pre-B cells but not mature B cells in vitro (G. Lee, Namen, Gillis,
Ellingsworth, & Kincade, 1989; Namen, Lupton, et al., 1988). These in vitro findings,
correlated with the phenotype of adult IL-7–/– mice that exhibited a block at the pro-B to
pre-B cell progression and resulted in reduced numbers of mature B cells in the periphery
and spleen (von Freeden-Jeffry et al., 1995). Carvalho et al., later showed that in the
absence of IL-7, fetal and perinatal B lymphopoiesis were normal while adult B
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lymphopoiesis was perturbed (Carvalho, Mota-Santos, Cumano, Demengeot, & Vieira,
2001), thus demonstrating that IL-7 independent B cell development occurs in the early
stages of life (Carvalho et al., 2001). }. Like IL-7–/– mice, in vivo B lymphopoiesis is also
perturbed at the pro-B cell stage onward by blocking IL-7 with a neutralizing anti-IL-7
monoclonal antibody (Grabstein et al., 1993). Mice deficient for IL-7Rα, exhibited a
block at the pre-pro B to pro-B transition, earlier than IL-7–/– mice (Peschon et al., 1994).
Kikuchi et al. demonstrated that the arrest at the pre-pro-B cell stage in adult IL-7 and IL7R deficient mice was because EBF and its target genes were not expressed (Kikuchi,
Lai, Hsu, & Kondo, 2005). While IL-7 deficiency results in loss of the earliest B cell
precursors, overexpression or administration of recombinant IL-7 in vivo, expanded early
B cell subsets and produced a lymphoproliferative disorder in cells bearing the immature
B cell phenotype (Akdis et al., 2011; Fry & Mackall, 2002).
Aside from IL-7’s role in B cell differentiation and proliferation, it also regulates
the survival of early progenitors via the Bcl-2 family of proteins. This function is
achieved by simultaneously activating the pro-survival members Bcl-2, Bcl-xL and Mcl1 (Clark, Mandal, Ochiai, & Singh, 2014; Lu, Chaudhury, & Osmond, 1999; Opferman et
al., 2003) while repressing the pro-death factors Bax and Bad (Clark et al., 2014; Lu et
al., 1999). The precise role of IL-7 in the survival of the earliest B cell progenitors
remains debatable, as others show that IL-7 does not regulate Bcl-2, Bcl-xL and Mcl-1 in
mouse pre-pro B cells (Kikuchi et al., 2005; Kondo, Akashi, Domen, Sugamura, &
Weissman, 1997).
While critical for murine B cell development, IL-7 is thought to be nonessential
for human B cell development. Patients with IL-7R defects displayed a T–B+NK+ SCID
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phenotype with normal to increased numbers of functionally deficient B cells (Giliani et
al., 2005; Puel, Ziegler, Buckley, & Leonard, 1998; Roifman, Zhang, Chitayat, & Sharfe,
2000). SCID is characterized by deficiencies in T or B cell and can extend to NK cells.
Symptoms including pneumonia, meningitis and recurring infections usually occur within
the first few months of life. Patients with mutations in IL-2RG and its associated kinase,
Janus Kinase 3 (JAK3), also presented with T–B+NK+ SCID and had normal to elevated
B cell numbers (Fry & Mackall, 2002).
Despite the absence of defects in human B cell numbers due to IL-7R mutations,
there is a growing body of evidence that supports a role for IL-7 in human B
lymphopoiesis. In vitro cultures of human fetal and adult BM derived B cell progenitors
demonstrate that they proliferate in response to recombinant IL-7 (Dittel & LeBien, 1995;
Goodwin et al., 1989; Namikawa, Muench, de Vries, & Roncarolo, 1996). IL-7R was
expressed at similar levels in pro-B and pre-B cells (Dittel & LeBien, 1995). Clinical
trials using recombinant hIL-7 (rhIL-7) to treat malignancy, demonstrated increased
expansion of pre-B cells in the BM and PB of patients in the study (Sportes et al., 2010).
Similar to the clinical trial results, patients with above-normal IL-7 levels, as seen in
advancing HIV, showed an increased frequency of immature B cell in the periphery
(Malaspina et al., 2006). While fetal B cells differentiated in response to IL-7, Pribyl et
al. showed that fetal BM CD34+ HSCs were also capable of IL-7 independent B cell
differentiation (Pribyl & LeBien, 1996). In addition to the effects on B cell proliferation
and differentiation, another recently identified function of IL-7 in human B cell
development is suppression of premature kappa light chain rearrangement in human B
cell precursors, (Nodland et al., 2011). The possibility that like the mouse, human B cell
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development is IL-7 independent in the perinatal/neonatal period and IL-7 dependency
increases with age will be explored in Chapter 2.

Thymic Stromal Lymphopoietin (TSLP)
TSLP, an IL-7 homologue, was originally identified in the supernatant of the
murine thymic stromal line, Z210R.1 (Friend et al., 1994). The mature mouse TSLP
protein is 121 amino acid (Sims et al., 2000), while the human counterpart is 131 amino
acids (Quentmeier et al., 2001). Both share 43% amino acid identity (Quentmeier et al.,
2001). Mouse TSLP mRNA was detected in the spleen, thymus, bone marrow and kidney
(Sims et al., 2000) while human TSLP has a broader range of expression being found in
the heart, liver, testis, prostate, lung, skeletal muscle, kidney, spleen and colon
(Quentmeier et al., 2001). Human TSLP is produced by a variety of cells including
keratinocytes (Soumelis et al., 2002), epithelial cells, endothelial cells, neutrophils,
macrophages, mast cells (Ying et al., 2005) dendritic cells and fibroblasts (Kashyap,
Rochman, Spolski, Samsel, & Leonard, 2011). Recent data identified TSLP as a key
mediator in allergic and inflammatory conditions, including arthritis, asthma and atopic
dermatitis (Bleck, Tse, Curotto de Lafaille, Zhang, & Reibman, 2008; Bleck, Tse,
Gordon, Ahsan, & Reibman, 2010; Koyama et al., 2007; E. B. Lee et al., 2010; Ying et
al., 2008). TSLP mediates its effects by binding a heterodimeric receptor complex of the
IL-7R and CRLF2 (cytokine receptor like factor-2, also known as TSLPR) chains
(Pandey et al., 2000; Park et al., 2000). Like its cognate cytokine, mouse and human
CRLF2 share low homology, ~35 % (Tonozuka et al., 2001). The low homology of
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mouse and human TSLP and CRLF2, suggests that the functions between the species
may be different
Initial in vitro experiments showed that TSLP induced proliferation and
differentiation of murine B cell precursors to the IgM+ stage in fetal liver and long-term
bone marrow culture (Friend et al., 1994; Ray, Furlonger, Williams, & Paige, 1996),
unlike IL-7, which induced differentiation to the earlier IgM– stage (Levin et al., 1999).
While the function of TSLP in in vitro B cell differentiation appears consistent, the in
vivo data is less so. Vosshenrich et al., supported the in vitro data with in vivo studies
showing that pro-B cells from fetal liver and pre-B cells from both fetal liver and adult
BM responded to TSLP (Vosshenrich, Cumano, Muller, Di Santo, & Vieira, 2003). B cell
precursors from adult BM required pre-BCR expression to respond to TSLP
(Vosshenrich, Cumano, Muller, Di Santo, & Vieira, 2004). Together these data suggest
that TSLP may have both ontogeny and tissue specific activities.
The effects of TSLP in B lymphopoiesis have been evaluated in several transgenic
models. In the absence of IL-7, TSLP stimulation increased fetal-derived B cell
precursors (Vosshenrich et al., 2003) and restored adult B and T lymphopoiesis in
primary and secondary organs (Chappaz, Flueck, Farr, Rolink, & Finke, 2007). In another
model, B cells were reduced in the bone marrow but normal numbers were found in the
spleen (Osborn et al., 2004). The results of TSLP overexpression were not only localized
to the BM but also systemic. Mice displayed increased immature B cell numbers in the
periphery (Astrakhan et al., 2007); developed a lethal systemic B lymphoproliferative
disorder upon B cell restoration (Demehri et al., 2008); developed a systemic
inflammatory condition (Taneda et al., 2001); exhibited cryoglobulinemia and immune
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complex disease (Taneda et al., 2001; Tsai et al., 2010) in alternative TSLP transgenic
models. Increased myelopoiesis often accompanied TSLP overexpression (Osborn et al.,
2004; Tsai et al., 2010).
The absence of the TSLP receptor (TSLPR) chain does not appear to impact
mouse B cell development. TSLPR–/– mice, exhibited no apparent loss of B or T cells
resulting from the absence of the TSLP receptor-signaling pathway (Carpino et al., 2004).
In a different TSLPR–/– mouse model, Jensen et al. showed that FL not TSLP was
responsible for IL-7 independent B lymphopoiesis (Jensen et al., 2008).
To date, the effects of TSLP on normal human B lymphopoiesis have been limited
to fetal tissues. Based on the in vitro findings that TSLP promoted B cell development
from murine fetal sources (Levin et al., 1999; Vosshenrich et al., 2003, 2004), Scheeren
et al. investigated the role of TSLP in human fetal B cell precursors. They found
increased B cell differentiation from fetal-liver derived CD34+ HSCs and increased
proliferation of pro-B and pre-B cells from the fetal liver in response to TSLP (Scheeren
et al., 2010). Fetal BM pro-B cells also were also TSLP-responsive while pre-B cells
were not (Scheeren et al., 2010).
TSLP-induced signals have been implicated in malignant B cell development.
Firstly, Brown et al. demonstrated that primary pre-B ALL cells increased proliferation
and viability in vitro when cultured with TSLP (Brown et al., 2007). Secondly,
overexpression of CRLF2 on the B cell surface was recently associated with a high-risk
form of pre-B acute lymphoblastic leukemia (pre-B ALL) (Cario et al., 2010; Mullighan
et al., 2009; Russell et al., 2009).
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It remains unknown if the effects of TSLP in human B cell development are
restricted to fetal tissues. We will explore a role for TSLP in conjunction with IL-7 in the
development of B cell precursors from postnatal and adult HSC in Chapters 3, 4 and 5.

IL-7 and TSLP Signaling in Mice and Humans
As demonstrated in Figure 3, the binding of IL-7 to the IL-7 receptor induces
dimerization of the receptor chains and cross-phosphorylation of the associated JAKs–.
JAK1 with IL-7R and JAK3 with the common gamma chain. This interaction results in
the phosphorylation, dimerization and translocation of signal transducer and activator of
transcription 5a/5b (STAT5a/b) to the nucleus (Isaksen et al., 1999; Johnson, Shah,
Panoskaltsis-Mortari, & LeBien, 2005). Activation of this pathway is common to B
lymphopoiesis in mice and humans (Johnson et al., 2005). IL-7 also activates the
phosphoinositol-3-kinase (PI3K)/AKT pathway in human thymocytes but not in B cell
precursors (Johnson, Shah, Bajer, & LeBien, 2008)
Like IL-7, TSLP ligation induces phosphorylation of STAT5 (Isaksen et al.,
1999), but early studies suggested that activation of STAT5 was independent of the
known JAKs (Isaksen et al., 1999; Ray et al., 1996). Rochman et al. later refined these
findings, demonstrating that JAK2 associated with CRLF2 and was cross-phosphorylated
by IL-7R-associated-JAK1 upon TSLP stimulation (Rochman et al., 2010). Unlike IL-7,
TSLP signaling also activates the PI3K/AKT pathway in B cell precursors (Brown et al.,
2007; Johnson et al., 2008; Tasian et al., 2012).
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Figure 3. TSLP and IL-7 signaling pathways activated in human B cells. The binding
of IL-7 to its receptor complex of α and IL2RG, and TSLP to its receptor of IL-7Ra and
CRLF2, facilitates the cross-phosphorylation of the JAKs-associated with the respective
chains. Phosphorylated-JAK1 in turn phosphorylates STAT5A/B, which dimerizes and
translocates to the nucleus. TSLP also activates the PI3K/AKT/mTOR and together
with STAT5 they regulate the processes of proliferation, survival and differentiation in
B cells.
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Models of B Cell Development
Several in vitro culture models have been used to explore the stages human of B
lymphopoiesis and the cytokines that influence these stages. Both stromal cell-dependent
and stromal-cell independent models have been developed to mimic the BM
microenvironment by providing intercellular contact and/or proper cytokine stimulation
for B cell development. The stromal cell-dependent models consist of culturing
hematopoietic progenitors on mouse or human stromal cell lines, for example, MS-5
(Berardi et al., 1997; Johnson et al., 2005), S17 (Cumano, Dorshkind, Gillis, & Paige,
1990; Dorshkind, Johnson, Harrison, & Landreth, 1989; Rawlings et al., 1995) and OP9
(Scheeren et al., 2010; Vodyanik, Bork, Thomson, & Slukvin, 2005). These cell lines
secrete cytokines and in vitro cultures may also be supplemented with recombinant
cytokines to induce early B cell differentiation. Another method of generating a stromal
cell-dependent culture model includes the use of primary bone marrow stromal cells
isolated from human bone marrow (Parrish et al., 2009; Pribyl & LeBien, 1996). Unlike
their cell line counterparts, these primary stromal cells do not produce high
concentrations of cytokines (Parrish et al., 2009). This is advantageous because it allows
the investigator to titrate varying concentrations of exogenous cytokine and evaluate their
effects on developing B cells without the need for elimination of confounding
endogenous cytokines.
As B cells develop, their cytokine requirements change. The high concentration of
cytokines, like IL-7, that are produced by stromal cell lines and are important for early B
cell development may hamper the maturation of the early B cell progenitors and
precursors (Ray et al., 1998). The stromal-cell independent model is an attractive
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prospect to address this concern because in lieu of stromal cells, the investigator
administers combinations of recombinant cytokines at different intervals during B cell
culture (Ichii et al., 2010; Kraus et al., 2014; Yoshikawa et al., 2000). This way the
effects of the cytokines can be evaluated without intervening stromal cells and the
uncharacterized proteins that they may secrete. Together, data from both stromal-cell
independent and dependent cultures have assisted in characterizing the discreet stages of
B cell development.
In vivo mouse models used to study human B cell development, take advantage of
the severe combined immune-deficient (SCID) mutation that does not affect myeloid
cells but renders intrinsic B and T cells functionally deficient (Bosma & Carroll, 1991).
The deficiency is due to a defect in the activity of the DNA repair enzyme, protein kinase
DNA activated catalytic polypeptide, Prkdc, resulting in incomplete VDJ recombination.
The antibody- and cellular-mediated immune systems are affected because B and T cell
do not mature, thus allowing the engraftment of human cells and tissues and the
reconstitution of human hematopoietic cell lineages. Variations of SCID mice have been
developed that demonstrate higher engraftment of human cells including the non-obese
diabetic (NOD)- SCID mice, in which the IL2RG is deleted (NSG mice) or truncated
(NOG mice) (M. Ito et al., 2002; Shultz et al., 2005). Although there are other strains of
immune deficient mice that permit the efficient engraftment of human cells (R. Ito,
Takahashi, Katano, & Ito, 2012), NSG mice rank highest and were thus selected for in
vivo experiments presented in Chapters 3 and 4.

19

References
Adams, B., Dorfler, P., Aguzzi, A., Kozmik, Z., Urbanek, P., Maurer-Fogy, I., &
Busslinger, M. (1992). Pax-5 encodes the transcription factor BSAP and is
expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev,
6(9), 1589-1607.
Ahsberg, J., Tsapogas, P., Qian, H., Zetterblad, J., Zandi, S., Mansson, R., . . .
Sigvardsson, M. (2010). Interleukin-7-induced Stat-5 acts in synergy with Flt-3
signaling to stimulate expansion of hematopoietic progenitor cells. J Biol Chem,
285(47), 36275-36284. doi: 10.1074/jbc.M110.155531
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000). A clonogenic common
myeloid progenitor that gives rise to all myeloid lineages. Nature, 404(6774),
193-197. doi: 10.1038/35004599
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., . . . Akdis, C. A.
(2011). Interleukins, from 1 to 37, and interferon-gamma: receptors, functions,
and roles in diseases. J Allergy Clin Immunol, 127(3), 701-721 e701-770. doi:
10.1016/j.jaci.2010.11.050
Akerblad, P., Rosberg, M., Leanderson, T., & Sigvardsson, M. (1999). The B29
(immunoglobulin beta-chain) gene is a genetic target for early B-cell factor. Mol
Cell Biol, 19(1), 392-401.
Astrakhan, A., Omori, M., Nguyen, T., Becker-Herman, S., Iseki, M., Aye, T., . . .
Rawlings, D. J. (2007). Local increase in thymic stromal lymphopoietin induces
systemic alterations in B cell development. Nat Immunol, 8(5), 522-531. doi:
ni1452 [pii]10.1038/ni1452
Badot, V., Luijten, R. K., van Roon, J. A., Depresseux, G., Aydin, S., Van den Eynde, B.
J., . . . Lauwerys, B. R. (2013). Serum soluble interleukin 7 receptor is strongly
associated with lupus nephritis in patients with systemic lupus erythematosus.
Ann Rheum Dis, 72(3), 453-456. doi: 10.1136/annrheumdis-2012-202364
Bain, G., Maandag, E. C., Izon, D. J., Amsen, D., Kruisbeek, A. M., Weintraub, B.
C., . . . et al. (1994). E2A proteins are required for proper B cell development and
initiation of immunoglobulin gene rearrangements. Cell, 79(5), 885-892.
Bain, G., Robanus Maandag, E. C., te Riele, H. P., Feeney, A. J., Sheehy, A., Schlissel,
M., . . . Murre, C. (1997). Both E12 and E47 allow commitment to the B cell
lineage. Immunity, 6(2), 145-154.
Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A. M., & Peault, B. (1992).
Isolation of a candidate human hematopoietic stem-cell population. Proc Natl
Acad Sci U S A, 89(7), 2804-2808.

20

Beck, K., Peak, M. M., Ota, T., Nemazee, D., & Murre, C. (2009). Distinct roles for E12
and E47 in B cell specification and the sequential rearrangement of
immunoglobulin light chain loci. J Exp Med, 206(10), 2271-2284. doi:
10.1084/jem.20090756
Berardi, A. C., Meffre, E., Pflumio, F., Katz, A., Vainchenker, W., Schiff, C., &
Coulombel, L. (1997). Individual CD34+CD38lowCD19-CD10- progenitor cells
from human cord blood generate B lymphocytes and granulocytes. Blood, 89(10),
3554-3564.
Bleck, B., Tse, D. B., Curotto de Lafaille, M. A., Zhang, F., & Reibman, J. (2008). Diesel
exhaust particle-exposed human bronchial epithelial cells induce dendritic cell
maturation and polarization via thymic stromal lymphopoietin. J Clin Immunol,
28(2), 147-156. doi: 10.1007/s10875-007-9149-0
Bleck, B., Tse, D. B., Gordon, T., Ahsan, M. R., & Reibman, J. (2010). Diesel exhaust
particle-treated human bronchial epithelial cells upregulate Jagged-1 and OX40
ligand in myeloid dendritic cells via thymic stromal lymphopoietin. J Immunol,
185(11), 6636-6645. doi: jimmunol.1000719 [pii]10.4049/jimmunol.1000719
Borge, O. J., Adolfsson, J., Martensson, A., Martensson, I. L., & Jacobsen, S. E. (1999).
Lymphoid-restricted development from multipotent candidate murine stem cells:
distinct and complimentary functions of the c-kit and flt3-ligands. Blood, 94(11),
3781-3790.
Bosma, M. J., & Carroll, A. M. (1991). The SCID mouse mutant: definition,
characterization, and potential uses. Annu Rev Immunol, 9, 323-350. doi:
10.1146/annurev.iy.09.040191.001543
Brown, V. I., Hulitt, J., Fish, J., Sheen, C., Bruno, M., Xu, Q., . . . Grupp, S. A. (2007).
Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia
and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha
signaling. Cancer Res, 67(20), 9963-9970. doi: 67/20/9963 [pii]10.1158/00085472.CAN-06-4704
Busslinger, M. (2004). Transcriptional control of early B cell development. Annu Rev
Immunol, 22, 55-79. doi: 10.1146/annurev.immunol.22.012703.104807
Cario, G., Zimmermann, M., Romey, R., Gesk, S., Vater, I., Harbott, J., . . . Stanulla, M.
(2010). Presence of the P2RY8-CRLF2 rearrangement is associated with a poor
prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in
children treated according to the ALL-BFM 2000 protocol. Blood, 115(26), 53935397. doi: Doi 10.1182/Blood-2009-11-256131
Carotta, S., Dakic, A., D'Amico, A., Pang, S. H., Greig, K. T., Nutt, S. L., & Wu, L.
(2010). The transcription factor PU.1 controls dendritic cell development and Flt3

21

cytokine receptor expression in a dose-dependent manner. Immunity, 32(5), 628641. doi: S1074-7613(10)00171-8 [pii]10.1016/j.immuni.2010.05.005
Carpino, N., Thierfelder, W. E., Chang, M. S., Saris, C., Turner, S. J., Ziegler, S. F., &
Ihle, J. N. (2004). Absence of an essential role for thymic stromal lymphopoietin
receptor in murine B-cell development. Mol Cell Biol, 24(6), 2584-2592.
Carvalho, T. L., Mota-Santos, T., Cumano, A., Demengeot, J., & Vieira, P. (2001).
Arrested B lymphopoiesis and persistence of activated B cells in adult interleukin
7(-/)- mice. J Exp Med, 194(8), 1141-1150.
Challen, G. A., Boles, N., Lin, K. K., & Goodell, M. A. (2009). Mouse hematopoietic
stem cell identification and analysis. Cytometry A, 75(1), 14-24. doi:
10.1002/cyto.a.20674
Chappaz, S., Flueck, L., Farr, A. G., Rolink, A. G., & Finke, D. (2007). Increased TSLP
availability restores T- and B-cell compartments in adult IL-7 deficient mice.
Blood, 110(12), 3862-3870. doi: blood-2007-02-074245 [pii]10.1182/blood-200702-074245
Clark, M. R., Mandal, M., Ochiai, K., & Singh, H. (2014). Orchestrating B cell
lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor
signalling. Nat Rev Immunol, 14(2), 69-80. doi: 10.1038/nri3570
Crawley, A. M., Faucher, S., & Angel, J. B. (2010). Soluble IL-7R alpha (sCD127)
inhibits IL-7 activity and is increased in HIV infection. J Immunol, 184(9), 46794687. doi: 10.4049/jimmunol.0903758
Cumano, A., Dorshkind, K., Gillis, S., & Paige, C. J. (1990). The influence of S17
stromal cells and interleukin 7 on B cell development. Eur J Immunol, 20(10),
2183-2189.
Davi, F., Faili, A., Gritti, C., Blanc, C., Laurent, C., Sutton, L., . . . Merle-Beral, H.
(1997). Early onset of immunoglobulin heavy chain gene rearrangements in
normal human bone marrow CD34+ cells. Blood, 90(10), 4014-4021.
DeKoter, R. P., Lee, H. J., & Singh, H. (2002). PU.1 regulates expression of the
interleukin-7 receptor in lymphoid progenitors. Immunity, 16(2), 297-309.
Demehri, S., Liu, Z., Lee, J., Lin, M. H., Crosby, S. D., Roberts, C. J., . . . Kopan, R.
(2008). Notch-deficient skin induces a lethal systemic B-lymphoproliferative
disorder by secreting TSLP, a sentinel for epidermal integrity. PLoS Biol, 6(5),
e123. doi: 07-PLBI-RA-3899 [pii]10.1371/journal.pbio.0060123
Dittel, B. N., & LeBien, T. W. (1995). The growth response to IL-7 during normal human
B cell ontogeny is restricted to B-lineage cells expressing CD34. J Immunol,
154(1), 58-67.

22

Dorshkind, K., Johnson, A., Harrison, Y., & Landreth, K. S. (1989). A colony assay
system that detects B cell progenitors in fresh and cultured bone marrow. J
Immunol Methods, 123(1), 93-101.
Dworzak, M. N., Fritsch, G., Froschl, G., Printz, D., & Gadner, H. (1998). Four-color
flow cytometric investigation of terminal deoxynucleotidyl transferase-positive
lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19
in early B-cell ontogeny. Blood, 92(9), 3203-3209.
Friend, S. L., Hosier, S., Nelson, A., Foxworthe, D., Williams, D. E., & Farr, A. (1994).
A thymic stromal cell line supports in vitro development of surface IgM+ B cells
and produces a novel growth factor affecting B and T lineage cells. Exp Hematol,
22(3), 321-328.
Fry, T. J., & Mackall, C. L. (2002). Interleukin-7: from bench to clinic. Blood, 99(11),
3892-3904.
Fuxa, M., & Skok, J. A. (2007). Transcriptional regulation in early B cell development.
Curr Opin Immunol, 19(2), 129-136. doi: S0952-7915(07)00010-6
[pii]10.1016/j.coi.2007.02.002
Galy, A., Travis, M., Cen, D., & Chen, B. (1995). Human T, B, natural killer, and
dendritic cells arise from a common bone marrow progenitor cell subset.
Immunity, 3(4), 459-473.
Ghia, P., ten Boekel, E., Sanz, E., de la Hera, A., Rolink, A., & Melchers, F. (1996).
Ordering of human bone marrow B lymphocyte precursors by single-cell
polymerase chain reaction analyses of the rearrangement status of the
immunoglobulin H and L chain gene loci. J Exp Med, 184(6), 2217-2229.
Giliani, S., Mori, L., de Saint Basile, G., Le Deist, F., Rodriguez-Perez, C., Forino,
C., . . . Notarangelo, L. D. (2005). Interleukin-7 receptor alpha (IL-7Ralpha)
deficiency: cellular and molecular bases. Analysis of clinical, immunological, and
molecular features in 16 novel patients. Immunol Rev, 203, 110-126.
Gisler, R., & Sigvardsson, M. (2002). The human V-preB promoter is a target for
coordinated activation by early B cell factor and E47. J Immunol, 168(10), 51305138.
Goodwin, R. G., Friend, D., Ziegler, S. F., Jerzy, R., Falk, B. A., Gimpel, S., . . . et al.
(1990). Cloning of the human and murine interleukin-7 receptors: demonstration
of a soluble form and homology to a new receptor superfamily. Cell, 60(6), 941951.
Goodwin, R. G., Lupton, S., Schmierer, A., Hjerrild, K. J., Jerzy, R., Clevenger, W., . . .
Namen, A. E. (1989). Human interleukin 7: molecular cloning and growth factor

23

activity on human and murine B-lineage cells. Proc Natl Acad Sci U S A, 86(1),
302-306.
Grabstein, K. H., Waldschmidt, T. J., Finkelman, F. D., Hess, B. W., Alpert, A. R.,
Boiani, N. E., . . . Morrissey, P. J. (1993). Inhibition of murine B and T
lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J Exp Med,
178(1), 257-264.
Gregory, S. G., Schmidt, S., Seth, P., Oksenberg, J. R., Hart, J., Prokop, A., . . . Multiple
Sclerosis Genetics, G. (2007). Interleukin 7 receptor alpha chain (IL7R) shows
allelic and functional association with multiple sclerosis. Nat Genet, 39(9), 10831091. doi: 10.1038/ng2103
Hagman, J., & Lukin, K. (2006). Transcription factors drive B cell development. Curr
Opin Immunol, 18(2), 127-134. doi: S0952-7915(06)00009-4
[pii]10.1016/j.coi.2006.01.007
Hao, Q. L., Zhu, J., Price, M. A., Payne, K. J., Barsky, L. W., & Crooks, G. M. (2001).
Identification of a novel, human multilymphoid progenitor in cord blood. Blood,
97(12), 3683-3690.
Hara, T., Shitara, S., Imai, K., Miyachi, H., Kitano, S., Yao, H., . . . Ikuta, K. (2012).
Identification of IL-7-producing cells in primary and secondary lymphoid organs
using IL-7-GFP knock-in mice. J Immunol, 189(4), 1577-1584. doi:
10.4049/jimmunol.1200586
Hardy, R. R., Carmack, C. E., Shinton, S. A., Kemp, J. D., & Hayakawa, K. (1991).
Resolution and characterization of pro-B and pre-pro-B cell stages in normal
mouse bone marrow. J Exp Med, 173(5), 1213-1225.
Hardy, R. R., & Hayakawa, K. (2001). B cell development pathways. Annu Rev Immunol,
19, 595-621.
Hystad, M. E., Myklebust, J. H., Bo, T. H., Sivertsen, E. A., Rian, E., Forfang, L., . . .
Smeland, E. B. (2007). Characterization of early stages of human B cell
development by gene expression profiling. J Immunol, 179(6), 3662-3671. doi:
179/6/3662 [pii]
Ichii, M., Oritani, K., & Kanakura, Y. (2014). Early B lymphocyte development:
Similarities and differences in human and mouse. World J Stem Cells, 6(4), 421431. doi: 10.4252/wjsc.v6.i4.421
Ichii, M., Oritani, K., Yokota, T., Schultz, D. C., Holter, J. L., Kanakura, Y., & Kincade,
P. W. (2010). Stromal cell-free conditions favorable for human B lymphopoiesis
in culture. J Immunol Methods, 359(1-2), 47-55. doi: S0022-1759(10)00167-5
[pii]10.1016/j.jim.2010.06.002

24

Isaksen, D. E., Baumann, H., Trobridge, P. A., Farr, A. G., Levin, S. D., & Ziegler, S. F.
(1999). Requirement for stat5 in thymic stromal lymphopoietin-mediated signal
transduction. J Immunol, 163(11), 5971-5977. doi: ji_v163n11p5971 [pii]
Ishii, T., Nishihara, M., Ma, F., Ebihara, Y., Tsuji, K., Asano, S., . . . Maekawa, T.
(1999). Expression of stromal cell-derived factor-1/pre-B cell growth-stimulating
factor receptor, CXC chemokine receptor 4, on CD34+ human bone marrow cells
is a phenotypic alteration for committed lymphoid progenitors. J Immunol,
163(7), 3612-3620. doi: ji_v163n7p3612 [pii]
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., . . . Nakahata,
T. (2002). NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse
model for engraftment of human cells. Blood, 100(9), 3175-3182. doi:
10.1182/blood-2001-12-0207
Ito, R., Takahashi, T., Katano, I., & Ito, M. (2012). Current advances in humanized
mouse models. Cell Mol Immunol, 9(3), 208-214. doi: 10.1038/cmi.2012.2
Jensen, C. T., Kharazi, S., Boiers, C., Cheng, M., Lubking, A., Sitnicka, E., & Jacobsen,
S. E. (2008). FLT3 ligand and not TSLP is the key regulator of IL-7-independent
B-1 and B-2 B lymphopoiesis. Blood, 112(6), 2297-2304. doi: blood-2008-04150508 [pii]10.1182/blood-2008-04-150508
Johnson, S. E., Shah, N., Bajer, A. A., & LeBien, T. W. (2008). IL-7 activates the
phosphatidylinositol 3-kinase/AKT pathway in normal human thymocytes but not
normal human B cell precursors. J Immunol, 180(12), 8109-8117. doi:
180/12/8109 [pii]
Johnson, S. E., Shah, N., Panoskaltsis-Mortari, A., & LeBien, T. W. (2005). Murine and
human IL-7 activate STAT5 and induce proliferation of normal human pro-B
cells. J Immunol, 175(11), 7325-7331.
Karsunky, H., Inlay, M. A., Serwold, T., Bhattacharya, D., & Weissman, I. L. (2008).
Flk2+ common lymphoid progenitors possess equivalent differentiation potential
for the B and T lineages. Blood, 111(12), 5562-5570. doi: 10.1182/blood-200711-126219
Kashyap, M., Rochman, Y., Spolski, R., Samsel, L., & Leonard, W. J. (2011). Thymic
stromal lymphopoietin is produced by dendritic cells. J Immunol, 187(3), 12071211. doi: jimmunol.1100355 [pii]10.4049/jimmunol.1100355
Kee, B. L., & Murre, C. (1998). Induction of early B cell factor (EBF) and multiple B
lineage genes by the basic helix-loop-helix transcription factor E12. J Exp Med,
188(4), 699-713.

25

Kikuchi, K., Lai, A. Y., Hsu, C. L., & Kondo, M. (2005). IL-7 receptor signaling is
necessary for stage transition in adult B cell development through up-regulation
of EBF. J Exp Med, 201(8), 1197-1203.
Klug, C. A., Morrison, S. J., Masek, M., Hahm, K., Smale, S. T., & Weissman, I. L.
(1998). Hematopoietic stem cells and lymphoid progenitors express different
Ikaros isoforms, and Ikaros is localized to heterochromatin in immature
lymphocytes. Proc Natl Acad Sci U S A, 95(2), 657-662.
Kondo, M., Akashi, K., Domen, J., Sugamura, K., & Weissman, I. L. (1997). Bcl-2
rescues T lymphopoiesis, but not B or NK cell development, in common gamma
chain-deficient mice. Immunity, 7(1), 155-162.
Kondo, M., Weissman, I. L., & Akashi, K. (1997). Identification of clonogenic common
lymphoid progenitors in mouse bone marrow. Cell, 91(5), 661-672.
Koyama, K., Ozawa, T., Hatsushika, K., Ando, T., Takano, S., Wako, M., . . . Nakao, A.
(2007). A possible role for TSLP in inflammatory arthritis. Biochem Biophys Res
Commun, 357(1), 99-104. doi: 10.1016/j.bbrc.2007.03.081
Kraus, H., Kaiser, S., Aumann, K., Bonelt, P., Salzer, U., Vestweber, D., . . . Rizzi, M.
(2014). A feeder-free differentiation system identifies autonomously proliferating
B cell precursors in human bone marrow. J Immunol, 192(3), 1044-1054. doi:
10.4049/jimmunol.1301815
LeBien, T. W. (2000). Fates of human B-cell precursors. Blood, 96(1), 9-23.
Lee, E. B., Kim, K. W., Hong, J. Y., Jee, H. M., Sohn, M. H., & Kim, K. E. (2010).
Increased serum thymic stromal lymphopoietin in children with atopic dermatitis.
Pediatr Allergy Immunol, 21(2 Pt 2), e457-460. doi: PAI919 [pii]10.1111/j.13993038.2009.00919.x
Lee, G., Namen, A. E., Gillis, S., Ellingsworth, L. R., & Kincade, P. W. (1989). Normal
B cell precursors responsive to recombinant murine IL-7 and inhibition of IL-7
activity by transforming growth factor-beta. J Immunol, 142(11), 3875-3883.
Levin, S. D., Koelling, R. M., Friend, S. L., Isaksen, D. E., Ziegler, S. F., Perlmutter, R.
M., & Farr, A. G. (1999). Thymic stromal lymphopoietin: a cytokine that
promotes the development of IgM+ B cells in vitro and signals via a novel
mechanism. J Immunol, 162(2), 677-683.
Lin, H., & Grosschedl, R. (1995). Failure of B-cell differentiation in mice lacking the
transcription factor EBF. Nature, 376(6537), 263-267.
Loken, M. R., Shah, V. O., Dattilio, K. L., & Civin, C. I. (1987). Flow cytometric
analysis of human bone marrow. II. Normal B lymphocyte development. Blood,
70(5), 1316-1324.

26

Lu, L., Chaudhury, P., & Osmond, D. G. (1999). Regulation of cell survival during B
lymphopoiesis: apoptosis and Bcl-2/Bax content of precursor B cells in bone
marrow of mice with altered expression of IL-7 and recombinase-activating gene2. J Immunol, 162(4), 1931-1940.
Lundstrom, W., Highfill, S., Walsh, S. T., Beq, S., Morse, E., Kockum, I., . . . Mackall,
C. L. (2013). Soluble IL7Ralpha potentiates IL-7 bioactivity and promotes
autoimmunity. Proc Natl Acad Sci U S A, 110(19), E1761-1770. doi:
10.1073/pnas.1222303110
Lupton, S. D., Gimpel, S., Jerzy, R., Brunton, L. L., Hjerrild, K. A., Cosman, D., &
Goodwin, R. G. (1990). Characterization of the human and murine IL-7 genes. J
Immunol, 144(9), 3592-3601.
Lyman, S. D., & Jacobsen, S. E. (1998). c-kit ligand and Flt3 ligand: stem/progenitor cell
factors with overlapping yet distinct activities. Blood, 91(4), 1101-1134.
Lyman, S. D., James, L., Escobar, S., Downey, H., de Vries, P., Brasel, K., . . . et al.
(1995). Identification of soluble and membrane-bound isoforms of the murine flt3
ligand generated by alternative splicing of mRNAs. Oncogene, 10(1), 149-157.
Lyman, S. D., James, L., Johnson, L., Brasel, K., de Vries, P., Escobar, S. S., . . .
McKenna, H. J. (1994). Cloning of the human homologue of the murine flt3
ligand: a growth factor for early hematopoietic progenitor cells. Blood, 83(10),
2795-2801.
Mackarehtschian, K., Hardin, J. D., Moore, K. A., Boast, S., Goff, S. P., & Lemischka, I.
R. (1995). Targeted disruption of the flk2/flt3 gene leads to deficiencies in
primitive hematopoietic progenitors. Immunity, 3(1), 147-161.
Magnon, C., & Frenette, P. S. (2008). Hematopoietic stem cell trafficking. doi:
NBK27034 [bookaccession]
Malaspina, A., Moir, S., Ho, J., Wang, W., Howell, M. L., O'Shea, M. A., . . . Fauci, A.
S. (2006). Appearance of immature/transitional B cells in HIV-infected
individuals with advanced disease: correlation with increased IL-7. Proc Natl
Acad Sci U S A, 103(7), 2262-2267.
Medina, K. L., Pongubala, J. M., Reddy, K. L., Lancki, D. W., Dekoter, R., Kieslinger,
M., . . . Singh, H. (2004). Assembling a gene regulatory network for specification
of the B cell fate. Dev Cell, 7(4), 607-617.
Mikkola, I., Heavey, B., Horcher, M., & Busslinger, M. (2002). Reversion of B cell
commitment upon loss of Pax5 expression. Science, 297(5578), 110-113. doi:
10.1126/science.1067518297/5578/110 [pii]

27

Monroe, J. G., & Dorshkind, K. (2007). Fate decisions regulating bone marrow and
peripheral B lymphocyte development. Adv Immunol, 95, 1-50. doi: S00652776(07)95001-4 [pii]10.1016/S0065-2776(07)95001-4
Mullighan, C. G., Collins-Underwood, J. R., Phillips, L. A., Loudin, M. G., Liu, W.,
Zhang, J., . . . Rabin, K. R. (2009). Rearrangement of CRLF2 in B-progenitorand Down syndrome-associated acute lymphoblastic leukemia. Nat Genet, 41(11),
1243-1246. doi: ng.469 [pii]10.1038/ng.469
Namen, A. E., Lupton, S., Hjerrild, K., Wignall, J., Mochizuki, D. Y., Schmierer, A., . . .
Gillis, S. (1988). Stimulation of B-cell progenitors by cloned murine interleukin7. Nature, 333(6173), 571-573.
Namen, A. E., Schmierer, A. E., March, C. J., Overell, R. W., Park, L. S., Urdal, D. L., &
Mochizuki, D. Y. (1988). B cell precursor growth-promoting activity. Purification
and characterization of a growth factor active on lymphocyte precursors. J Exp
Med, 167(3), 988-1002.
Namikawa, R., Muench, M. O., de Vries, J. E., & Roncarolo, M. G. (1996). The
FLK2/FLT3 ligand synergizes with interleukin-7 in promoting stromal-cellindependent expansion and differentiation of human fetal pro-B cells in vitro.
Blood, 87(5), 1881-1890.
Namikawa, R., Muench, M. O., & Roncarolo, M. G. (1996). Regulatory roles of the
ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis. Stem Cells,
14(4), 388-395.
Nichogiannopoulou, A., Trevisan, M., Neben, S., Friedrich, C., & Georgopoulos, K.
(1999). Defects in hemopoietic stem cell activity in Ikaros mutant mice. J Exp
Med, 190(9), 1201-1214.
Nodland, S. E., Berkowska, M. A., Bajer, A. A., Shah, N., de Ridder, D., van Dongen, J.
J., . . . van Zelm, M. C. (2011). IL-7R expression and IL-7 signaling confer a
distinct phenotype on developing human B-lineage cells. Blood, 118(8), 21162127. doi: blood-2010-08-302513 [pii]10.1182/blood-2010-08-302513
Noguchi, M., Nakamura, Y., Russell, S. M., Ziegler, S. F., Tsang, M., Cao, X., &
Leonard, W. J. (1993). Interleukin-2 receptor gamma chain: a functional
component of the interleukin-7 receptor. Science, 262(5141), 1877-1880.
Nutt, S. L., Heavey, B., Rolink, A. G., & Busslinger, M. (1999). Commitment to the Blymphoid lineage depends on the transcription factor Pax5. Nature, 401(6753),
556-562. doi: 10.1038/44076
Nutt, S. L., Urbanek, P., Rolink, A., & Busslinger, M. (1997). Essential functions of Pax5
(BSAP) in pro-B cell development: difference between fetal and adult B

28

lymphopoiesis and reduced V-to-DJ recombination at the IgH locus. Genes Dev,
11(4), 476-491.
O'Riordan, M., & Grosschedl, R. (1999). Coordinate regulation of B cell differentiation
by the transcription factors EBF and E2A. Immunity, 11(1), 21-31.
Okada, S., Nakauchi, H., Nagayoshi, K., Nishikawa, S., Miura, Y., & Suda, T. (1992). In
vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine
hematopoietic cells. Blood, 80(12), 3044-3050.
Opferman, J. T., Letai, A., Beard, C., Sorcinelli, M. D., Ong, C. C., & Korsmeyer, S. J.
(2003). Development and maintenance of B and T lymphocytes requires
antiapoptotic MCL-1. Nature, 426(6967), 671-676. doi: 10.1038/nature02067
Osborn, M. J., Ryan, P. L., Kirchhof, N., Panoskaltsis-Mortari, A., Mortari, F., & Tudor,
K. S. (2004). Overexpression of murine TSLP impairs lymphopoiesis and
myelopoiesis. Blood, 103(3), 843-851.
Pandey, A., Ozaki, K., Baumann, H., Levin, S. D., Puel, A., Farr, A. G., . . . Lodish, H. F.
(2000). Cloning of a receptor subunit required for signaling by thymic stromal
lymphopoietin. Nat Immunol, 1(1), 59-64.
Park, L. S., Martin, U., Garka, K., Gliniak, B., Di Santo, J. P., Muller, W., . . . Sims, J. E.
(2000). Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor:
Formation of a functional heteromeric complex requires interleukin 7 receptor. J
Exp Med, 192(5), 659-670.
Parrish, Y. K., Baez, I., Milford, T. A., Benitez, A., Galloway, N., Rogerio, J. W., . . .
Payne, K. J. (2009). IL-7 Dependence in human B lymphopoiesis increases during
progression of ontogeny from cord blood to bone marrow. J Immunol, 182(7),
4255-4266. doi: 182/7/4255 [pii]10.4049/jimmunol.0800489
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E.,
Gliniak, B. C., . . . et al. (1994). Early lymphocyte expansion is severely impaired
in interleukin 7 receptor-deficient mice. J Exp Med, 180(5), 1955-1960.
Pribyl, J. A., & LeBien, T. W. (1996). Interleukin 7 independent development of human
B cells. Proc Natl Acad Sci U S A, 93(19), 10348-10353.
Puel, A., Ziegler, S. F., Buckley, R. H., & Leonard, W. J. (1998). Defective IL7R
expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet,
20(4), 394-397.
Quentmeier, H., Drexler, H. G., Fleckenstein, D., Zaborski, M., Armstrong, A., Sims, J.
E., & Lyman, S. D. (2001). Cloning of human thymic stromal lymphopoietin
(TSLP) and signaling mechanisms leading to proliferation. Leukemia, 15(8),
1286-1292.

29

Rawlings, D. J., Quan, S. G., Kato, R. M., & Witte, O. N. (1995). Long-term culture
system for selective growth of human B-cell progenitors. Proc Natl Acad Sci U S
A, 92(5), 1570-1574.
Ray, R. J., Furlonger, C., Williams, D. E., & Paige, C. J. (1996). Characterization of
thymic stromal-derived lymphopoietin (TSLP) in murine B cell development in
vitro. Eur J Immunol, 26(1), 10-16.
Ray, R. J., Stoddart, A., Pennycook, J. L., Huner, H. O., Furlonger, C., Wu, G. E., &
Paige, C. J. (1998). Stromal cell-independent maturation of IL-7-responsive pro-B
cells. J Immunol, 160(12), 5886-5897.
Reynaud, D., Lefort, N., Manie, E., Coulombel, L., & Levy, Y. (2003). In vitro
identification of human pro-B cells that give rise to macrophages, natural killer
cells, and T cells. Blood, 101(11), 4313-4321.
Rochman, Y., Kashyap, M., Robinson, G. W., Sakamoto, K., Gomez-Rodriguez, J.,
Wagner, K. U., & Leonard, W. J. (2010). Thymic stromal lymphopoietinmediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key
difference from IL-7-induced signaling. Proc Natl Acad Sci U S A, 107(45),
19455-19460. doi: 1008271107 [pii]10.1073/pnas.1008271107
Roifman, C. M., Zhang, J., Chitayat, D., & Sharfe, N. (2000). A partial deficiency of
interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe
combined immunodeficiency. Blood, 96(8), 2803-2807.
Rossi, M. I., Yokota, T., Medina, K. L., Garrett, K. P., Comp, P. C., Schipul, A. H., Jr., &
Kincade, P. W. (2003). B lymphopoiesis is active throughout human life, but
there are developmental age-related changes. Blood, 101(2), 576-584.
Russell, L. J., Capasso, M., Vater, I., Akasaka, T., Bernard, O. A., Calasanz, M. J., . . .
Harrison, C. J. (2009). Deregulated expression of cytokine receptor gene, CRLF2,
is involved in lymphoid transformation in B-cell precursor acute lymphoblastic
leukemia. Blood, 114(13), 2688-2698. doi: blood-2009-03-208397
[pii]10.1182/blood-2009-03-208397
Ryan, D. H., Nuccie, B. L., Abboud, C. N., & Winslow, J. M. (1991). Vascular cell
adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell
precursors to cultured bone marrow adherent cells. J Clin Invest, 88(3), 995-1004.
Ryan, D. H., Nuccie, B. L., Ritterman, I., Liesveld, J. L., Abboud, C. N., & Insel, R. A.
(1997). Expression of interleukin-7 receptor by lineage-negative human bone
marrow progenitors with enhanced lymphoid proliferative potential and B-lineage
differentiation capacity. Blood, 89(3), 929-940.

30

Sanz, E., Alvarez-Mon, M., Martinez, A. C., & de la Hera, A. (2003). Human cord blood
CD34+Pax-5+ B-cell progenitors: single-cell analyses of their gene expression
profiles. Blood, 101(9), 3424-3430.
Sanz, E., Munoz, A. N., Monserrat, J., Van-Den-Rym, A., Escoll, P., Ranz, I., . . . de-laHera, A. (2010). Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19common lymphoid progenitor stages in two pro-B-cell development pathways.
Proc Natl Acad Sci U S A, 107(13), 5925-5930. doi: 0907942107
[pii]10.1073/pnas.0907942107
Scheeren, F. A., van Lent, A. U., Nagasawa, M., Weijer, K., Spits, H., Legrand, N., &
Blom, B. (2010). Thymic stromal lymphopoietin induces early human B-cell
proliferation and differentiation. Eur J Immunol. doi: 10.1002/eji.200939419
Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., . . .
Handgretinger, R. (2005). Human lymphoid and myeloid cell development in
NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human
hemopoietic stem cells. J Immunol, 174(10), 6477-6489.
Sigvardsson, M., Clark, D. R., Fitzsimmons, D., Doyle, M., Akerblad, P., Breslin, T., . . .
Hagman, J. (2002). Early B-cell factor, E2A, and Pax-5 cooperate to activate the
early B cell-specific mb-1 promoter. Mol Cell Biol, 22(24), 8539-8551.
Sigvardsson, M., O'Riordan, M., & Grosschedl, R. (1997). EBF and E47 collaborate to
induce expression of the endogenous immunoglobulin surrogate light chain genes.
Immunity, 7(1), 25-36. doi: S1074-7613(00)80507-5 [pii]
Sims, J. E., Williams, D. E., Morrissey, P. J., Garka, K., Foxworthe, D., Price, V., . . .
Paxton, R. J. (2000). Molecular cloning and biological characterization of a novel
murine lymphoid growth factor. J Exp Med, 192(5), 671-680.
Smith, E. M., Gisler, R., & Sigvardsson, M. (2002). Cloning and characterization of a
promoter flanking the early B cell factor (EBF) gene indicates roles for E-proteins
and autoregulation in the control of EBF expression. J Immunol, 169(1), 261-270.
Souabni, A., Cobaleda, C., Schebesta, M., & Busslinger, M. (2002). Pax5 promotes B
lymphopoiesis and blocks T cell development by repressing Notch1. Immunity,
17(6), 781-793. doi: S1074761302004727 [pii]
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., . . . Liu, Y. J.
(2002). Human epithelial cells trigger dendritic cell mediated allergic
inflammation by producing TSLP. Nat Immunol, 3(7), 673-680.
Spangrude, G. J., Heimfeld, S., & Weissman, I. L. (1988). Purification and
characterization of mouse hematopoietic stem cells. Science, 241(4861), 58-62.

31

Sportes, C., Babb, R. R., Krumlauf, M. C., Hakim, F. T., Steinberg, S. M., Chow, C.
K., . . . Gress, R. E. (2010). Phase I study of recombinant human interleukin-7
administration in subjects with refractory malignancy. Clin Cancer Res, 16(2),
727-735. doi: 10.1158/1078-0432.CCR-09-1303
Taneda, S., Segerer, S., Hudkins, K. L., Cui, Y., Wen, M., Segerer, M., . . . Alpers, C. E.
(2001). Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin
transgenic mice. Am J Pathol, 159(6), 2355-2369. doi: S0002-9440(10)63085-4
[pii]10.1016/S0002-9440(10)63085-4
Tasian, S. K., Doral, M. Y., Borowitz, M. J., Wood, B. L., Chen, I. M., Harvey, R. C., . . .
Loh, M. L. (2012). Aberrant STAT5 and PI3K/mTOR pathway signaling occurs
in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood,
120(4), 833-842. doi: 10.1182/blood-2011-12-389932
Tokoyoda, K., Egawa, T., Sugiyama, T., Choi, B. I., & Nagasawa, T. (2004). Cellular
niches controlling B lymphocyte behavior within bone marrow during
development. Immunity, 20(6), 707-718. doi: 10.1016/j.immuni.2004.05.001
Tonozuka, Y., Fujio, K., Sugiyama, T., Nosaka, T., Hirai, M., & Kitamura, T. (2001).
Molecular cloning of a human novel type I cytokine receptor related to
delta1/TSLPR. Cytogenet Cell Genet, 93(1-2), 23-25. doi: ccg93023 [pii]
Tsai, M., Chen, C. C., Mukai, K., Song, C. H., Thompson, L. J., Ziegler, S. F., . . . Galli,
S. J. (2010). Thymic stromal lymphopoietin contributes to myeloid hyperplasia
and increased immunoglobulins, but not epidermal hyperplasia, in RabGEF1deficient mice. Am J Pathol, 177(5), 2411-2420. doi: 10.2353/ajpath.2010.100181
Vodyanik, M. A., Bork, J. A., Thomson, J. A., & Slukvin, II. (2005). Human embryonic
stem cell-derived CD34+ cells: efficient production in the coculture with OP9
stromal cells and analysis of lymphohematopoietic potential. Blood, 105(2), 617626.
von Freeden-Jeffry, U., Vieira, P., Lucian, L. A., McNeil, T., Burdach, S. E., & Murray,
R. (1995). Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as
a nonredundant cytokine. J Exp Med, 181(4), 1519-1526.
Vosshenrich, C. A., Cumano, A., Muller, W., Di Santo, J. P., & Vieira, P. (2003). Thymic
stromal-derived lymphopoietin distinguishes fetal from adult B cell development.
Nat Immunol, 4(8), 773-779.
Vosshenrich, C. A., Cumano, A., Muller, W., Di Santo, J. P., & Vieira, P. (2004). Pre-B
cell receptor expression is necessary for thymic stromal lymphopoietin
responsiveness in the bone marrow but not in the liver environment. Proc Natl
Acad Sci U S A, 101(30), 11070-11075.

32

Wang, J. H., Nichogiannopoulou, A., Wu, L., Sun, L., Sharpe, A. H., Bigby, M., &
Georgopoulos, K. (1996). Selective defects in the development of the fetal and
adult lymphoid system in mice with an Ikaros null mutation. Immunity, 5(6), 537549. doi: S1074-7613(00)80269-1 [pii]
Ye, M., & Graf, T. (2007). Early decisions in lymphoid development. Curr Opin
Immunol, 19(2), 123-128. doi: S0952-7915(07)00015-5
[pii]10.1016/j.coi.2007.02.007
Ying, S., O'Connor, B., Ratoff, J., Meng, Q., Fang, C., Cousins, D., . . . Corrigan, C. J.
(2008). Expression and cellular provenance of thymic stromal lymphopoietin and
chemokines in patients with severe asthma and chronic obstructive pulmonary
disease. J Immunol, 181(4), 2790-2798.
Ying, S., O'Connor, B., Ratoff, J., Meng, Q., Mallett, K., Cousins, D., . . . Corrigan, C.
(2005). Thymic stromal lymphopoietin expression is increased in asthmatic
airways and correlates with expression of Th2-attracting chemokines and disease
severity. J Immunol, 174(12), 8183-8190. doi: 174/12/8183 [pii]
Yoshikawa, Y., Hirayama, F., Kanai, M., Nakajo, S., Ohkawara, J., Fujihara, M., . . .
Ikebuchi, K. (2000). Stromal cell-independent differentiation of human cord
blood CD34+CD38- lymphohematopoietic progenitors toward B cell lineage.
Leukemia, 14(4), 727-734.
Zeigler, F. C., Bennett, B. D., Jordan, C. T., Spencer, S. D., Baumhueter, S., Carroll, K.
J., . . . Matthews, W. (1994). Cellular and molecular characterization of the role of
the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. Blood, 84(8),
2422-2430.

33

CHAPTER TWO
IL-7 DEPENDENCE IN HUMAN B LYMPHOPOIESIS INCREASES DURING
PROGRESSION OF ONTOGENY FROM CORD BLOOD TO BONE MARROW1

Yasmin Khan Parrish,* Ineavely Baez,†‡ Terry-Ann Milford,‡ Abigail Benitez,‡ Nicholas
Galloway,‡ Jaqueline Willeman Rogerio,* Eva Sahakian,* Mercy Kagoda,‡ Grace
Huang,* Qian-Lin Hao,* Yazmar Sevilla,‡ Lora W. Barsky,* Ewa Zielinska,* Mary A.
Price,* Nathan R. Wall,‡ Sinisa Dovat§ and Kimberly J. Payne 2*†‡
*Division of Research Immunology and Bone Marrow Transplantation, Children’s
Hospital Los Angeles, Los Angeles, CA
†
Department of Pathology and Human Anatomy School of Medicine, Loma Linda
University, Loma Linda, CA
‡
Center for Health Disparities and Molecular Medicine, School of Medicine, Loma Linda
University, Loma Linda, CA
§
Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of
Wisconsin, Madison, WI

Published in Journal of Immunology

34

Abstract
IL-7 is critical for B cell production in adult mice, however its role in human B
lymphopoiesis is controversial. One challenge was the inability to differentiate human
cord blood (CB) or adult bone marrow (BM) hematopoietic stem cells (HSCs) without
murine stroma. Here, we examine the role of IL-7 in human B cell development using a
novel, human-only model based on co-culturing human HSCs on primary human BM
stroma. In this model, IL-7 increases human B cell production by >60-fold from both CB
and adult BM HSCs. IL-7-induced increases are dose-dependent and specific to CD19+
cells. STAT5 phosphorylation and expression of the Ki-67 proliferation antigen, indicate
that IL-7 acts directly on CD19+ cells to increase proliferation at the CD34+ and CD34–
pro-B cell stages. Without IL-7, HSCS in CB, but not BM give rise to a small but
consistent population of CD19LO B lineage cells that express EBF and PAX-5 and
respond to subsequent IL-7 stimulation. Flt3 ligand, but not thymic stromal-derived
lymphopoietin (TSLP), was required for the IL-7-independent production of human B
lineage cells. As compared to CB, adult BM shows a reduction of in vitro generative
capacity that is progressively more profound in developmentally sequential populations,
resulting in a ~50-fold reduction in IL-7-dependent B lineage generative capacity. These
data provide evidence that IL-7 is essential for human B cell production from adult BM
and that IL-7-induced expansion of the pro-B compartment is increasingly critical for
human B cell production during the progression of ontogeny.
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Abbreviations
CB

Umbilical Cord Blood

BM

Bone Marrow

HSC

Hematopoietic Stem Cell

TSLP

Thymic Stromal-Derived Lymphopoietin

IL-7R

IL-7 Receptor

LIN–

Lineage Marker Negative
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Introduction
Murine studies have provided evidence that B cell development is controlled by a
network of transcription factors and cytokine signaling that coordinates stage-specific
expression of B lineage genes (Medina & Singh, 2005; Singh, Pongubala, & Medina,
2007). In mice, signaling through two cytokine receptors, Flt3 (FMS-like tyrosine kinase
receptor) and the IL-7R are critical for B cell development. The combined loss of
signaling through both of these receptors completely blocks fetal and adult B cell
development (Sitnicka et al., 2003, Vosshenrich, 2003 #856) (Vosshenrich, Cumano,
Muller, Di Santo, & Vieira, 2003). Flt3 signaling upregulates IL-7R expression (Borge,
Adolfsson, & Jacobsen, 1999). In adult mice, signaling through the IL-7R upregulates
expression of Early B cell factor (EBF). EBF in turn regulates expression of a cascade of
B cell specific genes (Medina & Singh, 2005; Singh et al., 2007) required for the
transition from the common lymphoid progenitor to pro-B cells (Dias, Silva, Cumano, &
Vieira, 2005; Kikuchi, Kasai, Watanabe, Lai, & Kondo, 2008; Kikuchi, Lai, Hsu, &
Kondo, 2005). During fetal and neonatal life, IL-7-independent expression of EBF allows
early B lineage differentiation, but not proliferation, unless IL-7 is present (Kikuchi &
Kondo, 2006).
Human B cell development is thought to differ from that in mouse with respect to
the requirement for IL-7. Early evidence for the importance of IL-7 in murine B cell
production came from in vitro studies showing that B cell precursors derived from adult
BM increase by approximately 50 fold with the addition of IL-7 (Lee, Namen, Gillis,
Ellingsworth, & Kincade, 1989). Further evidence came from reports of blocked B cell
development in the initial in vivo studies that characterized mutant mice with defects in
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IL-7 (von Freeden-Jeffry et al., 1995), or in components of the IL-7 receptor (IL-7R)
(DiSanto, Muller, Guy-Grand, Fischer, & Rajewsky, 1995; Peschon et al., 1994). Parallel
in vitro studies of human B cell development were performed either using fetal
hematopoietic sources (Dittel & LeBien, 1995; Kurosaka, LeBien, & Pribyl, 1999;
Moreau, Duvert, Banchereau, & Saeland, 1993; Moreau, Duvert, Caux, et al., 1993;
Namikawa, Muench, de Vries, & Roncarolo, 1996; Saeland et al., 1991; Wolf, Buckley,
Goldfarb, Law, & LeBien, 1991) or using hybrid co-cultures with human progenitors and
murine stromal cell lines (Johnson, Shah, Panoskaltsis-Mortari, & LeBien, 2005;
Rawlings, Quan, Kato, & Witte, 1995; Taguchi et al., 2007). Inthose experiments IL-7
either had no effect on B cell production or resulted in IL-7-induced increases that were
10-fold less than those reported in the mouse. In vivo human data from clinical reports
indicated that patients having severe-combined-immunodeficiency due to defects in IL7/IL-7R signaling lack T cells, but have peripheral blood B cells (Macchi et al., 1995;
Noguchi et al., 1993; Puel, Ziegler, Buckley, & Leonard, 1998). These data have been
interpreted to mean that IL-7 is essential for normal murine, but not human, B cell
development (Bertrand et al., 2000; Espeli et al., 2006; LeBien, 2000; Munfus, Haga,
Burrows, & Cooper, 2007; Roifman, Zhang, Chitayat, & Sharfe, 2000).
More detailed studies in the mouse revealed a dramatic change in B cell precursor
requirements during ontogeny. IL-7 knockout mice show a block in adult B
lymphopoiesis, but not in the production of B cells during the fetal or neonatal period
(Carvalho, Mota-Santos, Cumano, Demengeot, & Vieira, 2001). More recently it has
been shown that IL-7-independent expression of EBF in the mouse allows B lineage
differentiation early in ontogeny resulting in a “developmental switch” in murine stem
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cells with IL-7-independent B cell production occurring during fetal development and
through the first two weeks of neonatal life, but not in the adult (Kikuchi & Kondo,
2006).Thus, it is not surprising that in vitro IL-7 effects on fetally-derived human B cell
precursors (Kurosaka et al., 1999; Moreau, Duvert, Banchereau, et al., 1993; J. R. Pribyl,
Dittel, & LeBien, 1995; Saeland, Duvert, Moreau, & Banchereau, 1993; Saeland et al.,
1991; Wolf et al., 1991) were minor when compared to those observed for adult B
lymphopoiesis in the mouse (Lee et al., 1989).Similarly, clinical data from patients with
IL-7/IL-7R signaling defects was obtained early in life and is consistent with
observations that fetal/neonatal B cell production is intact in mice with IL-7 defects.
It is also possible that residual, low level IL-7R signaling plays a role in B cell
production in patients with defects in the IL-7R or its signaling pathway. Phosphorylation
of STAT5 is a signaling event downstream of IL-7R ligation (Lin et al., 1995). Studies
that compare B cell development in mice that are STAT5 null with that in STAT
deficient mice that express a truncated form of STAT5 reveal that even low levels of
residual IL-7R signaling can maintain B cell production in adult mice (Dai et al., 2007;
Yao et al., 2006). Experiments to assess for IL-7 function in human patients with defects
in components of the IL-7R signaling pathway are limited by the number, type, and
quantity of specimens available for study. Thus, in vitro studies of human B cell
development are essential for determining the role of IL-7 in human B cell development
and whether humans exhibit the “developmental switch” that results in the loss of IL-7
independent B cell production observed in the mouse.
The association between ontogeny and IL-7 requirements has not been rigorously
examined in humans. In vitro studies that address the role of IL-7 in human B cell
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production during the neonatal period and through adulthood have been performed using
hybrid human-mouse co-culture models (Johnson et al., 2005; Rawlings et al., 1995;
Taguchi et al., 2007).The limitations of this model were highlighted by recent reports
demonstrating that murine IL-7 can stimulate signaling through the human IL7R(Barata et al., 2006; Johnson et al., 2005; Taguchi et al., 2007). Thus, the production
of murine IL-7 by stroma in hybrid human-mouse co-cultureshas rendered it difficult to
evaluate the precise contribution of human IL-7, and the magnitude of IL-7-dependent
effects in human B cell production from HSCs in CB and BM.
Here we describe a novel, entirely human model of in vitro B cell development
that is based on co-culturing human HSCs on primary human BM stroma. Using this
human-only model we show that human IL-7 increases the production of human B cell
precursors by more than 60 fold, both from HSCs in adult BM, and from the HSCs in CB
that give rise to B cells during the neonatal period. IL-7 effects were mediated through
the direct action of human IL-7 on human CD19+ pro-B cells to increase proliferation at
both the CD34+ and CD34– stages of B cell development. Adult BM, as compared to
CB, shows a reduction of in vitro generative capacity that is progressively more profound
in developmentally sequential populations, resulting in a ~50-fold reduction in B lineage
generative capacity. In the absence of IL-7, HSCS in CB, but not BM give rise to a small
but consistent population of CD19LO B lineage cells that express EBF, PAX-5 and
respond to IL-7 with increased cell size and upregulation of CD19. These data suggest
that in humans the role of IL-7 in B cell production becomes increasingly critical as
ontogeny progresses, and that it is an essential factor for B cell production in adults.
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Materials and Methods
Cells
CB was collected according to guidelines approved by the Institutional Review
Boards at Children’s Hospital Los Angeles and Loma Linda University. Adult human
BM was purchased from AllCells, LLC, Berkeley, CA; the National Disease Research
Interchange (NDRI), Philadelphia, PA; or Poietics Cell Systems of Lonza Walkersville,
Inc., Gaithersburg, MD. The leukopheresis product from a patient with pre-B ALL (>
90% CD19+ cells) served as a source of primary human pre-B ALL cells. The use of all
human tissues was reviewed and approved by the Institutional Review Boards at
Children’s Hospital Los Angeles and/or Loma Linda University. Primary murine BM was
obtained from normal adult control mice immediately after they were sacrificed as a part
of other studies approved by the Institutional Animal Care and Use Committees at
Children’s Hospital Los Angeles or Loma Linda University.
Lineage marker negative (Lin–) CD34+ cells were isolated by FACS sorting from
CD34-enriched CB and BM mononuclear cells as previously described (Payne et al.,
2003). Primary stromal cells from adult human or murine BM were obtained by plating
whole BM in Dexter’s original medium as described previously (Nolta et al., 2002).Nonadherent cells were removed on the second day and adherent cells were used through
passage six.
The murine S17 (Collins & Dorshkind, 1987) stromal cell line is a generous gift
from Dr. Kenneth Dorshkind, University of California Los Angeles and the murine MS-5
(Ohkawara et al., 1998) stromal cell line is a generous gift from Dr. Kazuhiro Mori.
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Cultures
Human CB and adult BM HSCs (typically ~10,000 and ~15,000 respectively)
were seeded onto murine stromal cells pre-plated at 3,500 cells/well (hybrid cultures) or
onto sublethally irradiated (2000 rads) primary human BM stromal cells plated at 7,000
cells/well (human-only cultures) in 96-well tissue culture plates in B cell medium: RPMI
medium (Irvine Scientific, Santa Ana, CA) containing penicillin/streptomycin, Lglutamine, 50 M 2-mercaptoethanol, and 5% FBS(Omega Scientific, Inc. Tarzana, CA)
lot tested for ability to support B cell production. Sublethal irradiation assured that
culture progeny did not arise from residual human HSCs that might be associated with
the BM-derived stroma. Control cultures were supplemented with IL-3 at 1 ng/ml (first
week only) and Flt-3 ligand at 1 ng/ml or 50 ng/ml (R&D Systems, Minneapolis, MN)
two cytokines that have previously been shown to support the production of human B
lineage cells in vitro (Crooks, Hao, Petersen, Barsky, & Bockstoce, 2000; Miller,
McCullar, Punzel, Lemischka, & Moore, 1999; Namikawa et al., 1996; Shah,
Smogorzewska, Hannum, & Crooks, 1996). Additional supplementation with
recombinant human cytokines and/or antibodies is described in fig. legends or as follows:
IL-7 at 5 ng/ml, stem cell factor at 25 ng/ml (R&D Systems) neutralizing anti-human IL7 antibody, or control antibody at 10 ng/ml (BD Pharmingen, San Diego, CA),
neutralizing anti-mouse IL-7 antibody (Abcam, Inc. Cambridge, MA) or control antibody
(Jackson ImmunoResearch, West Grove, PA), neutralizing anti-human TSLP antibody
(R&D) or control antibody (Jackson ImmunoResearch) at 1 ug/ml, neutralizing antihuman Flt-3 ligand or control antibody (R&D) at .6 g/ml. The ND50 for rabbit antimouse IL-7 neutralizing antibody was 0.012 to 0.02 g/ml of antibody for mouse IL-7 at

42

600 pg/ml. The ND50 for rat anti-human IL-7 neutralizing antibody was .0001 to
.001g/ml of antibody for human IL-7 at 167 pg/ml. The ND50 for sheep anti-human
TSLP was .05 to .25 g/ml for .5 ng/ml human TSLP. The ND50 for mouse anti-human
Flt-3 ligand was .02 to .06 g/ml for 5 ng/ml Flt-3 ligand.
For cultures described in Figure 4A each well contained 3 antibodies: either the
neutralizing antibody to Flt-3 ligand, IL-7, and/or TSLP, or the corresponding control
antibody at an identical concentration as neutralizing antibody. Wells to which
exogenous cytokine were added received the appropriated control antibody for that
cytokine. This assured that antibody isotypes and concentrations were the same in all
wells. To simplify, only neutralizing antibodies (and not control antibodies) are indicated
in the legend to Figure 4A.
CD19+ progeny from human-only cultures were enriched for apoptosis assays
using the Human B cell enrichment kit (StemCell Technologies, Vancouver, BC, Canada)
and for assays of STAT5 phosphorylation using the Miltenyi Biotech CD19 microbead
kit (Miltenyi Biotec, Auburn, CA).

FACS-Sorting and Flow Cytometry
For flow cytometry cells were surface stained as described previously, (Zhang et
al., 2005) and resuspended in PBSfor FACS sorting using the FACSVantage or
FACSAria cell sorter (Becton Dickinson Immunocytometry Systems, [BDIS] San Jose,
CA) or in PBS or 1% freshly prepared formaldehyde for analysis using the FACSCalibur
flow cytometer. The following antibodies were used: kappa FITC, lambda FITC, IgM
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FITC, IgM PE-Cy5 (Cychrome), CD19 APC, CD34 PerCP (BD Pharmingen), and IL7RPE (Beckman-Coulter Immunotech).
To assess and cytoplasmic mu (c) and Ki-67 expression, cells were first stained
for surface markers then stained with anti-IgM antibodies to detect intracellular c with
anti-Ki-67, or with an isotype-matched control antibody (BD Pharmingen) using the Fix
and Perm Cell Permeabilization Kit (Caltag Laboratories, Burlingame, CA) as per
manufacturer’s instructions.
For phospho STAT5 staining, cells were washed, fixed by incubating for 10 min
with 1.5% paraformaldehyde at room temperature, pelleted by centrifugation and then
paraformaldehyde was decanted off. To permeabilize, cells were vortexed, resuspended
in 100% methanol at 4o C, and incubated for 10 min at 4o C or at -20o C overnight. Cells
were pelleted by centrifugation, washed in PBS with 10% FBS and .01% sodium azide,
then incubatedwith anti-phospho STAT5 PE ormouse IgG1 PE isotype control antibody
(BD Pharmingen) for 30 min at room temperature.Cells were then washed and
resuspended in staining buffer for flow cytometry.
To assess apoptosis, harvested cells were incubated with CD19 APC and the
apoptosis indicator Annexin V FITC (BD Pharmingen) and prepared for flow cytometry
according to manufacturers instructions.
Fluorescence intensity on all flow cytometry dot plots and histograms is shown on
a log scale. Forward scatter (FSC) and percent maximum on histograms is shown in a
linear scale.
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ELISA
Primary murine and human BM stromal cells (non-irradiated, 3.5 X 105 cells or
sublethally irradiated [2000 rads], 7.0 X 105 cells) and murine MS5 and S17 stromal cells
(non-irradiated, 3.5 X 105 cells) were plated in 200 μl of B cell medium (described above)
without cytokines in individual wells of a 96-well plate. At weekly intervals 100 l of
culture medium was harvested, filtered with a 0.2 μm filter, and 100 l of new media
added to each well. Harvested supernatants were frozen, thawed, and IL-7 levels were
detected using the Mouse IL-7 or Human IL-7 ELISA kit (R&D Systems).

RT-PCR
cDNA was prepared as described previously. Reverse-transcription (RT)-PCR to
detect expression of IL-7 and 2 microglobulin was performed as described previously
(Payne et al., 2003). Intron-spanning PCR primers for mouse and human IL-7 and 2
microglobulin were as follows: human 2 microglobulin, 5’–CTC GCG CTA CTC TCT
CTT TC–3’ and 5’ –CAT GTC TCG ATC CCA CTT AAC–3’ (330 base product);
human IL-7, 5’–CTC CCC TGA TCC TTG TTC TG–3’ and 5’–TCA TTA TTC AGG
CAA TTG CTA CC–3’ (151 base product); mouse2 microglobulin, 5’–TGC TAT CCA
GAA AAC CCC TC–3’ and 5’–GGC ATG CTT AAC TCT GCA GG –3’ (259 base
product); and mouse IL-7,5’ –TGG AAT TCC TCC ACT GAT CC–3’and 5’ –TGG
TTC ATT ATT CGG GCA AT–3’ (160 base product): (Invitrogen Life Technologies,
Paisley, PA). PCR conditions for human IL-7 and B2 were as follows: 10 min 94° C (1
cycle); 94° C for 1 min, 50° C for 45 s, 72° C for 1 min and 15 s (5 cycles); 94° C for 1
min, 55° C for 30 s, 72° C for 1 min and 15 s (29 cycles); 72° C for 5 min (1 cycle). PCR
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conditions for mouse IL-7 and B2 were as follows: 15 min 95° C (1 cycle); 94° C for 30
s, 55° C for 30 s, 72° C for 30 s (35 cycles); 72° C for 10 min (1 cycle).
cDNA was amplified for detection of CD19, EBF, Pax-5, and GAPDH
(housekeeping gene) using the LightCycler 1.0 system real-time thermal cycler and the
LightCycler FastStart DNA MasterPLUS SYBR Green kit (Roche Applied Science,
Indianapolis, IN). The small numbers of B lineage cells produced in the absence of IL-7
activity precluded quantitative or semi-quantitative assessment of mRNA levels. The
assessment of samples as positive for expression was based on 1) observing reproducible
CT values in 2 replicates of the target gene where the GAPDH housekeeping gene
showing a CT value of <30 cycles and 2) melting curve analysis showing superimposable
melting curves across samples (including pre-B ALL cells as a positive control) and
replicates for a given target gene in the absence of a superimposable product in negative
control samples. Gene specific primer pairs were designed to span introns using Roche's
Assay Design Center at www.roche-applied-science.com. Primers were as follows:
GAPDH left 5'- GAG TCC ACT GGC GTC TTC AC; GAPDH right 5'- GTT CAC ACC
CAT GAC GAA CA; CD19 left 5'- TCC ACC TGG AGA TCA CTG CT; CD19
right 5'- GAC CTT CCA GCC ACC AGT C; Pax5 left 5'- GTC CCA GCT TCC AGT
CAC AG; Pax5 right 5'- GTG CTC ACC GAG GAC ACC; EBF left 5'-AGC TGC
CAA CTC CCC CTA T; EBF right Lower 5' GGG AGG CTT GTG GAG GAG. Cycling
parameters for all products: initial denaturation of 15 min at 95 degrees followed by 50
cycles of 10 s at 95°C (denaturing); 5 s at 60°C (annealing); 15 s at 72°C (elongation).
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Statistics and Data Analysis
In flow cytometry analysis, CD19+ B lineage cells and CD34+ HSC and
progenitor populations were identified based on light scatter within a
lymphocyte/progenitor light scatter gate and by expression of indicated surface markers.
CD19–CD34– non-B lineage cells were identified based on light scatter within a living
cell light scatter gate. Gates for determining percentages of cells positive for surface or
intracellular markers were set on similarly gated CD19+ B lineage and CD19– cells in
samples co-stained for CD19 and isotype-matched control antibodies.
Absolute numbers of culture progeny were determined by multiplying the fraction
of cells within a particular subset (gated based on surface immunophenotype: CD19–,
CD19+, CD19+CD34+IL-7R+, etc.) as a percentage of the cells within living cell light
scatter (assessed by flow cytometry) by the total count of living cells generated in the
culture (determined by hemocytometer count of cells negative for trypan blue staining or
by flow cytometry using Caltag Counting Beads, [Caltag Laboratories]). Relative
numbers of cells were determined by dividing the absolute number of cells of a particular
type generated in each experimental condition by the absolute numbers of the same type
of cells generated under control conditions (Figure 1, 2) or under control conditions plus
anti-human IL-7 neutralizing antibodies (Figure 3, 8) in each independent experiment.
Each independent co-culture experiment represents an independent FACS sort of
Lin–CD34+ BM or CB cells. In most cases adult BM in independent experiments is from
different donors and in all cases CB in each independent experiment is pooled from
multiple different donors. The hematopoietic cells for all conditions in each independent

47

experiment are aliquoted from a pool of cells FACS sorted at the same time from the
same donor(s).
Flow cytometry analysis was performed using FlowJo software (Tree Star, Inc.
Ashland, OR). Statistical analysis was performed using InStat3 software (GraphPad
Software, Inc., San Diego, CA).

Results
Human-Only Co-Cultures Support In Vitro Human B Lymphopoiesis
We developed a novel, human-only in vitro model of B cell development based
on co-culturing nonfetal human hematopoietic progenitors with primary human stroma
from adult BM (Figure 1A). Initial experiments used CB as a source of HSCs. While CB
contains fetally-generated B cells, the stem cells present in CB are of interest because
they give rise to B cells in the neonatal period and are increasingly used clinically as a
source of HSCs for transplant.
B cell production in human-only cultures was compared to that in an established
hybrid co-culture model (Crooks et al., 2000; Fluckiger et al., 1998; Hao, Smogorzewska,
Barsky, & Crooks, 1998; Rawlings et al., 1997) consisting of human HSCs and murine
S17 stroma. (Figure 1A).The emergence of human B lineage cells in human-only
cultures paralleled that observed in hybrid cultures with murine S17 stroma. CD19+ B
lineage cells were undetectable at one week and rare at two weeks (data not shown). At
three weeks, CD19+ B lineage cells were detectable in both human-only and hybrid S17
cultures under control conditions. However the frequency of B lineage cells was low in
human-only cultures (Figure 1B, middle panel). With the addition of human IL-7,
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human-only cultures produced a substantial population of CD19+ cells (Figure 1C,
middle panel). At 3 weeks, the CD19+ B lineage cells present in human-only cultures,
like those in hybrid cultures, were B cell precursors that did not express the cytoplasmic
mu (c) Ig heavy chain (Figure 1B, C, middle and left panels) or surface immunoglobulin
(Ig) as evidenced by the absence of kappa and lambda Ig light chains (data not shown).
At 5 weeks, surface IgM+ cells were observed in both human-only (Figure 1B, C, right
panels) and hybrid co-cultures (data not shown), and while the production of c+ and
IgM+ B cells in human-only cultures was inefficient (~11 to 16% of CD19+ cells), it was
consistently higher than that observed in hybrid co-cultures (~3% of CD19+ cells). These
data provide evidence that co-cultures with primary human BM stromal cells support the
production of human B cells and establish human-only cultures as an in vitro model for
studying early stages of human B lymphopoiesis.

Exogenous IL-7 Increases B Cell Production in Human-Only, but not Hybrid CoCultures with Murine Stromal Cell Lines
Using human-only and hybrid S17 cultures we characterized the effect of IL-7 on
the production of human B cell precursors from CB HSCs. The addition of IL-7 to
human-only, but not hybrid S17 cultures, significantly increased the production of
CD19+ B lineage cells as compared to cultures without IL-7 (Figure 1B, C, D).Stem cell
factor (SCF) had no significant effect on human B cell production, either alone or in
combination with IL-7 in human-only or hybrid S17 cultures (Figure 1D). Thus, humanonly cultures revealed specific, IL-7 effects on human B cell production.
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A titration of IL-7 into human-only cultures showed that IL-7-induced increases
in the production of B lineage cells were dose-dependent and specific to CD19+ cells,
achieving maximal effects (43-fold) at 10 ng/ml of IL-7 (Figure 1E). In contrast, IL-7induced increases observed in hybrid S17 cultures at 3 weeks never averaged more than
3-fold at any concentration of IL-7 (Figure 1E). These data provide evidence that IL-7
induces a lineage-specific increase in the in vitro production of human B cell precursors
that is not detectable in hybrid cultures with the murine S17 stromal cell line.
To determine if the inability to support IL-7-induced increases in human B cell
production is specific to murine S17 stroma,we examined IL-7 effects in hybrid cultures
with the MS-5 murine stromal cell line, another established model (Berardi et al., 1997;
Nishihara et al., 1998; Ohkawara et al., 1998) for in vitro human B lymphopoiesis. As
with S17 stroma, the addition of IL-7 did not significantly increase the production of
human B cell precursors in hybrid MS-5 cultures (data not shown). However, substantial
numbers of human B lineage cells were produced in the absence of exogenous IL-7 in
hybrid cultures with murine S17 and MS-5 stroma (Figure 1B and data not shown)
suggesting that another factor replaces human IL-7 in hybrid human-mouse co-cultures.
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Figure 1 (Figure 4). Exogenous IL-7 increases B cell production in human-only, but
not hybrid human-mouse co-cultures with murine stromal cell lines. (A) CB CD34+
cells that were negative for lineage markers (Lin–CD34+) were FACS-sorted and placed
in co-culture with murine S17 stroma (left panels) or with sub-lethally irradiated,
primary stroma from adult human BM (middle and right panels). Co-cultures were
supplemented with IL-3 (first week only) and Flt3 ligand (3, F; control conditions), with
or without the addition of IL-7 (5 ng/ml). Cells generated in cultures without IL-7 (B)
or with IL-7 (C) were harvested at 3 or 5 weeks and stained for flow cytometry to assess
for surface expression of the B lineage marker, CD19, and the presence of Ig heavy
chain protein (c in the cytoplasm or surface IgM as indicated. Plots are gated on
lymphocyte light scatter (gates not shown). CD19+ B lineage cells, as a percentage of
the total cells in living cell light scatter (mean + SEM) for 4 independent experiments
(see “Materials and Methods”) are given in left and middle panels. Percentages of IgM+
cells (mean + SEM) among total CD19+ cells at 5 weeks are given in right panels (8
independent experiments). (D) Hybrid S17 (left panel) and human-only cultures (right
panel) established under control conditions (3, F) as described above were
supplemented with stem cell factor (S), with IL-7 (7) or with a combination of IL-7 and
SCF and harvested at 3 weeks. Relative numbers of CD19+ and CD19– progeny were
determined as described in “Materials and Methods”. Data shown are the means + SEM
of 6 independent experiments. (* p = .012, ANOVA) (E) Hybrid S17 (left panel) and
human-only cultures (right panel) initiated as described above were supplemented with
increasing amounts of IL-7 as indicated. At 3 weeks culture progeny were harvested and
relative numbers of CD19– and CD19+ cells were determined. Data shown are the
means + SEM of 3 independent experiments with the exception of IL-7 at 100 ng/ml for
which n=2.
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IL-7 Activity is Critical for B Cell Production in Hybrid S17
and MS-5 Cultures
While early studies suggested that mouse IL-7 does not act on human cells
(Goodwin et al., 1989; Kroemer, Kroncke, Gerdes, & Richards, 1998), more recent
reports indicate that this is not the case (Barata et al., 2006; Johnson et al., 2005). A
titration of anti-mouse IL-7 neutralizing antibodies, but not control antibodies, into
hybrid cultures with murine stroma gave a dose-dependent reduction in human B cell
production. At the highest concentrations, anti-mouse IL-7 neutralizing antibodies
decreased B cell production from CB HSCs in hybrid S17 and MS-5 cultures by 10 and
17 fold, respectively, as compared to co-cultures with no neutralizing antibody (Figure
2A). The production of non-B lineage (CD19–) cells was not affected by anti-mouse IL-7
neutralizing antibodies (Figure 2B). These data provide evidence that endogenously
produced murine IL-7 is critical for the production of human B cell precursors in hybrid
co-cultures with murine S17 and MS-5 stroma.

Production of IL-7 by Primary Human and Murine BM Stroma
To determine if stromal cells can serve as a source of IL-7 for in vivo human B
cell development we examined the ability of primary human BM stroma to produce IL-7.
IL-7 mRNA was detected in primary adult human BM stroma as well as primary murine
BM stroma and murine stromal cell lines (Figure 2C). Next we compared the levels of
IL-7 protein produced by murine and human stroma grown as in co-cultures. Weekly
assessment of IL-7 by ELISA showed that primary adult human BM stroma produce low
levels of IL-7 in vitro (ranging from .15 to 1.02 pg/ml during a five week culture period)

53

and that IL-7 production is not affected by sub-lethal irradiation prior to plating for coculture.In contrast, the murine S17 and MS-5 stromal cell lines produced levels of IL-7
that were at least 40 fold higher than that of primary human BM stroma (Figure 2D).
However, in vitro IL-7 production by primary adult murine BM stroma, either with or
without sub-lethal irradiation, was below the threshold of detection by the ELISA for
mouse IL-7.Thus, the high level of in vitro IL-7 production by murine S17 and MS-5
murine stromal cell lines does not reflect that of primary murine BM stroma that support
in vivo IL-7-dependent B cell development in the mouse.
While the production of IL-7 from primary adult human BM stroma was
detectable with the much more sensitive ELISA assay for human IL-7, those levels would
have been below the sensitivity of the mouse IL-7 ELISA assay. These data provide
evidence that primary human adult BM stroma produce IL-7 and that the level of in vitro
IL-7 production by these cells is consistent with that observed for mouse, an animal
model where the physiological relevance of IL-7 in B cell development has been
demonstrated in vivo (Carvalho et al., 2001; von Freeden-Jeffry et al., 1995)
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Figure 2 (Figure 5). B cell production in hybrid human-mouse co-cultures is dependent
on murine IL-7 activity.FACS-sorted Lin–CD34+ CB cells were placed in hybrid cocultures with the murine S17 or MS-5 stromal cell lines and grown under control
conditions (3, F) or control conditions supplemented with increasing amounts of antimouse IL-7 neutralizing antibody or appropriate control antibody. Culture progeny were
harvested at 3 weeks and absolute numbers of CD19+ and CD19– cells were determined
as described in “Materials and Methods”. Absolute numbers of (A) CD19+ and (B)
CD19– progeny generated under increasing control and anti-IL-7 antibody
concentrations were compared to absolute numbers of CD19+ and CD19– cells
generated under control conditions with no antibody. Relative numbers of CD19+ and
CD19– cells (as compared to control conditions with no antibodies) are graphed. Data
shown are the means + SEM for 3 independent experiments. (C) RT-PCR analysis using
primers to detect IL-7 and 2 microglobulin (2m, ubiquitously expressed in nucleated
cells). Analyses from three different adult mice (age range 6-12 weeks), from the murine
S17 and MS-5 stromal cell lines (n=2) and from three different adult donors (age range
20-30) are shown. (D) ELISA assessment of in vitro IL-7 production from indicated
stromal cell lines (murine MS-5 and S17) or primary stroma. Stroma were plated under
conditions similar to those used for co-cultures (3,5000 non-irradiated MS-5 or S17 cells
per well and 7,000 sublethally irradiated primary human stroma per well in 96 well
plates).For comparison, non-irradiated primary human stroma were also plated at
3,500 cells per well. Media was harvested at weekly time points and assessed for IL-7
by ELISA. Note the difference in threshold for sensitivity of mouse and human IL-7
ELISA assays (murine: 3.5 - 8.3 pg/mL and human: <0.1 pg/ml). Primary adult murine
BM stroma was also assessed for IL-7 production, however data is not shown as the
levels of IL-7 production for both irradiated and non-irradiated primary adult murine
BM stroma were below the sensitivity of the murine IL-7 ELISA.
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IL-7 is Essential for the Production of B Lineage Cells from HSCs in Adult BM,
but not from HSCs in CB
To determine the extent to which B cell production is dependent on IL-7 and how
this might change during ontogeny, we compared the production of B cell precursors
from CB and adult BM HSCs in human-only cultures supplemented with anti-human IL7 neutralizing antibodies or with IL-7 (Figure 3A).A small population of CD19+ B
lineage cells were generated from CB HSCs in cultures where IL-7 activity was
neutralized. In contrast, B lineage cells derived from adult human BM were almost totally
absent from cultures with anti-IL-7 antibodies, (Figure 3A). These data suggest that
HSCs in CB but not adult BM have the potential for IL-7-independent human B
lymphopoiesis.
A comparison of human-only cultures initiated with CB and adult BM HSCs
showed that IL-7-induced increases in both cases were similar in magnitude and specific
to CD19+ cells (Figure 3B). However, the fraction of culture progeny comprised of B
lineage cells was significantly less in cultures with HSCs from adult BM (Figure 3A).
Therefore, we compared the generative capacities of CB and BM HSCs with respect to B
lymphoid (CD19+) and non-B lymphoid (CD19–) progeny and the effects of IL-7 on
these capacities (Figure 3C). For each Lin–CD34+ CB cell plated at culture initiation, an
average of 5.7 CD19+ cells were generated at 3 weeks in human-only cultures with IL-7.
Surprisingly, the average B lymphoid generative capacity of adult BM HSCs in identical
conditions was only .11 CD19+ cells/HSC plated. The capacities of CB and adult BM
HSCs to generate CD19– progeny were not significantly different and were unaffected by
IL-7. Thus, the in vitro B lymphoid generative capacity of adult BM HSCs is more than
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50 fold less thanthat of CB HSCs and this decreased generative capacity is specific to
CD19+ cells. These data suggest thatIL-7 is more critical in maintaining human B cell
production during adult life than during the neonatal period and that this may be due in
part to a selective decrease in the B lymphoid generative capacity of HSCs in adult BM
as compared to CB.
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Figure 3 (Figure 6). B cell production from adult BM HSCs is profoundly dependent
on IL-7. Human-only cultures were initiated with FACS-sorted Lin–CD34+ HSCs from
CB or BM under control (3, F) culture conditions (see Figure 1) supplemented with
exogenous human IL-7 or with neutralizing anti-human IL-7 antibodies as indicated.
At 3 weeks culture progeny were harvested, counted, and stained for flow cytometry to
detect expression of the B lineage marker, CD19.(A) Plots shown are gated on
lymphocyte light scatter (gates not shown) and display equal numbers of cells. CD19+
B lineage cells, as a percentage of the total cells in living cell light scatter (mean + SEM)
for 6 independent experiments are given. (B) Relative numbers of CD19+ and CD19–
culture progeny at three weeks were determined as described in “Materials and
Methods”.Data graphed are the increases in relative numbers of CD19+ and CD19–
cells in cultures supplemented with exogenous IL-7 as compared to cultures
supplemented with anti-IL-7 neutralizing antibodies (* p < .05, two-tailed paired t test).
(C) Shown are CD19+ and CD19– generative capacities of CB and adult BM (donor
age 20-30) HSCs under indicated conditions. Generative capacity was determined by
dividing the absolute numbers of CD19+ or CD19– progeny generated at 3 weeks by
the number of Lin–CD34+ HSCs plated at culture initiation. Data shown in panel C are
the means + SEM of 6 independent experiments (** p < .01, two-tailed Mann-Whitney
test).
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Flt3 Ligand, but not TSLP is Required for the IL-7-Independent Production of B
Lineage Cells from CB HSCs
Studies of mouse B cell development suggest that TSLP, a cytokine that signals
through the IL-7R and/or Flt3 ligand support the production of fetal/neonatal B cells in
the absence of IL-7 (Jensen et al., 2008; Vosshenrich et al., 2003). Therefore we
examined the extent to which the IL-7-independent production of B lineage cells from
CB HSCs in our human-only cultures (Figure 3A, left panel) is dependent on Flt3 ligand
and TSLP. The production of CD19+ cells from CB HSCs in human-only cultures
supplemented with Flt-ligand and anti-IL-7 was compared to that observed with
neutralizing anti-Flt-ligand, neutralizing anti-TSLP, or both. As shown in Figure 4A, the
addition of anti-TSLP antibodies had no effect on IL-7 independent production of B
lineage cells, while CD19+ B lineage cells were essentially absent in cultures that
contained anti-Flt3 ligand. These data show that Flt3 ligand, but not TSLP, is required for
the IL-7-independent production of B lineage cells from CB HSCs that we observed in
human-only cultures.

B Lineage Cells Produced in the Absence of IL-7 are Capable of
Subsequent IL-7 Responses
IL-7 has been reported to increase the expression of CD19 on fetally-derived
human B cell precursors (Wolf, Weng, Stieglbauer, Shah, & LeBien, 1993) and in the
presence of IL-7, IL-7R+ B cell precursors are larger in size than B cell precursors that
lack the IL-7R (Johnson et al., 2005). Consistent with this report, flow cytometry
analysis showed that the B lineage cells generated from CB and BM HSCs in human-only

60

cultures expressed high levels of CD19 in the presence of IL-7, while cultures
supplemented with anti-IL-7 neutralizing antibodies expressed much lower levels of
CD19 (Fig 3A). Human-only cultures supplemented with IL-7 also showed higher
frequencies of B cells that were larger (as indicated by increased forward scatter (FSC) in
flow cytometry analysis) as compared to those produced in cultures with anti-IL-7
neutralizing anti-bodies (see below).
To determine if the B lineage cells generated in the absence of IL-7 were capable
of responding to IL-7 by upregulating CD19 and exhibiting increased cells size
characteristic of cycling cells, we switched the culture progeny produced from CB HSCs
in human-only cultures supplemented with anti-IL-7 neutralizing antibodies to human
stromal cell cultures with IL-7 (anti-IL-7 to IL-7 switch cultures). After 3 days, anti-IL-7
to IL-7 switch cultures were compared to cultures that had been switched to human
stroma and anti-IL-7 (anti-IL-7 to anti-IL-7 switch cultures) or to human-only cultures
that had been both initiated with and switched to IL-7 supplementation (IL-7 to IL-7
switch cultures). The percentage of cells expressing high levels of CD19 (CD19HI) was
increased in anti-IL-7 to IL-7 switch cultures (Figure 4B, middle panel), as compared to
anti-IL-7 to anti-IL-7 switch cultures (Fig 4B, top panel), however, the percentages were
not as high as those observed among B lineage cells that were produced under continuous
exposure to IL-7 (Fig 4B, bottom panel, and Fig 4D). Cultures with B cell precursors that
were never exposed to IL-7 (anti-IL-7 to anti-IL-7 switch cultures) showed a low
frequency of cells with the high levels of FSC characteristic of cycling cells. The switch
from anti-IL-7 to IL-7 resulted in a significant increase in the frequency of cells that were
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FSCHI and an FSC histogram profile that was similar to that seen for IL-7 to IL-7 switch
cultures.
IL-7R-signaling, partially via upregulation of EBF, has been reported to be a
regulator of the transcription factor network that controls B cell development in the
mouse (Singh et al., 2007). Expression of EBF in the absence of IL-7 in fetal and
neonatal mice allows IL-7-indepdent B cell differentiation at early points in ontogeny
(Kikuchi & Kondo, 2006). Therefore we were interested in examining expression of EBF
and its downstream target PAX-5 (O'Riordan & Grosschedl, 1999) in the early B lineage
cells generated in our human-only cultures. CD19+ cells generated in switch cultures
were FACS-sorted for RT-PCR. Real time RT-PCR showed that B lineage cells
generated in all three switch culture conditions expressed mRNA for CD19, PAX-5, and
EBF, (Supplemental Data) however the small number of cells generated in cultures
initiated with anti-IL-7 precluded a quantitative comparison of mRNA levels. Taken
together these data provide evidence that the CD19LO cells generated from CB HSCs in
the absence of IL-7 are B lineage cells and have the capacity to respond to subsequent IL7 stimulation.

62

63

Figure 4 (Figure 7). IL-7-independent production of human B lineage cells is
dependent on Flt3 ligand and produces CD19+ B lineage cells that can respond to IL-7.
(A) Human-only cultures were initiated with FACS-sorted Lin–CD34+ HSCs from CB
and grown with indicated cytokines (+), with cytokine-specific neutralizing antibodies
(anti-) or without the indicated cytokine or its neutralizing antibody (-----).
Corresponding isotype control antibodies were added to all wells in which a specific
neutralizing antibody was not used but are not indicated in the graph—see “Materials
and Methods”. At 3 weeks, culture progeny were harvested, counted, stained for CD19
expression and the CD19+ generative capacity was determined as described in Figure 3
legend. Data in panel A are the means + SEM of 2 independent experiments with 3
replicates per experiment, (ANOVA, *** p < .001 for Bonferroni multiple comparisons
post test) (B, C) Human-only cultures were initiated with FACS-sorted Lin–CD34+
HSCs from CB under control (3, F) culture conditions and supplemented with
exogenous human IL-7 or with neutralizing anti-human IL-7 antibodies. After 3 weeks,
culture progeny were harvested and then switched to a second human-only culture for
3 days under indicated culture conditions (IL-7 to IL-7, anti-IL-7 to anti-IL-7, or antiIL-7 to IL-7). After 3 days, switch cultures were harvested, stained to detect CD19, and
the level of CD19 expression (panel B) and the size (as indicated by FSC, panel C) of
gated CD19+ B lineage cells was determined by flow cytometry analysis. Histograms
depicting CD19HI and FSCHI gates from a representative experiment are shown. D)
Graphed are the percentages of total CD19+ cells that fall within CD19HI and FSCHI
gates (mean + SEM for 6 independent experiments; * = p > .05, ** = p > .01, *** = p >
.001, two-tailed paired t test
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Supplemental Data (Figure 8). Expression of B cell-specific transcripts by CD19+
cells produced in human-only cultures. Culture progeny generated in switch cultures as
described in Figure 4B (IL-7 to IL-7, anti-IL-7 to anti-IL-7, or anti-IL-7 to IL-7) were
harvested, stained for flow cytometry, and CD19+ B lineage cells were FACs-sorted.
cDNA was prepared from sorted cells and from primary pre-B ALL cells (pos. ctrl.).
Real time PCR to detect GAPDH (housekeeping gene), CD19, Pax-5, and EBF was
performed as described in “Materials and Methods.” (A) Shown are the CT values for
2 replicates of real time PCR amplification of indicated cDNAs from Pre-B ALL cells
and from B lineage cells generated in indicated switch cultures. (B) Melting curves for
final round (cycle 50) PCR products generated using primers to detect GAPDH,, CD19,
PAX-5, EBF as indicated above each plot. Each plot shows the superimposed melting
curves (multiple colors) for PCR products from Pre-B ALL (2 replicates), for FACSsorted B lineage cells generated in each of the switch culture conditions (2 replicates
each), and for a negative control that contained water and no cDNA (1 replicate, color
as indicated). Note that all melting curves peak at or near 86 to 88 degrees C as expected
for these primers. (C) Shown are additional replicates from independent experiments of
positive (Pre-B ALL) and negative control (water) samples using the PAX-5 primer pair
which consistently generated a primer artifact peak. The melting curve of the primer
artifact showed a consistent peak (~80 degrees C) that was easily distinguishable from
the melting curve peak observed in the positive control (~86 degree C) and in CD19+
cells generated in all culture conditions as shown in the lower left plot in panel B.
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IL-7 Directly Targets B Cell Precursors in Human-Only Cultures
To identify the cellular targets of IL-7 we used flow cytometry to examine IL7R expression among cells present during in vitro B lymphopoiesis (Figure 5A). IL7R was not detectable on primary human BM stromal cells used in co-cultures (Figure
5B).Approximately 35% of CD19+ B cell precursors produced in co-culture expressed
the IL-7R, regardless of whether they arose from HSCs in CB or adult BM or whether
IL-7 was present (Figure 5C and Figure 5D, right panel). We gated CD19– cells into a
CD34– subset that included more mature non B-lineage cells and into a CD34+ subset
that included HSCs and progenitors present in the 3-week human-only cultures. Of the
CD19–CD34– non B lineage cells generated from CB and BM HSCs in human-only
cultures, 3-12 % expressed the IL-7R (Figure 5C, left panel) while 4-14% of the of the
CD19–CD34+ HSC and progenitor subset was IL-7R+ (Figure 5C, middle panel). The
percentage of cells in each subset that expressed IL-7R was not significantly different in
cultures initiated with CB and BM HSCs, and the presence or absence of IL-7 activity
had no significant impact on the percentage of cells expressing the IL-7R in any of the
subsets (Figure 5D). These data show that CD19+ B cell precursors represent the major
IL-7R+ population in human-only cultures and are therefore a potential IL-7 target
during in vitro B cell development.
To determine if IL-7 acts directly on B cell precursors we used flow cytometry to
assess phosphorylation of STAT5, an event downstream of IL-7R signaling (Lin et al.,
1995). CD19+ B cell precursors were isolated from human-only cultures and assessed by
flow cytometry for purity (based on CD19 expression) and for IL-7Rexpression (Figure
5E, left panel) and then for STAT5 phosphorylation following incubation with or without

67

IL-7 (Figure 5E, right panel). Phosphorylated STAT5 was detected in B cell precursors
incubated with IL-7, but not in B cell precursors cultured without IL-7 (Figure 5E, right
panel).The percentage of B cell precursors positive for phosphorylated STAT5 following
incubation with IL-7 was virtually identical to the percentage of cells expressing IL-7R
(Figure 5E, compare left and right panels). These data provide evidence that B cell
precursors are directly targeted by IL-7 in human-only cultures.
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Figure 5 (Figure 9). IL-7 directly targets B lineage cells. (A) Human-only cultures were
initiated with FACS-sorted Lin–CD34+ HSCs from CB or BM under controlconditions
(3, F) and supplemented with anti-IL-7 neutralizing antibodies or exogenous human IL-7.
At 3 weeks culture progeny were harvested and stained for flow cytometry to detect coexpression of CD19, IL-7R and CD34. Cells were gated into CD19+, CD19–CD34– and
CD19–CD34– subsets as indicated. Plot shown is from a CB culture with IL-7. (B) Flow
cytometry analysis of IL-7R expression among primary human BM stromal cells used in
human-only cultures. Data is representative of flow cytometry analysis of stroma from
three different donors. (C) Flow cytometry analysis showing IL-7R vs. CD19 expression
for human-only cultures of CB or BM HSCs supplemented with IL-7. Insets show isotype
antibody control vs. CD19 staining. Plots are gated on lymphocyte light scatter (gates not
shown) and display equal numbers of cells. (D) The percentages of cells in indicated
subsets (gated as shown in panel A) that express IL-7R are graphed. Data are from 3week, human-only cultures of CB and BM HSCs supplemented with anti-IL-7 or IL-7 as
indicated. Percentages are the means + SEM of 5 (CB) or 3 (BM) independent experiments
with 8 and 6 total replicates, respectively. (E) Human-only cultures were initiated with
CD34+ HSCs from CB under control conditions supplemented with exogenous human IL7. At 3 weeks, culture progeny were harvested and CD19+ B lineage cells were isolated by
magnetic separation. Aliquots of purified B cell precursors were co-stained for expression
of CD19 and IL-7R or with isotype-matched control antibodies (left panel). Plots shown
are gated on events falling within lymphocyte light scatter. Quadrants were set based on
isotype control staining (inset) and percentages of cells in each quadrant are shown. The
remaining purified precursors, after a minimum of 3 hours removal from IL-7, were
incubated with or without exogenous human IL-7 for 1 hour and then stained for flow
cytometry with an antibody to detect phosphorylated STAT5 or an isotype-matched control
antibody as describe in “Materials and Methods”. The percentage of cells positive for
phospho-STAT5 staining, based on isotype control staining (overlay) are shown (right
panel). Data shown is representative of two independent experiments.
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IL-7-Induced Increases in B Cell Production are Mediated Through
Increased Proliferation of B Cell Precursors
To determine if increased cell survival is involved in the IL-7-induced increases
observed in our co-cultures, we examined the effect of IL-7 on apoptosis among culturegenerated human B cell precursors. Human-only cultures initiated with CB HSCs were
harvested at 3 weeks and CD19+ cells (either enriched or unseparated from CD19– cells)
were placed in co-culture with fresh human stroma and supplemented with anti-IL-7
neutralizing antibodies, control antibodies, or IL-7.Cells were harvested at daily time
points and flow cytometric analysis of staining with the Annexin V apoptosis indicator
was used to determine the percentages of CD19+ B cell precursors undergoing apoptosis.
IL-7 had no effect on the percentages of CD19+ that were Annexin V+, whether they
were in co-culture alone or together with CD19– cells (data not shown). Similarly IL-7
had no effect on apoptosis among in vivo-generated B cell precursors (CD19+K/L–) that
were FACS sorted from adult BM and assessed in identical assays (data not shown).
These results suggest that IL-7 does not mediate protection from apoptosis and that
increased survival of CD19+ B cell precursors is unlikely to be a major mechanism by
which IL-7 increases human B cell production.
To determine if increased proliferation is a mechanism for IL-7-induced increases
in human B cell production, we used flow cytometry to examine expression of the Ki-67
proliferation antigen in cells harvested from human-only cultures supplemented with IL-7
or with anti-IL-7 neutralizing antibodies (Figure 6A). IL-7 did not change the percentage
of CD19– cells that were Ki-67+ in cultures of CB or BM HSCs (Figure 6A, B). In
contrast, in
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CB cultures the percentage of CD19+ cells expressing the Ki-67 was significantly higher
with IL-7 supplementation (Figure 6B). Cultures of BM HSCs generated too few B cell
precursors to be assessed for Ki-67 when anti-IL-7 antibodies were added. However, the
percentage of B cell precursors expressing Ki-67 was the same in CB and BM cultures
with IL-7 (Figure 6 A, B).
To verify that the increases in proliferation observed in cultures supplemented
with IL-7 were due to the direct action of IL-7 on B cell precursors, we compared Ki-67
expression (Figure 6C) and size (indicated by FSC, Figure 6D) in IL-7R+ and IL-7R–
B cell precursors generated in cultures with IL-7. For both CB and BM cultures, average
cell size and the percentages of cells expressing Ki-67 was significantly higher for IL7R+ than for IL-7R– B cell precursors. These data provide further evidence that IL-7
increases the production of human B lineage cells through increased proliferation due to
direct targeting of B cell precursors by IL-7.
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Figure 6 (Figure 10). IL-7-induced increases in the production of B lineage cells are
mediated through increased proliferation. Human-only cultures were initiated with
FACS-sorted Lin–CD34+ HSCs from CB or BM under control conditions (3, F) and
supplemented with anti-human IL-7 neutralizing antibodies or with exogenous human
IL-7. At 3 weeks, culture progeny were harvested, counted, and stained for surface
expression of IL-7R and/or the B lineage marker, CD19. Surface-stained cells were
fixed, permeabilized and stained with an antibody specific to the Ki-67 proliferation
antigen or an isotype-matched control antibody. (A) The plots shown are gated on living
cell light scatter and display equal numbers of cells. Gates shown were set based on
isotype control staining among CD19+ and CD19– cells (insets). (B) Graphed are the
percentages of CD19– (left panel) and CD19+ cells (right panel) positive for the Ki-67
proliferation antigen (mean + SEM) for n=5 (BM) and n=8 (CB) experiments. In cocultures with BM HSCs and with anti-IL-7 neutralizing antibodies, too few B cells were
generated to assess Ki-67 expression (ND, not done). (C, D) At 3 weeks co-cultures
supplemented with IL-7 were harvested, counted, and stained for surface expression of
IL-7R and/or the B lineage marker, CD19. Surface stained cells were fixed,
permeabilized and stained with an antibody specific to the Ki-67 proliferation antigen
or an isotype-matched control antibody. (C) The expression of Ki-67+ among gated
CD19+IL-7R– and CD19+IL-7R+ cells (gates not shown) are plotted in histograms (left
panels) and graphed (right panel). (D) The forward scatter (FSC, an indicator of cell
size) of gated (gates not shown) CD19+IL-7R– (shaded) and CD19+IL-7R+ (overlay)
cells are plotted in histograms (left panels). The relative forward scatter of CD19+IL7R+ cells as compared to CD19+IL-7R– cells is graphed in the panel at right. Data
shown in panels C and D are the mean + SEM for 5(CB) or 3 (BM) independent
experiments. (* p < .05;*** p < .001, paired t test).
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Expression of the IL-7R in Context of Human B Cell
Development In Vivo
To determine whether the IL-7 targets that we identified in our human-only
cultures are reflective of human B cell development in vivo, we examined the expression
of IL-7R in early B lineage cells that were generated in vivo in adult human bone
marrow. The average frequency of IL-7R+ cells among in vivo-generated B cell
precursors (CD19+K/L–) in adult human BM (Figure 7A, Table 1) was similar (32%) to
that observed for B cell precursors generated in vitro (35%) from HSCs in CB and adult
BM in human-only cultures (Figure 5C, D). The percentages of in vivo-generated
CD19+K/L– B cell precursors that we assessed in human subjects (Table 1) exhibited a
broad range in the percentage of cells that were IL-7R+ (17%-56%) and showed no
obvious correlation with age, gender, or race, suggesting that there is substantial natural
variation among adult individuals. Thus, the IL-7R+ population of B cell precursors
observed in human-only cultures is reflective of in vivo B cell development in adult
human BM and suggests a physiological role for IL-7 in human B cell development.
A substantial portion of the B cell precursors generated in human-only cultures
initiated with CB and BM HSCs were IL-7R–. This was also the case for CD19+K/L–
cells in adult BM. To determine if the expression of IL-7R correlated with the
expression of developmental markers during in vivo B cell differentiation we examined
IL-7R expression among developmental subsets of CD19+ K/L– B cell precursors
identified based on expression of CD34+ or cFigure 7B). The percentages of IL-7R+
cells were similar for all developmental subsets (c+, c–, CD34–, and CD34+) of
CD19+K/L– cells. Thus, the expression of IL-7Ramong B cell precursors produced in
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vivo does not appear to correlate with particular stages of development that can be
identified based on expression of CD34 or with successful rearrangement of the Ig heavy
chain as indicated by the expression of c (Figure 7B).

Figure 7 (Figure 11). The distribution of IL-7R+ cells in adult human B cell precursor
populations produced in vivo. (A) Primary adult human BM mononuclear cells, either
fresh or frozen and then thawed, were stained for flow cytometry to assess co-expression
of CD19, the kappa and lambda light chains, IL-7Rand either CD34 or the
cytoplasmic mu (c) Ig heavy chain. CD19+ B lineage cells falling within lymphocyte
light scatter (gates not shown) that were negative for the kappa and lambda light chains
(CD19+K/L–) were gated as shown (left panel) and the percentage of cells expressing
of IL-7R was determined (right panel, n=10).CD19+K/L– cells were gated into a
CD34+ and CD34– subsets (n=7) or into c– and c+ subsets (n=2). Percentages of
total CD19+K/L– or of the cells in each subset that were IL-7R are graphed.
Percentages are the mean + SD from the indicated (n) numbers of donors
.
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Table 1. Expression of IL-7R by in vivo-generated CD19+ K/L– B cell precursors

Donor
1
2
3
4
5
6
7
8
9
10
Avg

% IL-7R+
27.9
24.1
38.6
56.5
26.4
50.6
23.2
22.6
17.4
32.8
32.0

Age
----------49
25
25
22
25
22
20
19

Donor Information
Gender
Race
------------------------------Female
Caucasian
Male
Caucasian
Male
Caucasian
Female
African American
Male
Caucasian
Male
African American
Male
African American
Female
Caucasian

Precursor Populations Targeted by IL-7-Induced Expansion
in Human-Only Cultures
In the mouse, IL-7R signaling has been associated with distinct differentiation and
proliferation signals. Thus, while the expression of IL-7R may not correlate with
markers of development in CD19+ B cell precursors, it is possible that IL-7 may directly
target distinct developmental populations of IL-7R+ B lineage precursors for
proliferation or for differentiation. To identify the developmental targets of IL-7-induced
proliferation we examined IL-7-induced increases and expression of the Ki-67
proliferation antigen in four subsets that include developmentally sequential populations
of B cell precursors. FACS analysis of the cells present at 3 weeks in human-only
cultures was used to identify four populations (Figure 8A): 1) The most primitive IL-7R–
HSCs and progenitors (HSC) through which IL-7 effects might be indirectly mediated, 2)
IL-7R+ progenitors (IL-7R+ P) that would include the earliest CD19– lymphoid-
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committed progenitors that express the IL-7R(Hao et al., 2001) (Ryan et al., 1997) ; 3)
CD34+ pro-B cells (CD34+ B) and 4) CD34– pro-B cells (CD34– B).
Human-only cultures initiated with Lin–CD34+ cells from CB and BM and
supplemented with IL-7 showed significantly increased numbers of cells in the CD34+ B
and CD34– B subsets at three weeks when compared to cultures with anti-IL-7. The
relative numbers of CD34+ B cells increased by only 5 to 14-fold (CB and BM cultures
respectively) when IL-7 was present while CD34– B cells went up by 194 to 90-fold (CB
and BM cultures respectively). In contrast, the relative numbers of HSCs, and IL-7R+ P
were not significantly increased in cultures with IL-7 (Figure 8B). Consistent with the
IL-7 effects that we observed on cell numbers, CB cultures supplemented with IL-7
showed significantly higher percentages of Ki-67+ cells among the CD34+ B and CD34–
B, but not among the HSC or IL-7R+ P subsets (Figure 8C). The percentage of Ki-67+ B
cells among CD34– B cells in BM cultures was similar to that observed in CB cultures,
however there were too few CD19+ cells to assess in Ki-67 expression in any BM
cultures with anti-IL-7 or in the CD34+ B cells in BM cultures where IL-7 was present
(Figure 8C, right panel). Taken together these data provide evidence that IL-7 targets
both CD34+ and CD34– pro-B cells for increased proliferation. In contrast, in our culture
model we were unable to detect any significant changes in proliferation due to IL-7
effects among developmental subsets that would include CD19– B cell precursors.
In Figure 3 we showed that IL-7 is particularly critical for the production of B
lineage cells from adult BM because the capacity of adult BM to generate B lineage cells
is greatly reduced as compared to CB. To get a better understanding of the dynamics and
potential mechanisms that might be responsible for the changes in B cell development
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that occur during ontogeny, we compared the ability of CB and adult BM to generate the
developmental subsets observed in vitro in human-only cultures. In cultures with adult
BM the HSC generative capacity was about half, and the IL-7R+ P generative capacity
about 10 fold less than that observed for CB cultures (Figure 8D, Note the 10X scale
reduction in the right panel). In cultures with IL-7, the adult BM generative capacities
for cells in the CD34+ B and CD34– B subsets were ~40-fold and ~50-fold less,
respectively than those observed for CB. While BM cultures generated detectable CD19–
subsets, and the capacity to generate these cells was unaffected by IL-7, B lineage
precursors that reached the CD19+ stage of development were essentially absent in
cultures with anti-IL-7. These data suggest that there is a progressive loss of generative
capacity during the course of B lineage differentiation in adult BM, as compared to CB
and that as a consequence of this reduced B lineage generative capacity, IL-7 is more
critical for B cell development from HSCs in adult B and that as a consequence of this
reduced B lineage generative capacity, IL-7 is more critical for B cell development from
HSCs in adult BM.
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Figure 8 (Figure 12). Precursor populations targeted by IL-7-induced expansion. A)
Flow cytometry analysis of human-only cultures was used to identify four subsets of
cells that include developmentally sequential precursors to mature B cells: HSCs and
IL-7R– Progenitors (HSC), IL-7R+ progenitors (IL-7R+ P), CD34+ pro-B cells
(CD34+B), and CD34– pro-B cells (CD34–B). Surface immunophenotypes used to
identify each population in human-only cultures are indicated at the bottom of the panel.
Human-only cultures initiated with Lin–CD34+ cells from CB and BM and
supplemented with anti-IL-7 or with exogenous IL-7 were harvested at 3 weeks, and
counted and stained for flow cytometry to detect surface CD19, CD34, IL-7R and an
additional surface or intracellular marker. Cells in each subset were gated as shown in
Figure 5A, C and based on isotype control staining. (B) Relative numbers of cells in
each subset were determined as described in “Materials and Methods”. Data graphed
are the increases in relative numbers of cells in each subset in cultures supplemented
with exogenous IL-7 as compared to cultures supplemented with anti-IL-7 neutralizing
antibodies. Data shown are from 3 independent experiments and 6 total replicates. (C)
The percentage of cells in each gated subset that are positive for expression of the Ki67 proliferation antigen are graphed. Data shown are the means + SEM obtained from
3-7 independent experiments (D) The ability of CB and BM Lin–CD34+ cells to
generate cells in each subset under indicated conditions was determined by dividing the
absolute numbers of progeny in each subset, generated at 3 weeks, by the number of
Lin–CD34+ HSCs plated at culture initiation. Data shown were obtained from 3
independent experiments and 6 total replicates (HSC, IL-7R+ P) or from 6 independent
experiments (CD34+ B and CD34– B). (* p < .05, ** p <. 01, *** p < .001, **** p <
.0001, two-tailed paired t test).
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Discussion
Defining the role of IL-7 in human B cell development has been difficult for
several reasons. First, most early studies of IL-7 and human B cell development used
fetal hematopoietic sources. This is particularly relevant as subsequent murine studies
revealed that IL-7-dependent B lymphopoiesis is linked with ontogeny–only in the adult
mouse does B cell development become dependent on IL-7. Thus, differences in fetal and
adult B cell development have been interpreted as fundamental differences in mouse and
human B lymphopoiesis. Second, studies of humans that are defective in components of
the IL-7R signaling pathway are hampered by limitations in the number, type, and
quantity of specimens available for assessment of IL-7 function. Third, studies of
nonfetal B lymphopoiesis were hampered by the lack of an in vitro model of human B
cell development that reconstitutes the human BM stroma microenvironment without the
confounding factors introduced by murine stromal cell lines. Here we describe a novel
human-only model of in vitro B cell development based on co-culturing HSCs on
primary human BM stroma. We used this model to examine the role of IL-7 in human B
lymphopoiesis from HSCs in adult BM and from the HSCs in CB that give rise to B cells
during the neonatal period.
Using the human-only culture model we show that IL-7 increases the production
of human B cell precursors from HSCs in CB and adult BM by more than 60-fold as
compared to cultures with anti-IL-7 neutralizing antibodies (Figure 3). IL-7-induced
increases were dose-dependent (Figure 1E), specific to CD19+ cells (Figure 1E and 5),
and mediated through increased proliferation (Figure 6), but not increased cell survival
(data not shown). Expression of the IL-7Rand the induction of STAT5 phosphorylation
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following stimulation with IL-7 (Figure 5) indicate that IL-7 acts directly on CD19+c–
cells present in 3-week human-only cultures (Figure 1) to expand both the CD34+ and
CD34– pro-B cell compartments (Figure 8).
The IL-7-induced increases in B cell precursors that we observed in human-only
cultures were not detectable in hybrid cultures where human HSCs were co-cultured on
murine S17 or MS-5 stromal cell lines (Figure 1, 2). The absence of IL-7 effects that we
and others (Rawlings et al., 1995) (Nishihara et al., 1998) have observed in hybrid
cultures is likely due to high IL-7 production by MS-5 and S17 stromal cell lines (>40fold that of primary human or murine BM stroma [Figure 2]) since human B cell
production was reduced up to 17 fold (Figure 2A) by high levels of anti-mouse IL-7
neutralizing antibodies. Thus, the human-only model revealed IL-7 effects on human B
cell development that were not easily detectable in hybrid human-mouse co-cultures.
A critical role for IL-7 in adult B cell development has been demonstrated in vivo
in the mouse model (von Freeden-Jeffry et al., 1995)-(DiSanto et al., 1995; Peschon et
al., 1994). IL-7 expression by primary murine BM stroma (Figure 2) and the level of IL7 that elicits in vitro B cell precursor responses (1 ng/ml) in the mouse (Medina &
Kincade, 1994) are consistent with what we see during in vitro human B cell
development (Figure 1, 2). The expression of IL-7R by B cell precursors (Figure 7) and
of IL-7by stromal cells (Figure 5) in primary human BM suggests that the IL-7 effects
we observe in vitro are physiologically relevant for in vivo human B cell development.
Indirect evidence for the in vivo role of IL-7 in human B cell development comes from
patients with T cell lymphopenia in whom endogenous IL-7 is upregulated and expansion
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of the immature B cell pool correlates with increased serum levels of IL-7 (Malaspina,
Moir, Ho, et al., 2006), (Malaspina, Moir, Chaitt, et al., 2006).
Data obtained using our human-only culture model provide the first evidence that
human B cell production from HSCs in adult BM is dependent on IL-7. Robust IL-7independent B cell production has been reported in human fetal BM (J. A. Pribyl &
LeBien, 1996). In the absence of IL-7, we observed that HSCS in CB, but not BM
consistently give rise to a small population of CD19LO B lineage cells (Figure 3) that
express EBF and PAX-5 at three weeks and differentiate to generate very small numbers
of IgM+ B cells at 5 weeks (Figure 1). When switched to IL-7 at 3 weeks, CD19LO cells
generated in the absence of IL-7 respond by upregulating CD19 and exhibiting increased
cell size that is characteristic of cycling cells (Figure 4B-D). Studies of B cell
development in the mouse model suggest that IL-7-independent expression of EBF
allows early B lineage differentiation (but not expansion unless IL-7 is present) during
the fetal and neonatal period. This results in what has been described as a
“developmental switch” in stem cells with IL-7-independent B cell production occurring
through the first two weeks of neonatal life, but not in the adult (Kikuchi & Kondo,
2006). Our data showing that human B cell development from HSCs in adult BM is IL-7dependent, coupled with our characterization of B lineage cells generated from CB in the
absence of IL-7, provide the first evidence that that such a “developmental switch” may
also occur in human B lymphopoiesis.
We found that adult BM, as compared to CB, shows a reduction of in vitro
generative capacity that is progressively more profound in developmentally sequential
populations (Figure 3, 8). The ability of adult BM to generate HSCs, IL-7R+ progenitors,
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and pro-B cells after 3 weeks in human-only cultures with IL-7 was reduced by half, 10and 50-fold, respectively, of that observed for CB (Figure 8D). Indeed the CD19+
generative capacity of BM HSCs in the presence of IL-7 was similar to that of CB HSCs
in the absence of IL-7 activity (Figure 3). The B lymphoid-specific decrease in generative
capacity that we observed for human HSCs in adult BM, as compared to CB, is consistent
with a selective loss of B lymphoid generative capacity observed in xenograft transplant
models and in the clinical transplant setting (Arakawa-Hoyt et al., 1999; Inoue et al.,
2003).
The decline in IL-7-dependent B lymphoid generative capacity that we have
observed in adult versus fetal B cell development suggests, that a mechanism other than
the “developmental switch” observed in the mouse model may contribute to the decline
in IL-7-independent B cell production that occurs during the progression to adulthood. It
is possible that IL-7-induced expansion of the pro-B compartment (absent in the IL-7indepdent B cell production observed by Kikuchi et al.) is essential for B lymphopoiesis
from adult HSCs because of their reduced generative capacity. Further studies will be
needed to determine the extent to which the decline in B cell generative capacity
contributes to the loss of IL-7-independent B lymphopoiesis in adult humans and mice
and whether B cells arising from IL-7-dependent and IL-7-independent pathways in
humans are functionally distinct.
In summary, data obtained using our human-only culture model provide the first
evidence that B cell development from HSCs in adult BM is dependent on IL-7 and
characterize the progressive decline in developmentally sequential populations of B cell
precursors that correlates with B cell production that is the dependent on IL-7. These
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studies have implications for immune reconstitution following stem cell transplant with
CB versus BM in the clinical setting.
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Abstract
The cytokine, TSLP, stimulates in vitro proliferation of human fetal B cell precursors,
however, its in vivo role during normal human B lymphopoiesis is unknown. Genetic alterations
that cause overexpression of the TSLP receptor component, CRLF2, lead to B cell acute
lymphoblastic leukemia (CRLF2 B-ALL), implicating the TSLP-CRLF2 pathway in
leukemogenesis. The utility of classic patient-derived xenografts (PDX) for in vivo studies of the
TSLP-CRLF2 pathway in normal and malignant human B lymphopoiesis are limited because
available data suggest that mouse TSLP does not activate human CRLF2-mediated signals. First,
we show that mouse TSLP does not induce activation of CRLF-2 downstream pathways
(JAK/STAT5 and PI3K/AKT/mTOR) that are activated by human TSLP (hTSLP) in CRLF2 BALL cells. Next, we engineered xenograft mice to produce hTSLP (+T mice) by injection with
stromal cells transduced to express hTSLP. Control (–T) mice were produced using stroma
transduced with control vector. Normal serum levels of hTSLP were achieved in +T mice, while
hTSLP was undetectable in –T mice. PDX generated from +T as compared to –T mice showed a
3-6 fold increase in normal human B cell precursors that was maintained through later stages of B
cell development. Gene expression profiles in CRLF2 B-ALL from +T PDX indicate increased
mTOR pathway activation and are more similar to the original patient sample than those from –T
PDX. The novel +T/–T xenograft model developed here provides a preclinical model for
understanding the TSLP-CRLF2 pathway in B lymphopoiesis and identifying treatments for
CRLF2 B-ALL.
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Introduction
TSLP is an IL-7-like cytokine that plays key roles at several points in normal
hematopoietic cell development and function.(Ito et al., 2005; Siracusa et al., 2011; Ying et al.,
2005; Zhou et al., 2005) The role of TSLP in B lymphopoiesis has been evaluated almost
exclusively in mice.(Osborn et al., 2004; Ray, Furlonger, Williams, & Paige, 1996; Reche et al.,
2001; Sims et al., 2000) Knowledge of TSLP in normal human B-cell development is limited to a
single in vitro study showing that TSLP increases production of fetal B cell precursors.(Scheeren
et al., 2010) Genetic alterations that cause overexpression of the TSLP receptor component,
CRLF2, have been linked to B cell acute lymphoblastic leukemia (ALL), thus implicating the
TSLP pathway in leukemogenesis (Cario et al., 2010; Chapiro et al., 2010; Russell et al., 2009;
Yoda et al., 2010). The low homologies of murine and human TSLP and CRLF2
(~40%)(Quentmeier et al., 2001; Tonozuka et al., 2001) suggest the need for novel models to
study the in vivo role of TSLP in normal and malignant human B lymphopoiesis.
ALL is the most common childhood malignancy and primarily involves the B-lineage (BALL). Although cure rates approach 90%, approximately 10-20% of patients still relapse.(Hunger
et al., 2012; Raetz & Bhatla, 2012) Genomic profiling has identified several high-risk B-ALL
subtypes that are chemo-resistant. (Chen et al., 2012; Mullighan, 2011; Mullighan et al., 2009;
Mullighan et al., 2007) Included is CRLF2 B-ALL, a leukemia with genetic alterations causing
over-expression of the CRLF2 protein on the surface of B-ALL cells.(Cario et al., 2010; Chapiro
et al., 2010; Russell et al., 2009; Yoda et al., 2010) CRLF2 and the IL-7 receptor alpha chain (IL7R) together form the TSLP receptor signaling complex (Figure 1A).(Park et al., 2000; Reche et
al., 2001) Binding of TSLP induces CRLF2 and IL-7R dimerization leading to activation of the
JAK-STAT5(Rochman et al., 2010; Wohlmann, Sebastian, Borowski, Krause, & Friedrich, 2010)
and the PIK3/AKT/mTOR pathways, (Zhong et al., 2012; Zhong et al., 2014) as demonstrated in
CRLF2 B-ALL. (Tasian et al., 2012) The finding that JAK kinases are mutated in CRLF2 B-
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ALL(Harvey et al., 2010) suggested that CRLF2 and mutated JAK cooperate to induce
constitutive STAT5 activation in CRLF2 B-ALL.(Malin et al., 2010; Roll & Reuther, 2010)
However, approximately half of CRLF2 B-ALL, lack JAK mutations. Thus, the role of TSLP in
the leukemogenesis of CRLF2 B-ALL remains unclear and the mechanisms for its contribution to
chemoresistance are unknown.
The genetic landscape produced by inherited germline variations contributes to
leukemogenesis and disease outcome (Moriyama, Relling, & Yang, 2015) and is a biological
component that contributes to racial, ethnic and other health disparities in ALL (Lim, Bhatia,
Robison, & Yang, 2014). This is particularly relevant in CRLF2 B-ALL which occurs five times
more often in Hispanic children than others (Harvey et al., 2010) and comprises more than half of
the ALL cases in children with Down Syndrome (Hertzberg et al., 2010; Mullighan et al., 2009;
Russell et al., 2009). Patient-derived xenograft (PDX) models produced by injecting human cells
into immune deficient mice provide in vivo preclinical models for understanding disease
mechanisms and identifying effective therapies in context of the range of genetic landscapes
present in the human population. However, engineered cellular models (Reche et al., 2001)
suggest that mouse TSLP (mTSLP) is species-specific and unlikely to stimulate CRLF2-mediated
signaling in human cells (Park et al., 2000; Reche et al., 2001). Given the role of TSLP in
activating the CRLF2 pathway (Tasian et al., 2012) and the identification of CRLF2 as a
biological component of health disparities in CRLF2 B-ALL (Harvey et al., 2010; Hertzberg et
al., 2010; Mullighan et al., 2009; Russell et al., 2009), it is important that studies to identify
disease mechanisms and potential therapies for this leukemia be performed in preclinical models
that provide human TSLP (hTSLP).
Our goal was to develop and validate a xenograft model that can be used to study the role
of hTSLP in normal and malignant B-lymphopoiesis. Here we describe the development of a
novel xenograft model system comprised of mice that provide hTSLP (+T mice) and mice that do
not (–T mice). PDX generated from +T mice show functional in vivo hTSLP effects, expanding
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the production of normal B cell precursors from hematopoietic stem cells (HSCs) and inducing
changes in mTOR-regulated gene expression in primary CRLF2 B-ALL cells. These data validate
the +T/–T xenograft model system as an important new preclinical model for understanding the
role of hTSLP in normal and malignant B lymphopoiesis and for identifying therapies to treat
CRLF2 B-ALL.

Materials and Methods
Additional details are available in the Online Supplementary Methods.

Human Samples and Cell Lines
Human CRLF2 B-ALL cell lines MUTZ5 and MHH-CALL4 were from DSMZ
(Braunschweig, Germany) and the human stroma line HS-27a (HS27) from ATCC, (Manassas,
VA). Primary human CRLF2 B-ALL cells (Online Supplementary Table 1 and) and umbilical
cord blood (CB) were obtained in accordance with protocols approved by the Loma Linda
University Institutional Review Board (IRB) and with the Helsinki Declaration of 1975, as
revised in 2008. Details of HS27 stroma characteristics, CB CD34+ cell isolation, and culture
media are described in the Supplementary Methods.

Mice
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson
Laboratory) housed under pathogen-free conditions at Loma Linda University Animal Care
Facility. Studies were conducted in accordance with Loma Linda University Institutional Animal
Care and Use Committee (IACUC) approved protocols.
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Flow Cytometry
Cells were prepared for flow cytometry using specific antibody clones as described in
Supplementary Methods. Flow cytometry analysis was performed using a MACSQuant analyzer
(Miltenyi Biotec, Inc, Auburn, CA) and FlowJo analysis software (FlowJo, Ashland, OR).

Stromal Cell Transduction
Human HS27 stromal cells were transduced to express hTSLP (+T stroma) or with
control vector (–T stroma) at a multiplicity of infection of 0.5-5/cell overnight. After
transduction, cells were washed, expanded in culture, and frozen in aliquots. For the generation of
+T and –T mice, stromal cells were thawed, cultured, and injected into mice within 15 passages
after thawing. Details of lentiviral vector production and ELISAs to determine hTSLP levels are
available in Supplementary Methods.

Xenograft Transplantation
HS27 stroma transduced to be +T or –T were injected intraperitoneally into NSG mice at
doses of 5 or 10x106 cells at time points described in Results section. Mice were sub-lethally
irradiated with 225 cGy, then transplanted by tail vein injection with freshly thawed human
umbilical CB CD34+ cells (1x105) or primary CRLF2 B-ALL cells (5x105 Patient 1 and 1.5 x106
Patient 2).

Gene Expression Analysis in CRLF2 B-ALL Cells
Microarray analyses were performed by Miltenyi Biotec’s Genomic Services (Miltenyi
Biotec GmbH, Bergisch Gladbach) using Agilent Whole Human Genome Oligo Microarrays
(Design ID 039494, 8x60K v2). Libraries for RNA sequencing were prepared and sequenced by
the UCLA Clinical Microarray Core. Data discussed in this publication are deposited in NCBI's
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Gene Expression Omnibus (GEO).(Edgar, Domrachev, & Lash, 2002) Microarray and RNA
sequencing data are available through accession numbers GSE65274 and GSE74339 respectively
at (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSExxx). Gene Set Enrichment
Analysis (GSEA) was performed by Novogenix Laboratories, LLC (Los Angeles, CA). Details of
microarray, RNA sequencing, data processing, differential gene expression analysis, GSEA, and
quantitative RT-PCR analysis are in the Supplementary Methods.

Online Supplementary Methods
Cells and Cell Culture Media
The human stromal cell line HS-27a (HS27) was selected for use in our model
because 1) HS27 is one of a limited number of human bone marrow-derived stromal cell
lines; 2) HS27 secretes low levels of growth factors that do not support proliferation of
isolated progenitor cells in cocultures1; and 3) our laboratory has found that HS27 grow
robustly in culture. HS27 stroma were maintained in RPMI 1640 medium (Irvine
Scientific) supplemented with penicillin/streptomycin, L-glutamine, 50 μM 2-ME and
10% FBS (Omega Scientific). MUTZ5 and MHH-CALL4 were maintained in RPMI
1640 medium (Irvine Scientific, Santa Ana, CA) supplemented with
penicillin/streptomycin, L-glutamine, 50 μM 2-ME and 20% FBS (Omega Scientific,
Tarzana, CA). This media was also used for in vitro cultures with and without TSLP
(both for phosphoflow assays and for gene expression profiling in response to TSLP).

Flow Cytometry
For detection of surface antigens, cells were stained using standard flow
cytometry protocols, followed by fixation and permeabilization as described below to
detect intracellular antigens. To assess intracellular IgM, the Fix & Perm® cell fixation
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and permeabilization kit (Life Technologies, Grand Island, NY)) was used according to
manufacturer’s instructions. To discriminate living from dying cells, in some
experiments, cells were stained with fixable viability dyes (eBioscience, San Diego, CA),
per manufacturer’s instructions. All antibodies were monoclonal, anti-human antibodies,
unless otherwise stated. Specific antibody clones and conjugates are shown below.
Antibody
Ig κ light chain FITC

Clone
G20-193

Ig λ light chain FITC
CD66b FITC
CD34 APC
CD56 PE
CD79a PE
IgM PE.Cy-5
Anti-Phospho AKT (pS473) Alexa Fluor 488
Anti-phospho STAT5 (pY694) PE

JDC-12
G10F5
8G12
MY31
HM47
G20-127
M89-61
47/Stat5 (pY694)

Anti-Phospho S6 (pS235/S236) Alexa Fluor 488
CD10 APC.Cy7
CD14 APC
CD19 APC
CD19 Pacific Blue
CD34 PerCP

N7-548
HI10A
M5E2
HIB19
HIB19
581

CD38 Brilliant Violet 421
Ig κ light chain Pacific Blue
Ig λ light chain Pacific Blue
IgD PE
TSLPR APC
CD19 APC

HIT2
MHK-49
MHL-38
IA6-2
1B4
HIB19

CD19 PE.Cy7
CD45 PE.Cy7
Ig κ light chain eFluor 450
Ig λ light chain eFluor 450
CD19 APC
CD29 PE

SJ25C1
HI30
TB28-2
1-155-2
LT19
TS2/16

CD90 APC
CD127 PE (IL-7Ra)
Anti-Mouse CD45 FITC

DG3
MB15-18C9
30F11
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Manufacturer
BD Pharmingen
(San Jose, CA)
BD Biosciences
(San Jose, CA

BioLegend
(San Diego, CA)

eBioscience
(San Diego, CA)

Miltenyi Biotec
(Auburn, CA)

Statistical Analysis
Statistical analysis was performed using Students t test and data expressed as
mean ± SEM. Statistical significance was defined as p<0.05.

Phospho-Flow Cytometry Staining
Human CRLF2 B-ALL cell lines were harvested from continuous culture and
primary CRLF2 B-ALL cells were obtained as BM from patient-derived xenografts. Cells
were rested in culture without cytokines for 2 hrs, and then cultured with mTSLP, hTSLP
or no cytokine for 30 mins (S6 and AKT) or 1 hour (STAT5). Cells were then harvested
and stained with antibody to phosphorylated STAT5 (pSTAT5), AKT (pAKT) or S6
(pS6) as previously described for STAT5 (Parrish et al., 2009). Primary CRLF2 B-ALL
patient-derived samples were also stained with CD19 APC prior to fixation and
permeabilization for detection of phospho proteins and CD19+ cells were gated for
phospho-flow cytometry plots.

ELISA Assays of TSLP
Concentrations of hTSLP in the supernatant of transduced HS27 stromal culture
and in sera collected from NSG mice injected with transduced stroma were measured
using the Human TSLP ELISA MAX Kit (BioLegend, San Diego, CA). Stromal cell
supernatants were harvested from confluent flasks when stromal cells were passaged
(typically two times per week) and sera was obtained from mice at weekly time points at
the time of weekly stromal cell injection. Data was collected using the uQuant microplate
spectrophotometer (BioTek Instruments Inc., Winooski, VT) and analyzed using the KC
Junior, version 1.6 (BioTek Instruments, Inc., Winooski, VT)
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Lentivirus Vector and TSLP-Expressing Human Stromal Cells
TSLP vector was generated using standard molecular cloning techniques with
complementary DNA encoding human TSLP (purchased from Thermo Scientific Open
Biosystems). In this vector, the EF-1α promoter was used to drive TSLP expression. A
control vector with GFP was also generated. The lentiviral vector packaging and titering
were performed as previously described (Meng et al., 2012). In brief, VSV-G–
pseudotyped lentiviral vectors were prepared by calcium phosphate–mediated 3-plasmid
transfection of 293T cells. Briefly, 27 µg transfer vector construct, 17.5 µg secondgeneration gag-pol packaging construct pCMV.R8.74, and 9.5 µg VSV-G expression
construct pMD2.G were used for transfection of 12x106 293T cells overnight in 25 ml
DMEM with 10% fetal bovine serum. The cells were treated with 10 mM sodium
butyrate during the first of three 12-hour vector supernatant collections. The supernatant
was filtered through 0.22-µm-pore-size filters and concentrated 100-fold by
ultracentrifugation before freezing and storing at –80° C. All vector stocks were titered
by transducing HT1080 cells with analysis for GFP expression by flow cytometry or realtime PCR.
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Processing of Samples from Xenograft Mice
Flow cytometry analysis of peripheral blood (PB) was used to establish
chimerism with human cells prior to euthanasia. PB was collected using tail-tip excision
(tail nick) and placed into a microtainer serum separator tube (BD Gold, 200/cs). Samples
were centrifuged at 1500 rpm for 15 mins. Serum was removed for ELISA analysis.
Blood cells were subjected to red blood cell lysis (Kang et al., 2002) and remaining white
blood cells were stained for human surface markers. NSG mice were euthanized 5-7
weeks after CB CD34+ transplantation or 12 weeks after CRLF2 B-ALL transplantation.
On the day of euthanasia fresh bone marrow (BM), spleen and PB were harvested. Single
cell suspensions were obtained from the BM by using 26g syringe and PBS to flush the
femora and humeri and by filtering cells with a 70 micron cell strainer (BD Biosciences,
San Jose, CA). Cells obtained from all tissues were stained immediately for flow
cytometry analysis or were frozen for future use.

Microarray Analysis of Gene Expression in CRLF2 B-ALL Cells
Mice engineered to be +T and –T by stromal cell injection were transplanted with
primary CRLF2 B-ALL cells from a Hispanic pediatric patient. Following transplant,
mice received weekly intraperitoneal injection of 5X106 +T or –T stroma from
Transduction 1 (see Results section). Nine weeks post transplant, BM was harvested and
frozen for later use. For microarray to evaluate in vivo TSLP-induced changes in gene
expression, xenograft BM was thawed and human B-ALL cells were isolated by
magnetic separation using the Human CD19 microbead kit (Miltenyi Biotec, Inc., San
Diego, CA) according to manufacturer’s protocol and rapidly frozen on dry ice (Samples
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E1-E3 and F1-F3 described below). For microarray to evaluate in vitro TSLP-induced
changes in gene expression (Fig. 4), xenograft BM was thawed and cultured in vitro for 3
days with TSLP at 15ng/ml or without TSLP and with neutralizing anti-TSLP antibody
(R&D Systems, Minneapolis, MN) or control antibody (Jackson ImmunoResearch).
Following culture, cells were harvested and thawed and human B-ALL cells were
isolated by magnetic separation using the Human CD19 Microbead Kit according to
manufacturer’s protocol and rapidly frozen on dry ice (samples A1-A3, B1-B3, C1-C3
and D1-D3 as described below). Frozen cells were shipped to Miltenyi Biotec (Miltenyi
Genomic Services) for RNA isolation, sample preparation, whole genome microarray,
and discriminatory gene analysis (DGA) as follows:

Total RNA Isolation
Human total RNA was isolated using the NucleoSpin® RNA kit (MachereyNagel, Bethlehem, PA). RNA quality and integrity were determined using the Agilent
RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA). RNA was quantified by measuring A260nm on the ND-1000
Spectrophotometer (NanoDrop Technologies, Wilmington, DE).

RNA Amplification and Labelling
Sample labelling was performed as detailed in the “One-Color Microarray-Based
Gene Expression Analysis protocol (version 6.6, part number G4140-90040). Briefly, 50
ng RNA for the samples from groups A, B, E and F, 10 ng RNA for the samples of group
C and D, and the complete available amount of RNA for the samples C3 and D1 was
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used for the amplification and labelling step using the Agilent Low Input Quick Amp
Labelling Kit (Agilent Technologies). Yields of cRNA and the dye-incorporation rate
were measured with the ND-1000 Spectrophotometer (NanoDrop Technologies).
Microarray Sample Key

Sample

Source of Cells

E1, E2, E3

CRLF2 B-ALL cells from +T mice

F1, F2, F3

CRLF2 B-ALL cells from –T mice

Hybridization of Agilent Whole Human Genome Oligo Microarrays
The hybridization procedure was performed according to the “One-Color
Microarray-Based Gene Expression Analysis protocol (version 6.6, part number G414090040) using the Agilent Gene Expression Hybridization Kit (Agilent Technologies).
Briefly, 0.6 µg Cy3-labeled fragmented cRNA in hybridization buffer was hybridized
overnight (17 hours, 65 °C) to Agilent Whole Human Genome Oligo Microarrays 8x60K
v2 (AMADID 039494) using Agilent’s recommended hybridization chamber and oven.
Following hybridization, the microarrays were washed once with the Agilent Gene
Expression Wash Buffer 1 for 1 min at room temperature followed by a second wash
with preheated Agilent Gene Expression Wash Buffer 2 (37 °C) for 1 min.

Scanning and Data Analysis
Fluorescence signals of the hybridized Agilent Microarrays were detected using
Agilent’s Microarray Scanner System G2505C (Agilent Technologies). The Agilent
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Feature Extraction Software (FES) 10.7.3.1 was used to read out and process the
microarray image files.

Gene Set Enrichment Analysis
Microarray data was evaluated at the level of gene sets to define and quantitate
trends in gene expression similar to published data. Ranked gene lists were created and
submitted to the online public repository provided by the BROAD Institute for Gene Set
Enrichment Analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005) to evaluate
Oncogenic Signatures that are enriched in CRLF2 B-ALL cells expanded in +T as
compared to –T mice (www.broadinstitute.org/gsea).

Discriminatory Gene Expression Analysis
After probe summarization, quantile normalization and log2 transformation,
differentially expressed genes were identified by a combination of effect size and
statistical significance. For the analysis of the individual comparisons, only reporters with
an at least two-fold median up- or downregulation in +T samples compared to –T
samples and an adjusted p-value (Student’s t-test, two-tailed, equal variance, BenjaminiHochberg correction for multiple testing) p≤0.05 were considered relevant. In an
additional filtering step, only Agilent reporters with signal intensity values significantly
above local background (p<0.01 as calculated by the Rosetta Resolver® gene expression
data analysis system) in at least two samples of the group with higher median expression
were selected (Weng et al., 2006). All microarray data reported in this publication were
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deposited in the NCBI’s Gene Expression Omnibus at National Center for Biotechnology
Information and are accessible via the GEO series accession number GSE65274.

Real Time Quantitative RT-PCR
Expression of select genes observed in microarray results was validated using
quantitative reverse transcriptase - polymerase chain reaction (qRT-PCR) using primers
shown below. Total RNA (2.0μg) was reverse transcribed using poly d(T)20 primers and
SuperScript II reverse transcriptase (Life Technologies, Grand Island, NY). The resulting
cDNAs were used for qRT-PCR analysis of their mRNA levels on a StepOne Plus 7500
Real-time PCR system (Applied Bioscience Inc., Foster City, CA) using specific primers
for each gene (see supplemental table 2 for primer sequences) following the
manufacturer's instructions. The fluorescence threshold value was calculated and
normalized to the values of 18s rRNA. The fold change in mRNA expression of genes
between the TSLP-treated W31 cell group versus untreated group was achieved by the
ratio of fluorescence threshold value in the treated groups versus that of the untreated
group. The fold change for each gene was paired with that of microarray analysis. Linear
regression analysis of the fold change versus that of microarray was performed with
Origin 6.0. The graph shows the best-fit line, the formula for the best-fit line (Y = a +
bX), its correlation coefficient (r), and the probability (P) that the r value is a false
positive.
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Gene
BIVM
PTH2
FOSL2
RAMP1
SLC4A8
NR4A2
KCNH8
THSD7A
RAB26
RGS1
NELL1
MDF1
KREMEN2
CPNE8

Forward Primer
5’-GGCCAGAGGCAATGCAAAG
5’-CTGGTTCTCCACAGGTGATG
5’-AACACCCTGTTTCCTCTCCG
5’-GCAGGACCATCAGGAGCTACA
5’-TGGGTCCAGTAGGGAAAGGT
5’-GTAACTCGGCTGAAGCCATGC
5’- GCAAGATCAATTTGCATCCACTAT
5’- CCATCTCGAGTCTTTGTTCACATT
5’-CCAGGCCCTTCTGACTTTGT
5’-CTCCCTGGGTGAACAGCTTG
5’-GATATGAAGCCACCCGTGTT
5’-GAAGTTGCAGACACACCCATCTC
5’-TGAGGACCCAGAGGCCC
5’-CGCCTCCTCCCAATATGGAC

Reverse Primer
5’-TGAGGTCTAATACTTTCCGCTGT
5’-CATGTACGAGTTCAGCCACT
5’-ATCTACCCGGAATTTCTGCGG
5’-GCCTACACAATGCCCTCAGTG
5’-ACCGTCACCTGGTCTAGGAA
5’-GTCGTAGCCTGTGCTGTAGTT
5’- AAGGCAGGGCAGCGATTA
5’- CATTTGGGAATTGTGCTTCTCA
5’-CTGCTTGTTGGGACTGTTGC
5’-GCTTCTTCAACTCTGCGCCT
5’-CTGAAGGTCAGGGTCCATCC
5’-GTCCAGGACGATGTTGCACAG
5’-CAGACAGCTCCCCCAATCG
5’-ATTTCTGCAGGACACGGACA

RNA Sequencing and Analysis of Gene Expression in
CRLF2 B-ALL Cells
RNA libraries were prepared for sequencing by the UCLA Clinical Microarray
Core using TruSeq kits (Illumina). Libraries were sequenced on a HiSeq 2000/2500 at 1
X 50 bp. Transcript levels were estimated using RNA-Seq by Expectation Maximization

(Li & Dewey, 2011); Reads were mapped to the human genome (hg19) using
RefSeq annotation. Pairwise differential expression assessments were performed using
the method EBSeq(Leng et al., 2013); genes were considered to be differentially
expressed based on a False Discovery Rate of less than 5% (Posterior Probability of
being Differentially Expressed < 0.05). Gene Ontology (GO) analysis was performed
using DAVID. Gene Set Enrichment Analysis (GSEA) was performed using MSigDB.
Ranked lists of genes having a fold change of greater than 1.5 were used as input for
GSEA. The transcript per million (TPM) values from respective samples were clustered
using hierarchical clustering with R. Spearman rank correlation was used as the distance
metric followed by average linkage clustering.
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Results
Mouse TSLP does not Activate the Human TSLP Receptor Complex
Activation of the human TSLP receptor complex can be induced by hTSLP, but
not by mTSLP, in murine Ba/F3 cells transduced to express human CRLF2 and IL-7R
(Reche et al., 2001). However, the ability of mTSLP to activate CRLF2-signaling in
human cells, particularly those expressing high levels of CRLF2 observed in CRLF2 BALL, has not been reported. To determine if mTSLP can induce CRLF2-mediated signals
we tested its ability to activate downstream pathways in human CRLF2 B-ALL cells.
First, we verified that the CRLF2 B-ALL cell lines and primary CRLF2 B-ALL cells
used in our studies express the TSLP receptor components. Expression of IL-7R
well as high levels of CRLF2, was observed in both CRLF2 B-ALL cell lines and in the
two primary CRLF2 B-ALL samples used in studies described here (Figure 1B).
Next we used phospho-flow cytometry to determine whether mTSLP can activate
the JAK-STAT5 and PI3K/AKT/mTOR pathways activated by hTSLP in CRLF2 B-ALL
cells (Tasian et al., 2012). hTSLP induced robust increases in phosphorylated STAT5
(pSTAT5) and S6 (pS6, activated downstream of mTOR) and more modest increases in
phosphorylated AKT (pAKT) in CRLF2 B-ALL cell lines and primary CRLF2 B-ALL
cells (Figure 1C-E). In contrast, stimulation of CRLF2 B-ALL cells with mTSLP showed
no effect (Figure 1C-E)(Dann, Selvaraj, & Thomas, 2007) These data show that mTSLP
fails to induce the STAT5, AKT, or S6 phosphorylation that are characteristic of CRLF2mediated signals induced by hTSLP in human CRLF2 B-ALL cells. Thus, TSLP
produced in the existing mouse xenograft models does not induce human CRLF2mediated signals.

110

Figure 1 (Figure 13). Mouse TSLP does not activate the human TSLP receptor
complex. A) Pathways activated downstream of TSLP receptor signaling in human
cells. B) CRLF2 B-ALL cell lines (MUTZ5, MHH-CALL4) and primary CRLF2 BALL cells used to produce patient-derived xenografts (PDX) used in the studies
described here were stained for flow cytometry to detect the TSLP receptor components
(IL-7Rα and CRLF2). Plotted in red are CRLF2 B-ALL cells within living cell light
scatter. Quadrants shown are set based on unstained controls (blue overlay) C-E)
CRLF2 B-ALL cell lines and CRLF2 B-ALL cells from a PDX generated from the
primary cells in panel C were stimulated with human TSLP (hTSLP), mouse TSLP
(mTSLP), or no cytokine and evaluated for phosphorylated STAT5 (pSTAT5), AKT
(pAKT), and S6 (pS6) by phospho-flow cytometry.
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Engineering Xenograft Mice to Express Normal Serum Levels
of Human TSLP
We developed a strategy for engineering xenograft mice that provide hTSLP to
activate CRLF2-mediated signals (Figure 2A) by building on a previous cytokine
delivery approach (Dao, Pepper, & Nolta, 1997). Our goal was to produce stable,
sustained serum levels of hTSLP, similar to normal levels reported in children (range 1332 pg/ml(Lee et al., 2010)) by intraperitoneal injection of stromal cells transduced to
express high levels of hTSLP (+T mice, Figure 2A). Control mice (–T mice) were
produced by injecting stroma transduced with empty vector. Because the only difference
between +T and –T mice is the presence of hTSLP in +T mice, this model would allow
us to identify the in vivo effects of hTSLP by comparing hematopoiesis in +T and –T
PDX generated from these mice.
Human HS27 stromal cells (Graf, Iwata, & Torok-Storb, 2002) were transduced
with lentiviral vector containing hTSLP (+T stroma) or with control vector (–T stroma).
Culture supernatant collected from stroma after the initial transduction showed hTSLP
levels of ~500 pg/ml (Figure 2B, Transduction 1). The ability of +T stroma to generate
measureable serum levels of hTSLP in vivo was evaluated. NSG mice receiving weekly
intraperitoneal injections of 5X106 +T stroma showed serum hTSLP levels that were low
but detectable (4-10 pg/ml; data not shown). To achieve higher levels of sustained hTSLP
expression NSG mice were injected with 3 doses of 1X107 +T or –T stroma over a 1
week period (loading dose) followed by weekly injections of 1X107 stromal cells. Serum
collected at weekly time points showed serum hTSLP levels of ~80 pg/ml following the
initial 3 doses of +T stroma but quickly dropped to 15-20 pg/ml with +T stroma
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injections (Figure 2C, left panel). hTSLP was not detectable in the sera of mice
transplanted with –T stroma (Figure 2C). These data show that +T stroma can generate
normal serum levels of hTSLP and that serum levels of hTSLP correspond to the number
of stromal cells injected during the previous 1-2 week period. These data suggested that
stable, sustained hTSLP production might be more likely with weekly injections of
stroma that could deliver slightly higher doses of hTSLP.
A second stromal cell transduction produced hTSLP levels averaging ~900 pg/ml
in culture supernatants harvested at early, mid and late passages from +T stroma across
multiple thaws of frozen aliquots (Figure 2B, transduction 2). hTSLP was undetectable in
supernatant from similarly passaged –T stroma (Figure 2B, Transduction 2). NSG mice
transplanted at weekly time points with 5X106 stroma from transduction 2 showed serum
hTSLP levels of approximately 20 pg/ml that were stable up to 11 weeks (Figure 2D, and
data not shown). Evaluation of BM and spleen of +T and –T mice by flow cytometry
showed that HS27 stroma (CD29+CD90+) were not detectable in the either the spleen or
BM of PDX mice (Online Supplementary Figure S1). These data provide evidence that
the HS27 +T stroma in the peritoneal cavity give rise to normal serum levels of hTSLP in
PDX mice.
To verify that the hTSLP produced in our model induces CRLF2-mediated
signals, CRLF2 B-ALL cell lines were assessed for activation of the JAK/STAT5 and
PI3K/AKT/mTOR pathways. Supernatant from +T stroma induced robust pSTAT5 and
pS6 and minimal pAKT (Figure 2E-G). In contrast, CRLF2 B-ALL cells stimulated with
supernatant from –T stroma showed background levels of pSTAT5, pAKT, and pS6,
similar to cells incubated with medium alone (Figure 2E-G). These data show that +T
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stroma, but not –T stroma, used in our model produce hTSLP that can activate signaling
in human CRLF2 B-ALL cells.
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Figure 2 (Figure 14). Engineering xenograft mice to express normal serum levels of
human TSLP. (A) Strategy for developing the –/+hTSLP xenograft model. (B) Culture
supernatant from HS27 +T and HS27 –T stromal cells was collected after multiple
passages following the initial transduction (Transduction 1) and assessed by ELISA for
hTSLP protein production. Supernatant from Transduction 2 was collected at early
(passage 1-5), mid (passages 6-10) and late (passages 11-15) post thaw passages and
hTSLP levels were evaluated by ELISA. C-D) Serum levels of hTSLP in blood collected
at indicated time points from +T or –T mice injected with stroma as determined by
ELISA were as follows: (C) loading dose (3 doses of 1X107 in first week) followed by
weekly doses of 1X107 stromal cells (Transduction 1), graphed are the means ± SEM of
n = 2-7 mice at each time point. (D) injection of 5X106 stromal cells (Transduction 2)
at weekly intervals; graphed are the means ± SEM n ≥ 24 mice at each time point. (EG) CRLF2 B-ALL cell lines were stimulated with stromal cell supernatant
(Transduction 2) and levels of pSTAT5, pAKT and pS6 were measured by phosphoflow cytometry.
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Supplementary Figure 1 (Figure 15). HS27 stroma are not detectable in bone marrow
or spleen of xenograft mice. (A) Flow cytometry plots showing human CD29 and CD90
expression on HS27 stromal cells transduced to express human TSLP (+T HS27
stroma). Similar staining was observed for HS27 stroma transduced with empty vector
(–T HS27 stroma). +T or –T HS27 stroma were injected at weekly time points into
sublethally irradiated NSG mice for 13 weeks. Mice were euthanized and bone marrow
(BM) and spleen were harvested and stained for flow cytometry to detect human CD29
and CD90 co-expression as a means of identifying HS27 stroma in these tissues. Plotted
are 25,000 events from (B) BM and (C) spleen of +T mice showing that CD29+CD90+
HS27 stroma are not detectable in BM or spleen of +T NSG mice. Similar data were
obtained in –T NSG mice. Data shown are representative of n=5 +T mice and n=4 –T
mice.
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hTSLP Produced in Xenograft Mice Exerts In Vivo Functional Effects on
Normal Human B Lineage Cells
We evaluated the ability of hTSLP in +T PDX to induce in vivo functional effects
on human B lineage cells. hTSLP has been shown to increase the in vitro production of
normal human B cell precursors(Scheeren et al., 2010) despite their low levels of
CRLF2 expression (Online Supplementary Figure S2). Thus, expansion of normal human
B cell precursors provides a sensitive in vivo functional test of the hTSLP produced in
our xenograft model. We compared normal B cell production in +T and –T NSG mice
transplanted with umbilical CB CD34+ cells from 3 different donors (Figure 3A, S3A
and S4A). Five weeks post-transplant mice were euthanized and bone marrow (BM)
harvested for flow cytometry to evaluate the production of B lineage and other
hematopoietic cells. Mouse and human cells were identified based on expression of
mouse CD45 (mCD45) or human CD45 (hCD45), respectively (Figure 3B, S3B and
S4B). Flow cytometry analysis of hCD19 expression on gated human cells showed an
increase in the percentage of B lineage cells in +T as compared to –T PDX mice
generated from all 3 CB donors (Figure 3C, S3C and S4C). Pooled data comparing BM
cellularity in all three experiments showed that the total number of human cells
(hCD45+) was increased by 3-4 fold in +T as compared to –T PDX and this was due to
significant increases in CD19+ (B lineage) cells but not CD19– cells (Figure 3D). These
data suggest that hTSLP in +T PDX selectively expands human B lineage cells rather
than exerting global effects on hematopoiesis.
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Supplementary Figure 2 (Figure 16). Expression of CRLF2 and IL-7R on normal
human B cell precursors and CRLF2 B-ALL harvested from xenograft mice. (A) Bone
marrow was harvested from xenograft mice transplanted with human CD34+ cord blood
cells and stained for flow cytometry. Plotted is CRLF2 and IL-7Ra expression on B cell
precursors (hCD19+ and Ig kappa & lambda–). (B) Bone marrow was harvested from a
patient-derived xenograft generated using Patient 1 CRLF2 B-ALL cells. Plotted is the
CRLF2 and IL-7R staining on human CRLF2 B-ALL (hCD19+) cells. Gates were set
based on isotype control staining.
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Figure 3 (Figure 17). hTSLP produced in xenograft mice exerts in vivo functional
effects on normal human B lineage cells. (A) –T and +T NSG mice were transplanted
with 1X105 CD34+ human cord blood (CB) cells and injected with weekly doses of
5X105 stromal cells (Transduction 2 stroma). (B) Five weeks post-transplant, mice were
euthanized, BM harvested and cells were stained for flow cytometry to detect mouse
CD45 (mCD45), human CD45 (hCD45), and hCD19. Total living cells were gated and
mCD45 vs. hCD45 is plotted with gates to identify mouse and human leukocytes
respectively, in the BM. (C) hCD45+ cells were gated and hCD19 expression is shown
by histogram. Percentages are mean + SEM. Data shown in A-C were obtained from
CB2, n=2 –T PDX and n= 4 +T PDX; data from two additional CB samples (CB1 and
CB3) are shown in Online Supplementary Figures S3-S4. (D) Graphed are the fold
change in total human cells (hCD45+), human B lineage cells (CD19+), and human
non-B lineage cells (CD19–). Fold change was obtained by normalizing cell numbers
in +T animals to the average cell numbers in –T animals for each experiment. Data
shown in Panel D are pooled from 3 different experiments performed with CB samples
1-3. Total n=9 –T PDX mice and n=14 +T PDX mice. Statistical significance was
calculated using a 2-tailed, unpaired t-test (* P ≤ 0.05; ** P ≤ 0.05).
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Supplementary Figure 3 (Figure 18). Functional effects of hTSLP produced in +T
xenograft mice on normal human B lineage cells generated from CB 1. (A) –T and +T
NSG mice were transplanted with 1X105 CD34+ human cord blood cells (CB 1) and
injected with weekly doses of 1X107 stromal cells (transduction 1 stroma). (B) Five
weeks post-transplant, mice were euthanized, BM harvested and cells were stained for
flow cytometry to detect mouse CD45 (mCD45), human CD45 (hCD45), and hCD19.
Total living cells were gated and mCD45 vs. hCD45 is plotted with gates to identify
mouse and human leukocytes respectively, in the BM. (C) hCD45+ cells were gated and
hCD19 expression is shown by histogram. Percentages are mean + SEM. Data shown
in A-C were obtained from CB 1, n=3 –T PDX and n= 5 +T PDX.
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Supplementary Figure 4 (Figure 19). Functional effects of hTSLP produced in +T
xenograft mice on normal human B lineage cells generated from CB 3. A) –T and +T NSG
mice were transplanted with 1X105 CD34+ human cord blood cells (CB 3) and injected
with weekly doses of 5X106 stromal cells (transduction 2 stroma). B) Five weeks posttransplant, mice were euthanized, BM harvested and cells were stained for flow cytometry
to detect mouse CD45 (mCD45), human CD45 (hCD45), and hCD19. Total living cells
were gated and mCD45 vs. hCD45 is plotted with gates to identify mouse and human
leukocytes respectively, in the BM. C) hCD45+ cells were gated and hCD19 expression is
shown by histogram. Percentages are mean + SEM. Data shown in A-C were obtained from
CB 3, n=4 –T PDX and n= 5 +T PDX.
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B Cell Precursor Production is Increased in +T PDX Mice
To confirm that normal human B cell precursors are expanded in +T PDX, we
compared the production of human B cell subsets (Figure 4A) and non B-cell lineages in
–T and +T PDX. Staining of PDX BM for markers of human non-B cells showed that
human CD19– cells are comprised primarily of monocytes (CD14+), but also include
granulocytes (CD66B+), NK cells (CD56+), and CD34+ cells. The number of cells in
each non-B lineage was similar (data not shown) in the BM from –T and +T PDX,
indicating that the production of these cells is not skewed. However, the production of B
cell precursors was increased 3-6 fold at each stage of B cell development in +T PDX as
compared to –T PDX, beginning with the earliest CD34+ pro-B cells (Figure 4B). This
increase was maintained through the mature B cell stage in BM and spleen (Figure 4B)
with no skewing of B cell subsets in the BM (Figure 4C) or spleen (data not shown).
These data provide evidence that hTSLP produced in vivo in +T PDX has a functional
effect on normal human B cell precursors that express low levels of CRLF2.
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Figure 4 (Figure 20). B cell precursor production is increased in +T PDX. BM and spleen
were harvested from –T and +T PDX mice generated by from three different CB samples
as shown in Figure 3, and in Online Supplementary Figures S3-S4. (A) Harvested cells
were counted by hemocytometer and were stained for flow cytometry and to identify
progenitors and B cell subsets in the BM and spleen based on the indicated
immunophenotypes. (B) Total living cell counts and percentages of living cells in each
subset were used to calculate the number of cells in each subset. Graphed is the fold
changed in each subset obtained by normalizing cell numbers in +T animals to the average
cell numbers in –T animals for each experiment. (C) Graphed is the frequency of each
subset within the total CD19+ B lineage pool. Data shown are pooled from experiments
performed using PDX generated from CB 1-3. n=9 –T PDX mice and n =15 +T PDX mice.
Statistical significance was calculated using a 2-tailed, unpaired t-test (** P ≤ 0.01; *** P
≤0.001).
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hTSLP in Xenograft Mice Induces mTOR-Regulated Genes in
Primary CRLF2 B-ALL
To determine the ability of hTSLP in +T xenografts to activate CRLF2
downstream pathways in CRLF2-B-ALL cells we used primary samples obtained two
different Hispanic pediatric patients. (Patient characteristics shown in Online
Supplementary Table S1.) First, we evaluated the ability of NSG mice transplanted with
HS27 stroma to support engraftment of primary CRLF2 B-ALL cells. PDX from Patient
1 were generated using NSG mice injected with +T stroma from transduction 1 (stroma
injection schedule, Figure 5A). Serum levels of hTSLP produced in these mice were
detectable but below normal levels (4-10 pg/ml) and therefore provided a sensitive test of
in vivo hTSLP activity in +T PDX. +T and –T NSG mice were transplanted with primary
CRLF2 B-ALL cells (Figure 1B, right panel) from Patient 1. Mice were euthanized at 9
weeks when peripheral blood chimerism reached 80%. BM was harvested and stained for
mCD45 and human-specific markers (CRLF2 and CD19) to identify CRLF2 B-ALL cells
(Figure 5B). Flow cytometry analysis showed BM chimerism of human CRLF2 B-ALL
cells was >90% in +T and –T PDX (Figure 5B). These data show that NSG mice support
engraftment of primary B-ALL cells when injected with –T or with +T stroma.
The leukemia cell burden in the BM of –T and +T PDX generated from Patient 1
and from Patient 2 showed no consistent differences (Online Supplementary Figure S6).
Thus, our next question was whether hTSLP in +T animals induces gene expression
profiles associated with pathway activation downstream of CRLF2-mediated signaling in
primary CRLF2 B-ALL cells. Human CRLF2 B-ALL cells were isolated from the BM of
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+T and –T PDX generated from Patient 1 by magnetic separation. Gene expression was
compared by whole genome microarray performed in triplicate. Differential gene
expression analysis identified 280 gene reporters that were upregulated and 281 gene
reporters that were downregulated at least 2 fold (Figure 5C). Microarray was validated
by quantitative RT-PCR (qRT-PCR) analysis of selected differentially expressed genes
(Table S2). Changes in gene expression by microarray and qRT-PCR were strongly
correlated as indicated by linear regression (Figure 5D). GSEA(Mootha et al., 2003;
Subramanian et al., 2005) of whole genome microarray data showed a strong enrichment
for genes regulated downstream of mTOR activation in CRLF2 B-ALL cells from +T
PDX as compared to –T PDX (FDR q-value = 0.022, Figure 5E). These data provide
evidence that the hTSLP in +T PDX, even when present at low levels, acts on CRLF2 BALL cells to increase mTOR pathway activation downstream of CRLF2.
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Supplementary Table 1 (Table 2). CRLF2 B-ALL Patient Characteristics.
Patient
Designation

Gender

Age

Immunophenotypic
Markers

CRLF2 and
IKZF1
Status

Ethnicity

Patient 1

M

10
years

CRLF2
High
No IKZF1
deletion

Hispanic

Patient 2

M

18
years

CD10+
CD19+
CD20+
CD22 surface, dim
CD22 cytoplasmic,
dim
CD34 partial
CD38 partial
CD45 dim
CD58 dim
CD79a+
HLA-DR+
CD9+
CD10 partial
CD19+
CD20 partial
CD22 surface, dim
CD22 cytoplasmic,
dim
CD34 partial
CD38+
CD45 dim
CD79a+
HLA-DR+
TdT+
CD3 cytyoplasmic–
Kappa–
Lambda–
MPO–

CRLF2
High
IKZF1
deletion

Hispanic

IKZF1 deletion = deletion of one allele of IKZF1 (Ikaros) was determine as described10.
Both patients expressed high levels of CRLF2 as assessed by flow cytometry in Figure 1.
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Figure 5 (Figure 21). hTSLP in +T xenograft mice induces mTOR-regulated genes in
primary CRLF2 B-ALL. (A) –T and +T NSG mice were transplanted with primary
CRLF2 B-ALL cells from Patient 1 and injected weekly with 5X106 stromal cells
(transduction 1). (B) 9 weeks post-transplant, mice were euthanized, BM was harvested
and cells were stained with mCD45 and hCD19 to identify human B-ALL cells. CRLF2
staining (black overlay) on gated hCD19+ cells is shown in bottom panels. Isotype
control is shown in gray. (C) Human hCD19+ B-ALL cells were isolated by magnetic
separation and analyzed using whole genome microarray to identify genes that are
differentially regulated in +T as compared to –T PDX. Graphed are the numbers of
Agilent gene reporters up or downregulated (≥2 fold, p≤ .05) in CRLF2 B-ALL cells
from +T as compared to –T PDX. (D) qRT-PCR validation of whole genome
microarray. Regression analysis of fold changes measured by microarray versus fold
changes measured by qRT-PCR. (E) Gene Set Enrichment Analysis (GSEA) of whole
genome microarray data shows that CRLF2 B-ALL cells harvested from +T PDX
exhibit an increase in expression of genes regulated downstream of mTOR signaling as
compared to cells from –T PDX. The top half of the GSEA enrichment plot shows the
enrichment score for each gene and the bottom half shows the values of the ranking
metric moving down the list of the ranked genes
.
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Supplementary Figure S6 (Figure 22). CRLF2 B-ALL leukemia cell burden in BM
of –T and +T PDX. Bone marrow cells from +T and –T PDX generated from Patient 1
and Patient 2 and shown in Figure 5 and 6 were harvested, counted by hemocytometer,
and stained for flow cytometry to identify living CRLF2 B-ALL cells. Total living cell
counts and percentages of living CRLF2 B-ALL cells within the total living cells were
used to calculate the number of CRLF2 B-ALL cells per PDX. Graphed is the fold
change in living leukemia cells in +T PDX as compare to –T PDX obtained by
normalizing CRLF2 B-ALL cell numbers in +T animals to the cell numbers in –T
animals for each experiment.
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Supplementary Table 2 (Table 3). qRT-PCR validation of genes that are differentially
regulated in CRLF2 B-ALL cells expanded in +T as compared to –T xenograft mice.
Gene

Microarray
(fold change)

qRT-PCR
(fold change)

BIVM
PTH2
FOSL2
RAMP1
SLC4A8
NR4A2
KCNH8

4.440
3.477
2.793
2.725
2.628
2.138
2.154

6.907
2.784
1.843
2.227
6.417
3.548
2.355

THSD7A
RAB26
RGS1
NELL1
MDF1
KREMEN2
CPNE8

–3.628
–2.727
–2.749
–3.586
–2.168
–2.336
–3.008

–6.648
–2.726
–2.498
–3.143
–7.621
–2.003
–4.695

The table shows the list of genes that were selected from the microarray dataset for
validation by qRT-PCR analysis and their respective fold changes as determined by
microarray and by qRT-PCR.
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+T PDX Show Gene Expression Profiles that are More Similar to the Original
Patient Sample
Next we performed experiments to determine whether +T PDX provide an in vivo
environment more like the patient than –T PDX and if this could be achieved with short
term in vivo hTSLP exposure. PDX were established using CRLF2 B-ALL cells from
Patient 2. Injection of stromal cells from transduction 2 were not initiated until two weeks
prior to euthanasia (Figure 6A). At euthanasia BM was harvested and stained for flow
cytometry to verify CRLF2 B-ALL engraftment (Figure 6B). Human leukemia cells were
isolated from the BM of +T and –T PDX by magnetic separation for RNA sequencing.
Differential gene expression analysis identified 503 genes that were upregulated and 117
that were downregulated at least 2-fold in CRLF2 B-ALL cells from +T as compared to –
T PDX (Figure 6C). Similar to what we observed with Patient 1, GSEA analysis of RNA
sequencing data showed an enrichment for genes regulated downstream of mTOR in
CRLF2 B-ALL cells from +T as compared to –T PDX (FDR q-value = 0.00048, Figure
6D). A comparison of +T PDX to –T PDX showed similar immunophenotypes to each
other and to that reported for the respective original Patient 1 and Patient 2 samples
(Online Supplementary Table 1 and Figure S7), indicating that the differences in mTORregulated gene expression are unlikely due to selective survival of different clones. These
data demonstrate that in vivo hTSLP-induced changes in mTOR regulated gene
expression can be observed after short term stimulation and validate our model in a
second primary CRLF2 B-ALL patient sample.
To determine whether +T PDX provide an in vivo environment that is more
similar to the patient than –T PDX, we compared gene expression profiles of +T and –T

131

PDX to the original ex vivo CRLF2 B-ALL patient sample. Human leukemia cells were
isolated from the BM of +T and –T PDX generated from Patient 2, and from the original
primary Patient 2 sample by magnetic separation. RNA sequencing was performed to
determine whole genome expression. Analysis of gene expression by unsupervised
clustering and Spearman rank correlation show that gene expression in +T PDX, as
compared to –T PDX, is significantly more closely correlated to the original patient
sample (Figure 6E). These data validate the use of +T/–T xenograft mice as an in vivo
preclinical model system for studies to understand the role of hTSLP in normal human B
cell production and in the development and progression of CRLF2 B-ALL.
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Figure 6 (Figure 23). +T PDX show gene expression profiles that are more similar to
the original patient sample. (A) –T and +T NSG mice were transplanted with primary
CRLF2 B-ALL cells from Patient 2. Beginning at ten weeks after leukemia transplant
mice received two injections with 5X106 stromal cells (transduction 2 stroma) one week
apart. (B) Twelve weeks post-transplant, mice were euthanized, BM was harvested and
cells were stained with mCD45 and hCD19 to identify human B-ALL cells. CRLF2
staining (black overlay) on gated hCD19+ cells is shown in bottom panels. Isotype
control is shown in gray. (C) Human hCD19+ B-ALL cells were isolated by magnetic
separation and RNA sequencing with differential gene expression analysis was
performed to identify genes that are differentially regulated in +T as compared to –T
PDX. Graphed are the numbers of significantly up or down-regulated gene (≥2 fold, p≤
.05) in CRLF2 B-ALL cells from +T as compared to –T PDX. (D) GSEA of RNA
sequencing data shows that CRLF2 B-ALL cells harvested from +T PDX exhibit an
increase in expression of genes regulated downstream of mTOR signaling as compared
to cells from –T PDX. The top half of the GSEA enrichment plot shows the enrichment
score for each gene and the bottom half shows the values of the ranking metric moving
down the list of the ranked genes. (E) RNA sequencing was performed on CRLF2 BALL cells isolated by magnetic separation from 2 +T PDX mice (+T PDX M1 and M2)
and 2 –T PDX mice (–T PDX M1 and M2) and from the original Patient 2 primary
sample used to generate them. Graphed is a dendrogram of unsupervised hierarchical
clustering and heatmap of Spearman rank correlation values showing that gene
expression in +T PDX is significantly more closely correlated to the original sample
than is –T PDX. p<.0001. Spearman rank coefficients are shown in Online
Supplementary Figure S5. Significance of differences in correlation coefficients was
determined using Fisher’s r-to-z transformation.
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Supplementary Figure S5 (Figure 24). Spearman rank coefficients for comparisons of
gene expression in +T and –T PDX to original patient sample. A) CRLF2 B-ALL cells
from Patient 2 were used to generated –T and +T PDX mice as described in Figure 6. RNA
sequencing was performed on CRLF2 B-ALL cells isolated from 2 +T mice (+T PDX M1
and M2) and 2 –T PDX mice (–T PDX M1 and M2) and from the original Patient 2 primary
sample used to generate them. Spearman rank coefficients are shown for comparison of
gene expression in +T and –T PDX and in the primary patient sample. The comparisons
between +T and –T PDX and the primary patient sample are highlighted to match the
heatmap in Figure 6E.
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Supplemental Figure S7 (Figure 25). Surface immunophenotype CRLF2 B-ALL
from –T and +T PDX. +T and –T PDX were stained for flow cytometry to determine
immunophenotype with respect to marker expression on the original primary CRLF2
B-ALL patient sample (see Online Supplementary Table 1). Plotted is expression of
indicated markers on gated living human CD19+ leukemia cells in –T and +T PDX
samples from Patient 1 and Patient 2
.
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Discussion
PDX provide a critical complement to other models in understanding normal and
malignant human B lymphopoiesis in context of the broad background of human genetic
variation. A limitation of PDX is the reduced cross-species activity of some cytokines.
Classic immune deficient mice, including NSG mice, selectively support B lineage
differentiation. This is because IL-7, a cytokine important for human B cell production
(Parrish et al., 2009) shows high species cross reactivity (Johnson, Shah, PanoskaltsisMortari, & LeBien, 2005) while myeloid supportive cytokines do not. Here we show that
mTSLP does not induce the increases in STAT5 and PI3K/AKT/mTOR phosphorylation
induced by hTSLP in CRLF2 B-ALL cells (Figure 1). CRLF2 B-ALL cells express
abundant IL-7R and CRLF2 as compared to normal B cell precursors (Figure 1 and S1)
and thus provide a sensitive test for mTSLP activity. These data establish that the classic
mouse xenograft models do not provide cross-species activation of the human TSLP
receptor.
The goals of the studies described here were to develop a xenograft model that
expresses hTSLP and to validate the effects of hTSLP produced in the model on normal
and malignant B cell precursors. We engineered NSG mice that express normal serum
levels of hTSLP (+T mice) or that lack hTSLP (–T mice) (Figure 2) by intraperitoneal
injection with stroma transduced to express hTSLP (+T stroma) or with a control vector
(–T stroma) (Figure 2). hTSLP produced by +T stroma induced in vitro STAT5 and
PI3K/AKT/mTOR pathway activation (Figure 2) and showed in vivo functional effects as
indicated by selective expansion of normal B cell precursors (Figure 3-4, S3, S4) and
upregulation of the mTOR pathway in primary CRLF2 B-ALL cells (Figure 5-6). The
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studies described here establish and validate a novel hTSLP+/– xenograft model system
while providing the first data on the in vivo impact of hTSLP on normal B cell
development and primary CRLF2+ B-ALL cells.
Normal serum levels of hTSLP were achieved in our model, however, a novel
aspect of our model is the ability to modulate serum levels of hTSLP based on the timing
and number of stromal cells injected intraperitoneally. The ability to vary hTSLP levels
or initiate hTSLP at time points after transplant of hematopoietic cells offers advantages
for experimental design. The ability to modulate serum levels of hTSLP is also
biologically relevant because TSLP production is increased by environmental factors
such as pollutants and allergens and is upregulated in some autoimmune diseases and
solid tumors (Ziegler et al., 2013). TSLP is primarily produced by cells residing outside
the BM (immune cells, smooth muscle cells, gut and skin epithelial cells),(Takai, 2012)
although human BM stroma do produce hTSLP (Allakhverdi et al., 2013). Thus, the
major source of hTSLP that acts on normal and malignant B cells in vivo in patients is
likely to be produced outside the marrow as it is in our model.
Little is known about cellular mechanisms that contribute to the initiation,
progression and maintenance of CRLF2 B-ALL or the biological factors that contribute
to the health disparities associated with this disease. Studies of the relationship between
inherited genetic variation and susceptibility to ALL provide some clues to the
relationship of ALL to ethnicity (Xu et al., 2013). Patient-derived xenograft (PDX)
models are particularly critical for health disparities diseases where inherited genetic
variation or alterations such as Down Syndrome are likely to play a role in disease
progression (Liem et al., 2004; Lock, Liem, & Papa, 2005). The ability to generate PDX
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mice that provide hTSLP make it possible to study the initiation, progression and
maintenance of CRLF2 B-ALL from normal human progenitors transduced to
overexpress CRLF2 on a range of genetic backgrounds.
The +T and –T PDX generated in the studies described here did not show
consistent differences in the leukemia cell burden (Online Supplementary Figure S6).
However, changes in gene expression that contribute to chemoresistance would not
necessarily be expected to impact leukemia burden in untreated PDX, but would instead
be revealed following chemotherapy. CRLF2 B-ALL is a leukemia at high risk for
relapse and the mTOR pathway is known to play a role in chemoresistance in multiple
malignancies (Jiang & Liu, 2008). The ability of +T PDX to model TSLP-induced mTOR
activation makes this an important model for understanding and identifying therapeutic
strategies for overcoming chemoresistance in CRLF2 B-ALL. Our finding that gene
expression +T PDX is significantly more like the original patient sample than –T PDX
(Figure 6E, S5) support the use of +T PDX mice as a preclinical model of CRLF2 BALL. PDX generated from +T and –T mice and CRLF2 B-ALL samples obtained from
Hispanic or Down Syndrome pediatric patients will allow us to study disease mechanisms
1) in context of a genetic background associated with CRLF2 B-ALL health disparities
and 2) in context of TSLP-CRLF2 mediated signals present in vivo in the patient.
The model developed here provides an important new tool for understanding the
mechanisms of TSLP activity in normal and malignant B lymphopoiesis. It also provides
a preclinical model for identifying therapies to effectively treat CRLF2 B-ALL in an
environment that can induce the TSLP-mediated signals present in vivo in patients and in
context of the genetic background that leads to health disparities in this disease.
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Abstract
Thymic stromal lymphopoietin (TSLP) and IL-7 are cytokines that signal via the
IL-7 receptor alpha (IL-7R) to exert both overlapping and unique functions during early
stages of mouse B cell development. In human B lymphopoiesis the requirement for IL7RΑ

the roles of IL-7 and TSLP are less clear. Here we

evaluated human B cell production using novel in vitro and xenograft models of human B
cell development that provide selective IL-7 and human TSLP (hTSLP) stimulation. We
show that in vitro human B cell production is almost completely blocked in the absence
of IL-7RΑ

-7 can provide a signal critical for the

production and proliferation of human CD19+ PAX5+ pro-B cells. Analysis of primary
human bone marrow (BM) stromal cells show that they express both IL-7 and TSLP
providing an in vivo source of these cytokines. Using novel xenograft models we show
that the in vivo production of human pro-B cells under the influence of mouse IL-7 is
reduced by anti-IL-7 neutralizing antibodies, and this loss can be restored by hTSLP at
physiological levels. These data establish the importance of IL-7R-mediated signals for
normal human B cell production.
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Abbreviations
BM

Bone Marrow

CB

Umbilical Cord Blood

FMO

Fluorescence Minus One

hTSLP

Human Thymic Stromal Lymphopoietin

IL-7R

IL-7 Receptor Alpha

TSLP

Thymic Stromal Lymphopoietin
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Introduction
IL-7R
cell production is IL-7RΑ-independent (von Freeden-Jeffry et al., 1995). IL-7R
component of two distinct cytokine receptor complexes with different secondary chains,
one activated by IL-7 and the other by TSLP (Zhang et al., 2001). In adult mice where
IL-7 is knocked out, there is a block in B cell precursor production that can be restored by
TSLP, but only at the supra-physiological levels achieved in TSLP transgenic mice
(Chappaz, Flueck, Farr, Rolink, & Finke, 2007).
The role of IL-7R signals in human B cell development is controversial (Corfe
& Paige, 2012; Sportes, Gress, & Mackall, 2009). Patients with defective IL-7R signaling
exhibit severe combined immunodeficiency (SCID) characterized by a loss of T cells
(Macchi et al., 1995; Noguchi et al., 1993; Puel, Ziegler, Buckley, & Leonard, 1998;
Russell et al., 1995). Although B cell function may be compromised in these patients, B
cell numbers are normal (Giliani et al., 2005), suggesting that human B lymphopoiesis
differs from that in mice with respect to the requirement for IL-7R-mediated signals.
However, these data are obtained during the first year of life consistent with fetal B cell
production through an IL-7R-independent process similar to mouse. Early in vitro
studies also suggested that human B cell production is IL-7-independent, however, these
were often performed using fetal hematopoietic sources or culture models that produced
mouse IL-7 which was later shown to activate human IL-7R (Johnson, Shah,
Panoskaltsis-Mortari, & LeBien, 2005). Although fetal B cell production is not dependent
on IL-7 or TSLP, both of these cytokines can stimulate in vitro proliferation of human
fetal B cell precursors (Scheeren et al., 2010).
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Our previous in vitro studies, performed using a human-only co-culture model,
showed that human B cell production beyond the fetal period is increasingly dependent
on a signal that can be provided by IL-7 (Parrish et al., 2009). The ability of TSLP to
replace IL-7 in providing this signal is unknown and the importance of IL-7R–IL7R

n for in vivo human B lymphopoiesis has not been demonstrated.

Recently we developed a novel xenograft model and it showed that physiological levels
of human TSLP (hTSLP) increase human B cell production, in vivo, in context of IL-7
(Francis et al., 2015). Here we use novel in vitro and xenograft models, engineered to
provide selective IL-7 and hTSLP stimulation, to evaluate the requirement for IL-7R IL7R signals in post-fetal human B cell production and the ability of hTSLP to induce
these signals at physiological levels.

Results and Discussion
TSLP or IL-7 can Provide a Signal Critical for the In Vitro Production of Human
B Cell Precursors
To investigate the role of IL-7R signals induced by TSLP and IL-7 in early
stages of human B cell production, we developed a human-only co-culture model that
supports the production of human pro-B cells and provides selective IL-7 or TSLP
stimulation. Human umbilical cord blood (CB) CD34+ cells were cultured with primary
human bone marrow (BM) stromal cells in media supplemented with human serum.
Selective cytokine stimulation was achieved with combinations of exogenous human IL-7
or TSLP and with neutralizing antibodies to counter activity of endogenously produced
IL-7 and TSLP (Fig 1A). CB CD34+ cells were grown under selective cytokine
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conditions for 3 weeks. Culture progeny were harvested and stained for flow cytometry to
identify CD19+ PAX5+ B lineage cells. Control cultures that lacked TSLP or IL-7
produced small numbers of B lineage cells (Fig 1B). In contrast, TSLP and IL-7 cultures
showed robust production of CD19+ PAX5+ B lineage cells (Fig 1B). Cultures with
TSLP or IL-7 produced similar numbers of B cell precursors (Fig 1C).
To determine if TSLP-induced proliferation contributes to the increased
production of human B cell precursors from CB CD34+ cells, we compared BrdU
incorporation in cells generated under selective cytokine conditions (Fig 1D).
Proliferation in TSLP cultures was significantly increased as compared to control cultures
lacking IL-7R

-7 (Fig 1E). These data

demonstrate that TSLP can replace IL-7 in providing signals critical for in vitro
production and proliferation of human CD19+ PAX5+ pro-B cells and that human B cell
production is almost completely blocked in the absence of IL-7R stimulation.
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Figure 1 (Figure 26). TSLP can replace IL-7 in supporting the in vitro production
and proliferation of human CD19+ PAX5+ B cell precursors. (A) Human-only
cultures were produced by plating primary human CB CD34+ cells on primary human
BM stroma. Selective cytokine stimulation was achieved by supplementing cultures
with exogenous IL-7 or TSLP or neutralizing antibodies to TSLP (anti-T) or IL-7
(anti-7) as indicated. Cultures without a particular neutralizing antibody were
supplemented, as a control, with non-specific isotype-matched antibodies (ctrl Ig). All
culture conditions included IL-3 and Flt-3 ligand. Cultures were maintained for 3
weeks, then harvested and stained for flow cytometry. (B) Dot plots of CD19 vs.
PAX5 staining in each culture condition are shown (representative of n=3 independent
experiments). PAX5 fluorescence minus one (FMO) control is displayed in inset. (C)
Graphed are the relative numbers of CD19+ cells (mean± SEM) generated in vitro
under indicated conditions at three weeks (n=14). D) Representative dot plots of CD19
vs BrdU staining in indicated conditions. BrdU FMO control is displayed in the inset
of the Ctrl dot plot. (E) Graphed is the percent BrdU+ cells (mean± SEM) in the total
CD19+ population generated under indicated conditions at three weeks (n=8).
Statistical analysis was performed using one-tailed, t-test, *p<0.05, **p<0.001. Error
bars represent mean ± SEM.
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Human Bone Marrow Stromal Cells Express TSLP, as well as IL-7
To determine if the BM provides an in vivo source of TSLP we evaluated the
ability of primary human BM stroma to produce TSLP. For comparison we evaluated IL7, which we have previously shown to be expressed by human BM stroma (Parrish et al.,
2009). RT-PCR analysis of stromal cells cultured from healthy donors showed TSLP and
IL-7 transcripts (Fig 2A) that resulted in protein production as evidenced by TSLP and
IL-7 in supernatants harvested from cultured cells (Fig 2B). These data demonstrate that
human BM stroma provide an in vivo source of both cytokines in the normal human BM
microenvironment where B cell precursors are generated.

Figure 2 (Figure 27). IL-7 and TSLP are produced by human BM stroma. (A) RTPCR, was used to detect TSLP, IL-7 or beta-2 microglobulin (2M, control) transcripts
in primary human BM stromal cells from different human donors – pediatric (BM #1
and BM #2) and adult (BM #3) or culture medium as a negative control. Each patient
sample was assessed in two or more different PCR reactions. (B) Supernatant from
confluent BM stromal cell cultures were assessed by ELISA for TSLP and IL-7
protein production. Data are expressed as mean ± SEM of triplicate values for TSLP,
and duplicate values for IL-7. Dashed lines (---) represent ELISA threshold of
detection.
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IL-7R Signals Induced by TSLP or IL-7 Increase the In Vivo
Production of Human B Cell Precursors
Next we evaluated the in vivo role of IL-7R-mediated signals in human B cell
development and the ability of physiological levels of TSLP to replace IL-7 in the
induction of these signals. Mouse TSLP does not show cross-species activity on human
cells (Francis et al., 2015) although IL-7 does (Barata et al., 2006; Johnson et al., 2005).
Thus, classic xenografts provide IL-7, but not TSLP that can stimulate IL-7R signals.
We used a novel human-mouse xenograft that provides normal serum levels of hTSLP
(+T mice) and control (–T mice) that lack hTSLP (Francis et al., 2015) as an in vivo
system for human B cell precursor production. To study in vivo human B cell precursor
production under selective IL-7 and hTSLP stimulation, we established +T and –T
xenografts with CB CD34+ cells and treated for two weeks with antibodies that
neutralize mouse and human IL-7 (Grabstein et al., 1993) (Fig 3A). This allowed us to
compare B lymphopoiesis in mice with 1) no hTSLP and reduced IL-7 (–T–7 mice); 2)
no hTSLP and normal IL-7 (–T+7 mice); and 3) physiological hTSLP and reduced IL-7
(+T–7 mice).
Human progenitors and B cell subsets in the bone marrow of xenograft mice were
identified by flow cytometry (Fig S1 in online Supporting Information) and cell numbers
were compared (Fig 3). No differences in numbers of human hematopoietic stem cells or
multi-potential progenitors was observed, including the earliest IL-7R+ progenitors
(CD19–CD34+IL-7R+) (Fig 3B). In contrast, mice with normal IL-7 or with
physiological levels of hTSLP showed a human pro-B compartment that was increased
by 2-3 fold as compared to that observed in –T–7 mice (Fig 3C). Increases observed with
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physiological hTSLP extended to the pre-B cell stage, although significant increases in
pre-B cells were not achieved in –T+7 mice (Fig 3C). Later stages of B cell development
were not impacted, which was not surprising, given the short anti-IL-7 treatment period
(Fig 3C). No significant differences were detected in the numbers of non-B cells
generated in mice with hTSLP or IL-7 as compared to –T–7 xenografts (Fig 3D). T
lineage cells are not generated in xenograft mice at this time point and so were not a part
of the non-B lineage compartment. These data show that the in vivo production of human
pro-B cells under the influence of IL-7 is reduced by anti-IL-7 neutralizing antibodies,
and this loss can be restored by hTSLP at physiological levels.
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Figure 3 (Figure 28). IL-7 and TSLP increase the in vivo production of human B cell
precursors in human-mouse xenografts. (A) Immune deficient NSG mice were
engineered to express physiological levels of hTSLP (+T mice) or without hTSLP (–T
mice) as described (Francis et al., 2015). CB CD34+ cells were injected by tail vein
into –T and +T mice. Five weeks later, –T mice and +T mice were treated for two weeks
with anti-human/mouse IL-7 antibody or isotype-matched control antibody to generate
–T–7 mice (no hTSLP and reduced IL-7), –T+7 mice (no hTSLP and normal IL-7), and
+T–7 mice (physiological hTSLP and reduced IL-7). At 7 weeks post-transplant, mice
were euthanized and BM harvested and stained for human specific markers to identify
hematopoietic subsets (for gating see Fig S1 in online Supporting Information.)
Graphed are the absolute numbers of cells in (B) progenitor populations, (C) B cell
subsets, and (D) non-B cells in the BM of xenograft mice. Data shown were obtained
from two different CB donors with a total of four mice per group. Statistical analysis
was performed using one-tailed, unpaired t-test, *p<0.05 compared to –T–7 mice. Error
bars represent mean ± SEM.
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Supplemental Figure S1 (Figure 29). Flow cytometry to identify hematopoietic subsets
in xenografts with selective IL-7 and hTSLP stimulation. Human CB CD34+ cells were
injected by tail vein into mice engineered to express hTSLP (+T mice) or that lacked
hTSLP (–T mice) as described in methods and previously reported (Francis, et al 2015).
Beginning 5 weeks after injection of CD34+ cells, mice were treated for two weeks with
neutralizing anti-human/mouse IL-7 antibody or isotype-matched control antibody to
generate mice with no hTSLP and reduced IL-7 stimulation (–T–7 mice); mice with no
hTSLP and normal IL-7 (–T+7 mice); and mice with physiological hTSLP and reduced
IL-7 (+T–7 mice). Mice were euthanized seven weeks post-transplant and BM harvested
and stained for human specific markers to identify progenitors, developmentally sequential
B cell subsets and non-B cells in the BM of indicated xenograft groups. (A) Surface
immunophenotypes used to identify indicated hematopoietic subsets in xenograft mice. (BD) Flow cytometry plots showing gating and representative data from n=4 xenografts in
each group (B) –T–7 xenografts (C) –T+7 xenografts and (D) +T–7 xenografts. Gates were
set based on isotype controls.
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Concluding Remarks
In summary, we used in vitro selective cytokine cultures to show that the
production of human B lineage cells beyond the fetal period is dependent on an IL-7Rmediated signal that can be provided by either TSLP or IL-7. We demonstrate that both
of these cytokines are produced by normal human BM stroma. The validity of these
findings for in vivo B lymphopoiesis is supported by the reduction in human B cell
precursors observed following treatment with IL-7 neutralizing antibodies in xenografts
and the ability of hTSLP to restore this loss.
These studies provide in vivo evidence that IL-7R signals are required for
normal human B cell production and proliferation beyond the fetal period and suggest
that TSLP can replace IL-7 in providing these signals. Our data provide a potential
explanation for the recent report that B lineage commitment is not blocked in SCID
patients who have defects in IL-7 signaling components (common gamma chain and
JAK3), but have an intact TSLP receptor signaling pathway (Kohn et al., 2014). Our
studies suggest that therapies to stimulate or block IL-7- and TSLP-mediated IL-7R
signals are likely to impact B cell production. Consistent with this, data from clinical
trials showing that the administration of recombinant human IL-7 can increase newly
formed B cells in the periphery and expand the bone marrow lymphoid compartment
(Mackall, Fry, & Gress, 2011).

Materials and Methods
Additional details are available in the online Supporting Information.
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Human Samples
Umbilical CB and BM were obtained in accord with Loma Linda University
Institutional Review Board (IRB) protocols and the Helsinki Declaration of 1975, as
revised in 2008. Isolation of CB CD34+ cells and detection of TSLP production in BM
stroma are described in online supplementary methods.

Selective-Cytokine Co-Cultures
CB CD34+ cells were seeded on primary human BM stroma and maintained as
described (Parrish et al., 2009) with media containing 5% human AB serum (Omega
Scientific, Tarzana, CA). All cultures, including control, were supplemented with IL-3
and Flt-3 Ligand. For selective cytokine stimulation, hTSLP and/or IL-7 (R&D Systems
Inc., Minneapolis, MN) were added. If neither TSLP nor IL-7 was added, cultures were
further supplemented with neutralizing antibodies to counter activity of endogenously
produced TSLP and/or IL-7. Cultures without cytokine-specific neutralizing antibody
were supplemented with an isotype-matched control. Co-cultures were harvested at 3
weeks. BrdU (Sigma-Aldrich, St. Louis, MO) was added for the final 24 hours in some
cultures.

Animal Studies
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
(Jackson Laboratory) under protocols approved by the Loma Linda University
Institutional Animal Care and Use Committee (IACUC). Mice were engineered by
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intraperitoneal injection with stroma transduced to express hTSLP (+T mice) or with
control vector (–T mice) as described (Francis et al., 2015). +T and –T mice were
transplanted with CD34+ cells by tail vein injection, after sub-lethal irradiation. Five
weeks after CB transplantation, anti-mouse/human IL-7 neutralizing antibody or isotypematched control (BioXCell, West Lebanon, NH) was injected as described in previous
studies that used this anti-IL-7 antibody to inhibit in vivo mouse B lymphopoiesis
(Grabstein et al., 1993).

Supplementary Methods
Human Samples
Umbilical cord blood (CB) and bone marrow (BM) were obtained in accordance
with protocols approved by the Loma Linda University Institutional Review Board (IRB)
and with the Helsinki Declaration of 1975, as revised in 2008. Umbilical cord blood (CB)
was obtained from placentas after caesarean section delivery of full-term neonates at
Loma Linda University Medical Center. Mononuclear cells were isolated using FicollPaque Plus (GE Healthcare Bio-Sciences, AB) or by red blood cell (RBC) lysis (Kang et
al., 2002). CD34+ cells were isolated by magnetic separation with CD34+ microbeads
(Miltenyi Biotec, Auburn, CA) and stored in liquid nitrogen for subsequent use. Pediatric
BM samples were obtained as waste samples remaining after clinical procedures under an
LLU Institutional Review Board (IRB)-approved protocol. Adult BM and stromal cells
were purchased from Lonza Inc. (Walkersville, MD). Stromal cells were isolated from
pediatric and adult BM as previously described (Nolta et al., 2002) and maintained in
IMDM medium supplemented with 15% horse serum, 15% FBS, hydrocortisone, 2mercaptoethanol, penicillin-streptomycin and L-glutamine.
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In Vitro Co-Cultures
Human-only in vitro co-cultures were initiated as previously described (Parrish et
al., 2009) which primarily yield pro-B cells. Briefly, CB CD34+ cells were seeded onto
pre-plated primary human BM stromal cells, at 10,000 to 20,000 cells per well in 96-well
plates. For some experiments, numbers were scaled up to give equivalent cell densities in
6-well and 12-well plates. Cultures were maintained in RPMI 1640 medium (Irvine
Scientific, Santa Ana, CA) supplemented with penicillin/streptomycin, L-glutamine, 50
uM 2-mercaptoethanol and 5% human AB serum lot tested to support human B cell
production (Omega Scientific, Tarzana, CA). All cultures, including control, were
supplemented with IL-3 (1 ng/ml; first week only) and Flt-3 Ligand (1 ng/ml,
continuously), two cytokines that support early lymphoid progenitors (Crooks, Hao,
Petersen, Barsky, & Bockstoce, 2000; Shah, Smogorzewska, Hannum, & Crooks, 1996).
For selective cytokine stimulation human TSLP (10 ng/ml) or human IL-7 (5 ng/ml) or
no cytokines (control cultures) were added. All cytokines were from R&D Systems Inc.
(Minneapolis, MN). If TSLP or IL-7 was not added, cultures were further supplemented
with an anti-human neutralizing antibody to counter activity of any endogenously
produced TSLP or IL-7. Cultures without a specific neutralizing antibody (anti-IL-7 or
anti-TSLP) were supplemented with an isotype-matched control for the neutralizing
antibody. Anti-human neutralizing or control antibody for IL-7 was used at 10 ng/ml (BD
Pharmingen, Franklin Lakes, NJ). Anti-human neutralizing or control antibody for TSLP
was used at 1 ug/ml (R&D Systems and Jackson ImmunoResearch, West Grove, PA).
Media, cytokines, and antibodies were replenished weekly. Cultures were maintained for
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three weeks, and then harvested. For BrdU incorporation, selective cytokine cultures
-Aldrich, St. Louis, MO) for the final 24 hours of
culture.

Flow Cytometry
For detection of surface antigens, cells were stained using standard flow
cytometry protocols, followed by fixation and permeabilization as described below to
detect intracellular antigens. To discriminate living from dying cells, in some
experiments, cells were stained with fixable viability dyes (eBioscience, San Diego, CA),
per manufacturer’s instructions.
To assess intracellular IgM, the Fix & Perm® cell fixation and permeabilization
kit (Life Technologies, Grand Island, NY)) was used according to manufacturer’s
instructions. All antibodies were monoclonal, anti-human antibodies, unless otherwise
stated. Intranuclear detection of BrdU was performed using BrdU Flow Kit option no. 2
(BD Pharmingen) according to manufacturer’s instructions. Briefly, cells were harvested,
surface stained, washed then fixed with BD cytofix/cytoperm buffer (BD Biosciences) for
15-30 minutes at room temperature. Cell suspensions were washed, then stored overnight
in freezing medium (90% FBS and 10% DMSO) at –80ºC. The following day, thawed
cells were washed, re-fixed in BD cytofix/cytoperm buffer and washed with BD
perm/wash buffer. Cells were treated with DNase (300 ug/ml, Sigma-Aldrich) for 1 hour
at 37ºC, washed then stained with anti-BrdU FITC or isotype-matched control for 20
minutes at room temperature. Cells were washed then resuspended in 1% PFA for
acquisition. To assess intracellular PAX-5, cells were first surface stained for viability
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and surface markers, then fixed and permeabilized with FoxP3 fix/perm buffer
(eBioscience) for 30-60 minutes at 4ºC in the dark. Cells were washed, resuspended in
permeabilization buffer and stained with PAX-5 PE or isotype-matched controls for 30
minutes at room temperature. Cells were washed then resuspended in 1% PFA for
acquisition. In some experiments, cells were simultaneously stained for PAX-5 and
BrdU. In these experiments cells were first stained for PAX-5 according to
manufacturer’s directions, followed by BrdU staining according to manufacturer’s
instructions.
Antibody
BrdU FITC
Ig κ light chain FITC
Ig λ light chain FITC
IgM PE Cy-5
CD19 APC
CD34 PerCP
CD34 APC
CD34 APC.Cy7
IgD PE
CD19 APC
CD19 PE.Cy7
CD45 PE.Cy7
CD127 PE
Ig κ light chain eFluor 450
Ig λ light chain eFluor 450
PAX-5 PE
Anti-Mouse CD45 FITC
CD19 APC
CD34 APC
CD127 PE

Clone
B44
G20-193
JDC-12
G20-127
HIB19
8G12
8G12
581
IA6-2
HIB19
SJ25C1
HI30
eBioRDR5
TB28-2
1-155-2
1H9
30F11
LT19
AC136
MB15-18C9
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Manufacturer
BD Biosciences (San Jose, CA)

Biolegend (San Diego, CA)
eBioScience (San Diego, CA)

Miltenyi Biotec (Auburn, CA)

Polymerase Chain Reaction
Total RNA was extracted from 8 to 9 x 105 human stromal cells with RNA-STAT
60 reagent (Tel-Test Inc., Friendswood, TX). cDNA was synthesized using Omniscript
Reverse Transcriptase (Qiagen, Valencia, CA). The expression of TSLP, IL-
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microglobulin as a control, were assessed by touch down PCR. The primers used were:
TSLP forward 5’-TCG TAA ACT TTG CCG CCT AT-3’ and reverse 5’-TGG TGC TGT
GAA ATA TGA CCA-3’ (324 bp); IL-7 forward 5’- CTC CCC TGA TCC TTG TTC TG
and reverse 5’- TCA TTA TTC AGG CAA TTG CTA CC-
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microglobulin forward 5’-CTC GCG CTA CTC TCT CTT TC-3’ and reverse 5’-CAT
GTC TCG ATC CCA CTT AAC-3’ primers.
Touch-down PCR conditions for TSLP were as follows: 95°C for 5 min (1 cycle);
95°C for 1 min, 61°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 59°C for 30
sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 57°C for 30 sec. 72°C for 1 min (2
cycles); 95°C for 1 min, 55°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 53°C
for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 51°C for 30 sec. 72°C for 1 min
(30 cycles); 72°C for 10 min (1 cycle); and final hold step of 4°C.
Touchdown PCR conditions for IL-7 were as follows: 95°C for 5 min (1 cycle);
95°C for 1 min, 63°C for 45 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 61°C for 45
sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 59°C for 45 sec, 72°C for 1 min (2
cycles); 95°C for 1 min, 57°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 55°C
for 45 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 53°C for 45 sec. 72°C for 1 min
(30 cycles); 72°C for 10 min (1 cycle); and final hold step of 4°C.
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Amplified PCR products were visualized with a 2.2% FlashGel (Lonza,
Walkerswood, MD). PCR products were purified with QIAquick PCR purification kit
(Qiagen, Valencia, CA) and sequenced at the Genomics Core (University of California,
Riverside, CA).
Animal Studies
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
(Jackson Laboratory). Mice were housed under specific pathogen-free conditions in the
Loma Linda University animal facility and studied in accordance with an Institutional
Animal Care and Use Committee (IACUC) approved protocols. Mice were engineered by
intraperitoneal injection with HS-27 stromal cells (ATCC, Manassas, VA) that had been
transduced to express human TSLP (+T mice) or transduced with empty vector (–T mice)
as previously described (Francis et al., 2015). Transduction of stroma and injection of
stromal cells were performed as described (Francis et al., 2015). Mice were transplanted
by tail vein injection with freshly thawed, CB CD34+ cells after sub-lethal irradiation at
225 cGy. Five weeks after CB transplant, 3 mg MAb anti-mouse/human IL-7 (clone:
M25) or IgG2b isotype-matched control (clone: MPC-11, BioXCell, West Lebanon, NH)
was injected, i.p. every 3–4 days for 2 weeks as described in previous studies that used
this anti-IL-7 antibody to inhibit in vivo mouse B lymphopoiesis (Grabstein et al., 1993).
NSG mice were euthanized by CO2 asphyxiation, seven weeks after CB CD34+
transplantation and BM was harvested and frozen for flow cytometry analysis.
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CHAPTER FIVE
UNPUBLISHED DATA: EFFECTS OF TSLP ON B CELL DIFFERENTIATION
FROM HUMAN ADULT BONE MARROW HAEMATOPOIETIC STEM CELLS

Abstract
Studies from mice suggest that during ontogeny, B cell progenitors respond
differently to TSLP. The ability of TSLP to expand B cell production from adult bone
marrow HSCs has not been evaluated in humans. Using an innovative human selective
cytokine co-culture, we demonstrate that in the absence of IL-7, TSLP does not increase
the production of B cell progenitors. This data suggests that TSLP may not be as
important for adult lymphopoiesis.

Introduction
In mice and men, the bone marrow (BM) is the primary organ of post-natal B
lymphopoiesis and identifying the cytokines that drive the differentiation and growth of B
cell progenitors in this organ has been a major topic of study. TSLP and IL-7, members
of the same cytokine family (Sims et al., 2000), were initially found to have overlapping
yet distinct functions in promoting B cell development in mice. In culture, both mouse
TSLP and IL-7 stimulated the proliferation of B cell precursors. TSLP facilitated
differentiation to the IgM+ stage, while IL-7 supported differentiation to an earlier IgM–
stage (Levin et al., 1999). In addition to that difference, data from other studies suggest
that TSLP may play a role at different points in mouse ontogeny. B cell progenitors from
fetal liver were TSLP-responsive, while those from the BM were responsive only after
the pre-B cell receptor was expressed (Vosshenrich, Cumano, Muller, Di Santo, & Vieira,
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2003, 2004). Furthermore, in the absence of IL-7, intrinsic TSLP levels were unable to
sustain B cell production in the bone marrow of these (Vosshenrich et al., 2003).
However when overexpressed, TSLP restored the B cell compartment in adult IL-7
deficient mice (Chappaz, Flueck, Farr, Rolink, & Finke, 2007).
While the ability of TSLP to replace IL-7 has been evaluated in the mouse, little is
known about its role in modulating human B cell differentiation from HSCs. To date, a
single study exists, which examined human TSLP in fetal B lymphopoiesis. Like the
mouse, human fetal B cell precursors, proliferated in response to human TSLP (Scheeren
et al., 2010). Our group recently found that human TSLP increased the numbers of B cell
precursors generated in in vivo (Chapter 3) (Francis et al., 2015) and in vitro (Chapter 4)
models of CB lymphopoiesis. Here we set out to determine if human TSLP also
promoted the growth and differentiation of B cell progenitors from adult bone marrow
HSCs, similarly to fetal HSCs. These preliminary findings suggest that TSLP may not be
a major player in human adult B cell development.

Materials and Methods
Cell Sources
Human adult BM and stromal cells were purchased from Lonza Inc.
(Walkersville, MD) and mononuclear cells were isolated by density-gradient
centrifugation using Ficoll-Paque Plus (GE Healthcare Bio-Sciences, AB) or by red blood
cell (RBC) lysis buffer (Kang et al., 2002). The adult BM mononuclear cells were
enriched for CD34+ hematopoietic stem cells (typically >80% purity as determined by
post isolation flow cytometry analysis) using a direct CD34+ cell isolation kit (Miltenyi
Biotec, Auburn, CA). CD34+ cells were frozen and stored in liquid nitrogen until further
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use. Adult BM stromal cells were isolated from total BM as previously described (Nolta
et al., 2002). The stromal cells were maintained in IMDM medium supplemented with
15% horse serum, 15% FBS, hydrocortisone, 2-mercaptoethanol, penicillin-streptomycin
and L-glutamine. All cells were used in accordance with the Institutional Review Board
(IRB) guidelines of Loma Linda University.

In Vitro Co-Cultures
Human only co-cultures were initiated as previously described (Parrish et al.,
2009). Briefly, adult BM CD34+ cells were seeded unto pre-plated primary human BM
stromal cells, at 20,000 to 32,000 cells per well in 96-well plates. For some experiments
numbers were scaled up to give equivalent cell densities in 6-well and 12-well plate.
Cultures were maintained in B cell medium [RPMI 1640 medium (Irvine Scientific),
penicillin/streptomycin, L-glutamine, 50 uM 2-ME and 5 % human AB serum lot tested
to support B cell production (Omega Scientific)]. Cultures were supplemented with 1
ng/ml IL-3 during the first week only and 1 ng/ml Flt-3 Ligand, 10 ng/ml TSLP and/ or 5
ng/ml IL-7. All cytokines were from R&D Systems Inc. (Minneapolis, MN). Cultures
were further supplemented with anti-human neutralizing or control antibody for Flt3Ligand at 0.05 ug/ml (R&D Systems); anti-human neutralizing or control antibody for
IL-7 at 10 ng/ml (BD Pharmingen); or anti-human neutralizing or control antibody for
TSLP at 1 ug/ml (R&D Systems and Jackson ImmunoResearch, respectively). Each
week, half of the old medium was removed and replaced with fresh medium
supplemented in the same way. Neutralizing antibodies were added at saturating
concentration. Cultures were maintained for three weeks then harvested.
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Flow Cytometry
In vitro cultures were harvested, surface stained then resuspended in 1% PFA as
previously described (Zhang et al., 2005). Data were acquired on either a FACSCalibur
(BD Immunocytometry Systems) or MACSQuant® (Miltenyi Biotec), and then analyzed
with FlowJo software v8 or v9 (FlowJo, Ashland, OR). All antibodies are monoclonal,
anti-human antibodies unless otherwise stated. Clones are included in parentheses. From
BD Biosciences (San Jose, CA): CD19 APC (HIB19), CD24 FITC (ML5), CD34 PerCP
(8G12), and IgM PE.Cy5 (G20-127). From Biolegend (San Diego, CA): CD19 Pacific
Blue (HIB19), CD24 PE.Cy7 (ML5) and CD34 APC.Cy7 (581). From eBioscience (San
Diego, CA): CD19 APC (HIB19), CD127 Alexa-Fluor 647 (eBioRDR5) and CD127 PE
(eBioRDR5). From Miltenyi Biotec (Auburn, CA): CD19 APC (LT19) and CD127 PE
(MB15-18C9).

Statistics
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software,
Inc., La Jolla, CA).

Results and Discussion
It is not known if TSLP-induced effects on human B cell development extend to
the adult bone marrow or if they are restricted to HSCs from fetal and post-fetal sources.
To evaluate the effects of TSLP in adult B cell development, BM CD34+ cells were
enriched by magnetic separation and cultured on primary human BM stroma as
previously described (Parrish et al., 2009). As shown in Figure 30A, four culture
conditions were created from combinations of IL-3, Flt-3 ligand, TSLP and/or IL-7. In
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control conditions with IL-3 and Flt-3 ligand, a few B cell progenitors were produced
(Figure 30B and C). While the size of this B cell progenitor population significantly
increased with the addition of IL-7, TSLP supplementation did not increase the number
of B cell precursors above control conditions (Figure 30B and C). Conditions with both
TSLP and IL-7 stimulation generated similar numbers of B cell precursors to the IL-7
only condition (Figure 30B and C). Allakhverdi et al. demonstrated that human CD34+
progenitors express both IL-7R and TSLPR chains and are responsive to TSLP in an
allergy model (Allakhverdi et al., 2009). Therefore we do not attribute the failure to
impact B cell production on the absence of the receptor components.
As TSLP has been shown to promote the differentiation of adult mouse B cells to
the IgM+IgD– immature B cell stage (Levin et al., 1999), we also evaluated IgM
expression on B cell progenitors generated in our selective cytokine cultures. No IgM+
immature B cells were produced in control, TSLP, IL-7 nor TSLP+IL-7 conditions
(Figure 30B). Signaling through IL-7R is known to upregulate CD19 expression in
human B cell progenitors (Billips et al., 1995; Parrish et al., 2009; Wolf, Weng,
Stieglbauer, Shah, & LeBien, 1993). As expected, pro-B cells generated with IL-7 had
higher levels of CD19 than control (Figure 30B, D and data not shown). However, pro-B
cells from TSLP conditions did not exhibit increased CD19 expression.
Collectively, these initial data suggest that B cell progenitors, produced from
adult bone marrow CD34+ cells, are not responsive to TSLP stimulation, like their
neonatal CD34+ cells are in our selective cytokine cultures (Chapter 4). It will be of
interest to evaluate adult B cell differentiation in the +TSLP mice, as they permit the
differentiation of B cell progenitors through the mature B cell stage.
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Figure 30. TSLP does not increase B cell production from human adult bone marrow (BM)
HSCs in selective cytokine co-cultures. (A) Experimental design of selective cytokine cocultures. Adult BM CD34+ HSCs were cultured on primary human BM stromal cells with
combinations of IL-3 (1 ng/ml, for the first week only), Flt-3 ligand (1 ng/ml) and TSLP
(10 ng/ml) and/or IL-7 (5 ng/ml) for 3 weeks as illustrated. Neutralizing antibodies to TSLP
and/or IL-7 were added to the cultures to counter the effects of any endogenously produced
cytokines if TSLP or IL-7 was not added. Cultures were harvested and stained with
antibodies to identify (B) B cell precursors (CD19+ CD34+ or CD34–) generated in vitro.
(C) Graphed is the relative number of total B cell precursors (CD19+) produced in each
condition. Relative cell number was determined by normalizing the number of CD19+ cells
generated in each condition to the total CD19+ cells generated in all 4 conditions. (D)
Cultures were also stained with antibodies to distinguish immature B cells (CD19+IgM+)
from B cell precursors (CD19+ IgM-). Data shown are representative of, or pooled from 6
independent co-cultures initiated with adult BM HSCs. Statistical significance was
determined by unpaired t test, 2-tailed (*, p< 0.05).
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Abstract
IL-7 receptor (IL-7R) signaling is essential for mouse B cell development,
however its role in human B lymphopoiesis is controversial. Here we provide the first
evidence that expression of a single marker, the IL-7R chain, can identify a lymphoidrestricted CD19–CD34+ human progenitor population (IL-7R+ progenitors) that is
completely devoid of myeloid potential. Single cell assays show that IL-7R+ progenitors
include bi-potential B-NK cells, as well as lineage-committed B and NK progenitors. In
vitro-generated IL-7R+ progenitors produced B and NK cells in xenograft mice. IL-7R+
progenitors were able to differentiate into T lineage committed cells with Notch
signaling. IL-7R+ progenitors are rare (<2% of CD19–CD34+ cells) in circulating
umbilical cord blood (CB), but comprise 20%-30% of CD19–CD34+ cells produced from
CB CD34+ cells cultured in vitro or in vivo in the human-mouse xenograft model. These
data suggest that IL-7R+ progenitors are common lymphoid progenitors in CB
lymphopoiesis, previously undetected because of their low frequency in circulating CB.
These committed lymphoid progenitors may provide a therapeutic alternative that have
impact on clinical outcome such as immune reconstitution after CB stem cell transplant if
proved to be expandable efficiently.
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Introduction
Insufficient lymphopoiesis can lead to compromised, adaptive immune function
with increased susceptibility to infection and death. Insufficient lymphopoiesis is a
feature of the early stages of immune reconstitution following hematopoietic stem (HSC)
transplant (Fry & Mackall, 2005). It can also be a consequence of the myeloid skewing of
hematopoiesis that has been associated with chronic inflammation (Esplin et al., 2011;
Nagai et al., 2006) and with aging of the immune system (Ergen, Boles, & Goodell, 2012;
Ergen & Goodell, 2010). The lymphocytes that are present in these cases often result
from clonal expansion of mature cells, and thus the diversity of the adaptive immune
response is also limited (Blackman & Woodland, 2011; Fry & Mackall, 2005).
Identifying the lymphoid-restricted progenitor populations that are intermediates in the
differentiation of lymphoid lineage cells from HSCs will provide a foundation for
developing therapies to augment the production of lymphocytes. These populations could
potentially be targeted for ex vivo (Zakrzewski et al., 2006) or in vivo (Liuba, Pronk,
Stott, & Jacobsen, 2009) expansion to increase the de novo production of lymphocytes
and restore a robust and diverse polyclonal adaptive immune response.
Umbilical cord blood (CB) is a hematopoietic source used increasingly for HSC
transplant, even in adults (Jacobson et al., 2012). As compared to adult BM and
mobilized peripheral blood, CB transplant results in lower incidences of graft versus host
disease (Broxmeyer, 2008). Thus, CB is an ideal source of stem/progenitors for
augmenting lymphoid reconstitution. Previous studies aimed at identifying lymphoidrestricted progenitors in CB lymphopoiesis have focused on cells present in circulating
CB. The CD19–CD34+ progenitors in those studies were identified based on expression
CD7 and/or CD10 and required the use of multiple lineage markers and additional
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surface markers to eliminate cells with myeloid lineage potential (Hao et al., 2001; Rossi
et al., 2003)
In the mouse, expression of the IL-7 receptor α chain (IL-7R) is a distinguishing
feature of the earliest lymphoid-restricted progenitors with B cell potential (Kondo,
Weissman, & Akashi, 1997). Human B cell development has been thought to differ from
that in mouse concerning the requirement for IL-7 (Lee, Namen, Gillis, Ellingsworth, &
Kincade, 1989; Namen et al., 1988). However, in our previous studies we used a novel
human-only co-culture system to show that IL-7 is critical for expanding human CD19+
B cell progenitors produced from HSCs in CB and for the production of human B lineage
cells from adult BM. Here we show that IL-7R expression can be used alone to identify
CD19–CD34+ progenitors that give rise to B/NK cells as well as T cells, but completely
lack myeloid differentiation potential. These IL-7R+ progenitors are rare in circulating
CB but comprise a substantial fraction of the CD19–CD34+ progenitors generated from
HSCs during CB lymphopoiesis in vitro and in vivo in the xenograft model. Thus, IL7R+ progenitors represent a potential target population for therapies aimed at augmenting
lymphocyte production to increase adaptive immune responses.

Materials and Methods
Cell Sources
Cord blood samples were obtained by informed consent in accordance with
approved Loma Linda University Institutional Review Board (IRB) protocols. Adult
human BM was purchased from Poietics Cell Systems (Lonza, Walkersville, Inc.,
Gaithersburg, MD). The murine S17 stromal cell line was kindly provided by Dr.
Kenneth Dorshkind (Cumano, Dorshkind, Gillis, & Paige, 1990). The murine
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OP9/OP9Delta1 stromal cell lines were kind gifts from J. C. Zuniga-Pflucker (University
of Toronto, Ontario, Canada).

Cell Cultures
Human CB CD34+ cells were seeded onto primary human BM stromal layers
plated at 7000 cells/well in 96-well tissue culture plates. Cultures were maintained in B
cell medium supplemented with IL-3 at 1 ng/ml (first week only) and Flt-3 ligand (FL) at
1 ng/ml (both from R&D Systems Inc., Minneapolis, MN), as described previously
(Parrish et al., 2009). After 2 weeks of culture, CD34+CD19– cells were harvested and
FACS-sorted into IL-7R– and IL-7R+ subpopulations, which were used for lineage
specific differentiation both in vitro and in vivo. For clonal myelo-erythroid assays 500 to
1000 FACS sorted cells were plated into 1-mL of 1% methylcellulose media
(MethoCultGFH4434; Stem Cell Technologies, Vancouver, BC). Colony Forming Units
(CFUs) including CFU-GM, BFU-E/CFU-E and CFU-GEMM were counted after 14
days in culture.
To evaluate B and NK lineage potential, CB-derived cells cultured with the
murine S17 stromal line for 2 weeks in B cell medium supplemented with IL-7 (5ng/mL),
Flt-3 ligand (5ng/mL), and IL-15 (20 ng/mL), all from R&D Systems (Minneapolis, MN)
(Hao et al., 2001). FACS Sorted CB cells (3000-5000 cells per well for bulk cultures or
single cells per well for clonal assays) were seeded onto S17 stromal cells in 96-well
plates. In vitro T-cell development cultures were carried out as described previously (La
Motte-Mohs, Herer, & Zuniga-Pflucker, 2005). OP9-control and OP9-DL1 monolayers
were prepared 1 day in advance by plating stromal cells at 2x105 cells/well in 6-well
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culture dishes, and progenitor cell populations were plated at 1x105 cells per well onto
stromal layer in α-MEM media (Cellgro) containing 20% fetal calf serum (FCS),
supplemented with L-glutamine and penicillin/streptomycin. Culture medium was
supplemented with 5 ng/mL of IL-7 and FL (R&D Systems, Minneapolis, MN). Media
containing cytokines was replaced every 2-3 days and cells were transferred to new
layers of OP9/OP9Delta1 stromal cells weekly. Cultures were evaluated weekly for T cell
differentiation status.

Flow Cytometry and Cell Sorting
Cells were stained for flow cytometry analysis with standard protocols using the
following mouse-anti-human antibodies: CD34 PerCP, CD19 Pacific Blue or APC, CD7
PE or PE-Cy5, CD45-PE-Cy7, CD56 FITC and CD1a efluor450 from eBioscience; IL7Rα-PE from Miltenyi Biotec Inc; CD10 APC-Cy7, CD11b PE, CD5 APC from BD
Pharmingen. Flow cytometry acquisition and analysis were performed using a
MACSQuant® Analyzer (Miltenyi Biotec Inc. Auburn, CA) and FlowJo data analysis
software v9 (FlowJo LLC, Ashland, OR). Cell sorting was performed using a FACSAria
(BD Biosciences Immunocytometry Systems).

Transplantation Studies in NOD/SCID/-2mnull mice.
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD/SCID/-2mnull; NSG) mice were
purchased from Jackson Laboratory (Bar Harbor, ME) and housed and bred under
pathogen-free conditions in the Loma Linda University animal facility and studied in
accordance with the Institutional Animal Care and Use Committee (IACUC) approved
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protocol. CB CD34+ HSCs (2X104) or sorted IL-7R+ and IL-7R- progenitors (1.5X104)
were intravenously injected into sublethally irradiated (225 cGy) 4 to 6 week-old NSG
mice. 5–7 weeks after transplantation, mice were sacrificed and cells were harvested from
BM.
Results
IL-7R+ Progenitors are Produced In Vitro from CD34+ CB Cells,
but are Rare in Circulating CB
Using a novel human-only co-culture system, our previous studies showed that
IL-7 is essential for adult human B lymphopoiesis and critical for B cell production from
HSCs in CB (Parrish et al., 2009). To identify the earliest CD19– lymphoid progenitors
that are potentially targeted by IL-7 we used flow cytometry to evaluate expression of IL7R on CD19–CD34+ progenitors produced from CB CD34+ co-cultured with primary
human BM stroma (human-only co-cultures). As shown in Figures 1A (left panel) and
1C, approximately 20% of the CD19–CD34+ progenitors generated in vitro were
comprised of IL-7R+ cells (designated IL-7R+ progenitors here). Surprisingly, the
frequency of IL-7R+ progenitors in uncultured CB was significantly lower, making up
only ~2% of the CD19–CD34+ cells present in circulating CB (Figure 1B, left panel, and
Figure 1C).
This led us to ask whether progenitor populations that express CD7 or CD10, two
markers previously used to identify lymphoid progenitors (Galy, Travis, Cen, & Chen,
1995; Hao et al., 2001; Rossi et al., 2003) were similarly under-represented among
circulating CB cells as compared to their counterparts generated in vitro. As shown in
Figures 1A–C, the CD19–CD34+ cord blood progenitors that express CD10 or CD7 are
present at similar frequencies in the in vitro-generated progeny of CB CD34+ cells and in
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uncultured CB. Taken together, these data show that 1) IL-7R+ progenitors are a major
progenitor population produced from CB HSCs during in vitro culture and 2) unlike
CD7+ and CD10+ progenitors, IL-7R+ progenitors are largely absent from circulating
CB.

Figure 1 (Figure 31). IL-7R+ progenitors are produced in vitro from CD34+ CB cells,
but are rare in circulating CB. Samples were harvested from a “human-only” culture
based on co-culturing human CB CD34+ HSCs on primary human BM stroma with FL
for 2 weeks, supplemented with IL-3 for the first week only. (A) The expression of IL7Rα, CD10 and CD7 were evaluated on cultured CD34+CD19– cells. (B) The
representative expressions of IL-7Rα, CD10 and CD7 in CD34+CD19– populations
were also analyzed in unmanipulated CB samples. Data shown in each dot plot are the
mean ± SEM of three to 12 independent experiments. Isotype controls are displayed in
the lower left or right corner of each larger dot plot. Summarized in (C) are the
frequencies of IL-7Rα, CD10 and CD7 cells in either cultured cells or unmanipulated
CD19–CD34+ cells, where n = three to 12 independent experiments, **** P < 0.0001.

185

IL-7R Expression Identifies an In Vitro-Generated Progenitor Population with
Lymphoid but not Myeloid Differentiation Potential
To determine the differentiation potential of the IL-7R+ progenitors, CFU assays
were used to assess myeloid lineage potential and stromal cell co-cultures were used to
determine B and NK lineage potential. CD19–CD34+ cells generated in vitro from
cultures of CB CD34+ cells (Figure 2A) were FACS sorted into IL-7R– and IL-7R+
subsets and assessed for myeloid and lymphoid differentiation potential. For comparison,
culture-generated CD19–CD34+ cells were also FACS sorted into CD10– and CD10+, as
well as CD7– and CD7+ subsets.
CFU assays showed that the IL-7R– subset of CD19-CD34+ cells generated
myeloid and erythroid colonies, whereas IL-7R+ progenitors were completely devoid of
myeloid or erythroid differentiation potential (Figure 2B, top panel). In contrast, both
CD10– and CD10+ subsets of CD19–CD34+ cells retained substantial myelo-erythroid
potential, although CD10+ cells formed significantly lower numbers of colonies when
compared to CD10– cells (Figure 2B, middle panel). No difference was observed
between the ability of CD19– CD34+ cells that were CD7– or CD7+ to generate myeloid
and erythroid colonies (Figure 2B, bottom panel). These data suggest that IL-7R+
progenitors generated in vitro from CD34+ CB cells have lost myelo-erythroid
differentiation potential.
To determine the B and NK potential of IL-7R+ progenitors, we seeded these
cells into murine S17 stromal cell co-cultures under lymphoid conditions (FL, IL-15
and/or IL-7) as previously described (Hao et al., 2001). As a control, CD19–CD34+
progenitors that were IL-7R– were also evaluated. Distinct populations of CD19+ and
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CD56+ cells were identified in bulk cultures from both the IL-7R– and IL-7R+
progenitors (Figures 2C and D). These data provide evidence that IL-7R, but not CD10 or
CD7, can be used as a single marker to identify an early lymphoid progenitor population
in CB lymphopoiesis that is completely devoid of myelo-erythroid potential. These
results also demonstrate that that IL-7R+ progenitors can give rise to both B and NK
cells.
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Figure 2 (Figure 32). Expression of IL7R, but not CD10 or CD7 identifies CB-derived
progenitors with B-NK but not myeloid differentiation potential. (A) Schema of study
design. “Human-only” co-cultures were used to generate progenitor cells as described
in Figure 1. CD34+CD19– cells were sorted based on expression of IL-7R, CD10 and
CD7 and assayed in lineage-specific in vitro assays. (B) CD34+CD19–IL-7R+/IL-7R–
, CD34+CD19–CD10+/CD10– and CD34+CD19–CD7+/CD7– cells were seeded in
triplicate in methylcellulose-based myeloid-erythroid cultures (CFU-Assay). CFUs
were counted on day 14. Data are summarized as the number of CFU per progenitor
plated. Data are presented as mean values ± SEM of triplicate determinations from three
to seven individual experiments, ** p< 0.01, ****p < 0.0001. CD34+CD19–IL-7R+/IL7R– cells were also cultured in B and NK lineage differentiation cultures, supplemented
with FL, IL-7 and IL-15. Cells were harvested on day 14 and analyzed by flow
cytometry. Displayed in (C) are representative dot plots of CD19 versus CD56 staining
from cultures initiated with sorted CD34+CD19–IL-7R+/IL-7R– cells. (D) Graphed is
the percent (mean ± SEM) of CD19+ and CD56+ cells generated from cultured IL-7R–
and IL-7R+ cells in three – five experiments.

188

CB CD34+ Cells Produce Lymphoid-Restricted IL-7R+ Progenitors In Vivo in
the Human-Mouse Xenograft Model
To determine if IL-7R+ progenitors are generated during in vivo differentiation
from CB CD34+ cells we used a human-mouse xenograft model. Xenograft mice were
produced by transplanting human CB CD34+ cells into sublethally irradiated, immune
deficient NSG mice. BM was harvested 5–7 weeks post transplant and stained for flow
cytometry to detect human cells generated in vivo (Figure 3A). Flow cytometry showed
that human cells (hCD45+) comprised ~90% of harvested BM (Figure 3B, left panel) and
that CD19–CD34+ cells made up ~13% of the human cells in BM (Figure 3B, middle
panel). Approximately one third of the CD19–CD34+ cells generated in vivo expressed
the IL-7R (Figure 3B, right panel). These data show that IL-7R+ progenitors are
produced from CB CD34+ cells in vivo in the human-mouse xenograft model and suggest
that IL-7R+ progenitors represent a major intermediate during in vivo hematopoiesis from
CB HSCs.
Next we evaluated the lymphoid and myeloid differentiation potential of IL-7R+
progenitors produced in vivo. hCD45+CD19–CD34+ cells harvested from BM of human
mouse xenografts were FACS-sorted into IL-7R– and IL-7R+ subsets and evaluated for
myeloid potential in CFU assays and for lymphoid potential in stromal cell co-cultures.
Data obtained from human progenitors generated in vivo in the xenograft model was
similar to that from culture-generated cells: the IL-7R– progenitor population gave rise to
myeloid and erythroid colonies in CFU assays, however, no CFU colonies were produced
from IL-7R+ progenitors (Figure 3C). In stromal cell co-cultures grown under lymphoid
conditions, both IL-7R– and IL-7R+ subpopulations gave rise to CD19+ and CD56+ cells
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(Figures 3D and E). These data show that IL-7R+ progenitors generated in vivo from CB
HSCs have B and NK, but lack myeloid differentiation potential.

Clonal Analysis of IL-7R+ Progenitors in a Single Cell Assay of
Figure 3 (Figure 33). CD34+CD19-IL7R+ progenitors generated in the human-mouse
xenograft model possess only B-NK potential. (A) Schema of study design. 2x104
CD34+ CB CD34+ stem cells were transplanted into sublethally irradiated (225 cGy)
NOD/SCID/-2mnull (NSG) mice, BM cells were harvested five to seven weeks later
and analyzed by flow cytometry. A representative diagram of IL-7R expression gated
on human (h) CD45+CD34+CD19– cells is shown in (B), where isotype controls are
displayed in either the lower right corner or the lower left corner of the respective plots.
Data are presented as mean values ± SEM of three separate experiments. Cells were
sorted into hCD45+CD34+CD19–IL-7R– and hCD45+CD34+CD19–IL-7R+
populations and evaluated in various assays. (C) CFU assays were performed on these
sorted cells as described in Figure 2. Data are presented as mean ± SEM of CFU per
progenitor cell from three separate experiments performed in triplicate, ** p < 0.01.
Cells were also analyzed after being cultured in B cell and NK cell differentiation
conditions for 2 weeks. The expressions of CD19 and CD56 on the cultured cells were
analyzed by flow cytometry. Representative plots of CD19 and CD56 expression are
shown in (D) and data presented as mean values ± SEM of three separate experiments
are shown in (E).
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B and NK Potential
To determine whether the IL-7R+ progenitor population is comprised of multilineage lymphoid progenitors or a mixture of B- and NK-committed cells, we evaluated
in vitro- and in vivo-generated IL-7R+ progenitors in single cell assays. IL-7R– and IL7R+ cells generated in human only co-cultures or in human-mouse xenografts from
CD19–CD34+ progenitors, were FACS-sorted as described in Figures 2 and 3. Single
cells were FACS sorted into co-culture with murine S17 stroma in individual wells of 96well plates and grown under lymphoid conditions. After two weeks of culture, each well
was harvested and evaluated by flow cytometry to detect the presence of B (CD19+)
and/or NK (CD56+) lineage cells.
Consistent with enrichment of lymphoid progenitors, the total cloning frequency
in lymphoid conditions was ~3 fold higher for IL-7R+ progenitors as compared to cells
that were IL-7R– (Table 1). Bi-potential, B-NK progenitors gave rise to one in 25 of the
total clones produced from in vitro-generated IL-7R+ progenitors and one in 18 of the
total clones produced from IL-7R+ progenitors generated in vivo. Single lineage, B- or
NK-committed cells comprised the majority of in vitro and in vivo-generated IL-7R+
progenitors. Taken together with CFU data these results provide evidence that IL-7R+
progenitors are a lymphoid committed progenitor population that includes bi-potential BNK progenitors, as well as more differentiated B- and NK-committed progenitors.
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Table 1 (Table 4). In vitro Analysis of the Lymphoid Lineage Potential of Single CD19–
CD34+ IL-7R– and CD19- CD34+ IL-7R+ Progenitors
In Vitro-Generated
Progenitors

Xenograft-Generated
Progenitors

Progenitor Subset

IL-7R–

IL-7R+

IL-7R–

IL-7R+

Total Cloning Frequency
(#Total clones detected)

3.7%
(403)

12.4%
(404)

1.4%
(479)

4.71%
(576)

B-NK Cloning Frequency
(# B-NK Cell Clones)

0%
(0)

.5%
(2)

0%
(0)

.2%
(1)

B-Only Cloning Frequency
(# B Cell-Only Clones)

1.7%
(7)

5.9%
(24)

1.3%
(6)

3.3%
(15)

NK-Only Cloning Frequency
(# NK Cell-Only Clones)

2.0%
(8)

5.9%
(24)

0%
(0)

.5%
(3)

In Vitro Exposure of IL-7R+ Progenitors to OP9-Delta1 Co-Culture
Induces Phenotypic Changes that are Consistent with Early
T-Cell Development
The initiation of commitment to the T cell lineage by human HSC/progenitor cells
is marked by expression of CD7 (Hoebeke et al., 2007) as well as CD1a (Haddad et al.,
2006; La Motte-Mohs et al., 2005) and CD5 (Awong et al., 2009). Specifically,
CD34+CD7+ cells are the earliest T progenitors detected in cultures induced by the
Notch signaling (Awong et al., 2009) . To determine the T lineage potential of IL-7R+
progenitors generated in vitro and in vivo, IL-7R+ cells were cultured on OP9-DL1 or
OP9-control cells with FL and IL-7 as previously described (La Motte-Mohs et al., 2005).
As controls, purified CD34+ stem cells and IL-7R– progenitors were also evaluated.
Purified CD34+ CB cells and IL-7R– progenitors sorted from in vitro cultures and in
vivo xenograft animals cultured on OP9-DL1, produced a small population of cells
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expressing CD7 within the first week of culture (data not shown). CD7 expression
continued to increase between weeks 1 to 2 and corresponded with the emergence of a
CD34–CD7+ population (Figure 4A, Rows 1–2). The CD34−CD7+ population continued
to increase through week 6 of culture. A T-cell committed progenitor subset expressing
CD5 and CD1a emerged from within the CD34−/CD7+ population between weeks 2 and 3
and peaked between weeks 4 and 5 (Supplemental Figure 1A-B). A higher percentage of
CD5+CD1a+ cells was generated from IL-7R– sorted cells than purified CD34+ cells
(Supplemental Figure 1A-B). In contrast, IL-7R+ progenitors, gave rise to a lower
percentage of CD34+CD7+ early T cell progenitors but higher percentage of CD34–
CD7+ in the first two weeks of culture (Figures 4A–B, third row), suggesting that at the
beginning of the culture, this population is more differentiated than IL-7R– cells.
Consistently, IL-7R+ progenitors generated a higher percentage of CD7+CD5+CD1a+ T
lineage committed cells during the first two weeks of culture in contrast to 3–4 week
from IL-7R– cells (Figure 4B). Robust, early T cell differentiation continued through
week 6. CD34+CD7+ early T cell progenitors and CD7+CD5+CD1a+ T lineage
committed cells were not detected in the negative control of CD34+ stem cells on OP9control . This data show that IL-7R+ progenitors are able to produce early T cell
commited progenitors.
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Figure 4 (Figure 34). IL-7R+ progenitors generated in vitro and in vivo, produce CD7+
T cell progenitors. CD34+CD19-IL-7R– and CD34+CD19-IL-7R+ progenitors
generated (A) in vitro as described in Figure 2 or (B) in vivo as described in Figure 3
were FACS-sorted and cultured on OP-9DL-1 cells. Total CD34+ cells were cultured
on OP9–DL1 cells or OP9 cells for positive or negative controls, respectively. Cultures
were harvested at the intervals shown and cells stained for flow cytometry to identify
CD34– CD7+ T cell progenitors
.
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Supplemental Figure 1 (Figure 35). CD5+CD1a+ T cell committed progenitors are
generated from IL-7R+ progenitors. Cells were generated and cultured as in Figure 4
CD5 and CD1a expression were evaluated on CD7+ CD34+/– cells shown in Figure 4.
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Culture-Generated IL-7R+ Progenitors are Enriched for Cells with
B and NK Differentiation Potential In Vivo
To determine the in vivo differentiation capacity of in vitro-generated IL-7R+
progenitors, we evaluated hematopoietic differentiation in NSG mice transplanted with IL7R+ progenitors and IL-7R– progenitors for comparison, produced in human-only cocultures (Figure 5A). Human CD45+ cells were detected in all recipients (Figures 5B and
C). Recipients of IL-7R+ cells showed BM chimerism that was ~10 fold lower than that
observed for recipients of IL-7R– cells (0.18 % and 10.85% respectively). As shown in
Figure 5B, the majority of the human cells produced from transplanted IL-7R+ progenitors,
fell within lymphoid light scatter gates, while those from recipients of IL-7R– progenitors
include cells with lymphoid and myeloid light scatter (Figure 5B, left panel). In vivo
differentiation of IL-7R+ progenitors produced primarily B lineage cells with limited NK
cell (~5% of hCD45+ cells) and virtually no myeloid cells (Figures 5 D-F, right panels and
G). In contrast, IL-7R– progenitors showed multi-lineage engraftment that include
approximately equal proportions of B and myeloid lineage cells and NK cell production
similar to that observed for IL-7R+ progenitors (Figures 5 D-F, left panels and G). These
data show that IL-7R+ progenitors generated in vitro from CB CD34+ cells retain in vivo
B and NK differentiation but lack myeloid differentiation potential.
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Figure 5 (Figure 36). CD34+CD19-IL7R+ progenitors generated in vitro culture are
enriched for B-NK but lack myeloid differentiation potential in the human-mouse
xenograft model. (A) Schema of study design. Cells generated in “Human-only” cocultures described in Figure 2 were FACS-sorted into CD34+CD19-IL-7R– and
CD34+CD19-IL-7R+ populations. Sorted CD34+CD19-IL-7R– or CD34+CD19-IL-7R+
cells, were transplanted into sublethally irradiated (225 cGy) NSG mouse at 1.5x104. Six
weeks later, animals were sacrificed and BM harvested where lymphoid and myeloid
lineage markers were evaluated by flow cytometry. Representative dot plots of human
CD45 (hCD45) versus mouse CD45 (mCD45) engraftment in animals transplanted with
either IL-7R– or IL-7R+ cells are shown in (B). The forward scatter (FSC) and side scatter
(SSC) properties of engrafted hCD45+ cells are shown in the lower left dot plots.
Displayed in (C) is the engraftment of hCD45 cells from IL-7R– and IL-7R+ mice, * p <
0.05. Representative diagrams of the myeloid marker, CD11b; B cell marker, CD19 and
NK cell marker CD56 are shown in (D), (E) and (F), respectively. (G) Data shown are the
frequencies (mean ± SEM) of CD11b, CD19 and CD56 in total hCD45+ produced in the
BM of xenograft mice from CD34+CD19-IL-7R+ and CD34+CD19-IL-7R– cells. n = 3, *
p < 0.05.

197

Discussion
Our studies identify a lymphoid progenitor population with B–, NK– and T–
lineage potential, that suggest a transitional phase between the primitive hematopoietic
stem cell and early lymphoid commitment in cord blood lymphopoiesis. While these IL7R+ progenitors are relatively rare in circulating CB, they can be efficiently cultured in
vitro and in vivo (Figure 1A). Furthermore, IL-7R+ progenitors when generated in vitro
(Figure 2), then transplanted into xenograft mice (Figure 5) or in vivo (Figure 3), retain
their ability to produce B and NK lineages. These progenitors are also capable of
producing early T cell progenitors (Figure 5 and Supplemental Figure 1).
The expression of IL-7R (IL-7R) by Lin–Thy-1–Sca-1loc-Kitlo murine bone
marrow (BM) progenitors, has been used to identify lymphoid-restricted progenitors in a
primary pathway of mouse B cell development (Kondo et al., 1997). However the utility
of IL-7R expression in defining the human CLP counterpart has not previously been
evaluated. In attempts to define a CLP in humans, other groups have used expression of
CD10 and CD7 by primitive CD34+CD38– progenitors from CB and BM, as markers of
a multi-lymphoid lineage progenitor (Galy et al., 1995; Hao et al., 2001; Six et al., 2007).
We found that CD34+ progenitors that expressed CD10+ or CD7+ retained the ability to
generate myeloid and erythroid progenitors as compared to IL-7R+ progenitors that did
not (Figure 2).
The IL-7–IL-7R interaction has been seen as unimportant for human lymphoid
development for the following reasons. Firstly, IL-7R is expressed at low levels on the
human hematopoietic stem cell (HSC) (Hao et al., 2001; Ryan et al., 1997). Secondly, in
vitro studies of human progenitors cultured on murine stromal cell lines, showed minimal
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or reduced IL-7 effects on B cell production, as compared to mice (Rawlings, Quan,
Kato, & Witte, 1995; Taguchi et al., 2007). Thirdly, early clinical observations of patients
with severe combined immunodeficiency disease (SCID) due to defects in IL-7R
signaling, had peripheral B cells, but lacked T cells (Puel, Ziegler, Buckley, & Leonard,
1998). A previous study from our lab, using a novel “human-only” culture model showed
that human B cell development is no different from that of mouse, with respect to the
requirement of IL-7 (Parrish et al., 2009). This study demonstrated that IL-7/IL-7R
signaling is also important in human B cell development. Recent clinical reports
highlight the relationship between IL-7/IL-7R signaling and B cells. A correlation
between B-cell dysregulation and IL-7/IL-7R expression aberration has been described in
active HIV-infected children and adult patients or HIV-exposed neonates (BorgesAlmeida et al., 2011; Cagigi et al.; Malaspina, Moir, Chaitt, et al., 2006; Malaspina,
Moir, Ho, et al., 2006). Therefore, the implications of IL-7R signaling in human
lymphoid progenitor development, previously ignored, needs to be investigated.
CB CD34+ cells are a hematopoietic source used increasingly for stem cell
transplant in a clinical setting. Slow immune cell reconstitution, especially T cells, is a
major concern after transplantation. The first few weeks after transplant are characterized
by a period of lymphopenia followed by rapid recovery of NK cells but a slower recovery
of T cells (Charrier et al., 2013; Jacobson et al., 2012; Thomson et al., 2000). The slow
pace of T cell recovery increases opportunistic infections in the patient (Charrier et al.,
2013). B cell recovery may begin as early as 3 to 6 months post-CB transplantation
(Nakatani et al., 2014) but can take up to 2 years (Seggewiss & Einsele, 2010). Therefore,
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co-transplantation of CLPs with HSCs may be an important strategy to accelerate
immune reconstitution, especially for B and T cells.
In summary, this is the first report to use IL-7R for characterizing a human
lymphoid progenitor population. These committed lymphoid progenitors may prove
useful as targets for expansion and genetic manipulation for clinical purposes, thus
providing a therapeutic alternative that can impact clinical outcome such as immune
reconstitution after CB stem cell transplant and also reduction of incidences of acute
GVHD and transplant related mortality. Moreover, as CD10 and CD7, the previously
described lymphoid markers do not possess discriminative power for lymphoid
restriction, at least in CB, further studies on the relationship between IL-7R, CD10 and
CD7 expressions are warranted.
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CHAPTER SEVEN
DISCUSSION

The interactions of hematopoietic progenitors with the bone marrow
microenvironment; age and immune status of the individual; along with genetic and
environmental factors, all contribute to creating an adaptive, complex process (Thomas,
2015). Although an increasing body of data suggests that IL-7R ligands can impact
human B cell development (S. E. Johnson, Shah, Panoskaltsis-Mortari, & LeBien, 2005;
Malaspina, Moir, Chaitt, et al., 2006; Malaspina, Moir, Ho, et al., 2006; Scheeren et al.,
2010; Wolf, Weng, Stieglbauer, Shah, & LeBien, 1993), their roles remain controversial.
Using a unique, in vitro model of B lymphopoiesis, we demonstrate that IL-7 is
required for the development of B cells in adulthood (Chapter 2), while TSLP may be
dispensable at this later point in ontogeny (Chapter 5). We also investigated the
contribution of TSLP and/or IL-7 in an innovative xenograft model with continuous
human TSLP, and found that in the bone marrow, the increases were specific to the B
cells and were maintained in the spleen (Chapter 3). Furthermore, in both in vitro and in
vivo models of B cell differentiation, B cell precursors expanded from post-fetal HSC
sources in response to TSLP or IL-7 stimulation (Chapter 4). Using CB HSCs, we
identified a lymphoid progenitor-intermediate, the IL-7R+ progenitor. Although present
at low frequency in CB, IL-7R+ progenitors were generated both in vitro and in vivo
(Chapter 6). Collectively, we show that the IL-7R ligands, TSLP and/or IL-7, are
important for the expansion of early B cell precursors from postnatal sources.
The cytokines that drive human B cell development remain elusive while those in
the mouse have been extensively delineated both in vitro and in vivo. Together these data
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show that the requirement for IL-7 and TSLP during B lymphopoiesis, change during the
life of the mouse. During fetal life, B cells undergo IL-7 independent development, while
in adulthood IL-7 is required for maturation of B cell progenitors beyond the pro-B stage
of differentiation (Carvalho, Mota-Santos, Cumano, Demengeot, & Vieira, 2001; Kikuchi
& Kondo, 2006; von Freeden-Jeffry et al., 1995). Conversely, in the absence of IL-7,
TSLP stimulation supported the proliferation of fetal but not adult pro-B cells
(Vosshenrich, Cumano, Muller, Di Santo, & Vieira, 2003, 2004). In opposition to the
previous finding, Jensen et al demonstrated that Flt-3 ligand is a primary cytokine
responsible for IL-7 independent B lymphopoiesis (Jensen et al., 2008). The importance
of IL-7R signaling in developing B cells is further reinforced in adult IL-7R knockout
mice, which suffer from a more severe B lymphopenia, at an earlier developmental stage
than IL-7 knockout mice (Kikuchi, Lai, Hsu, & Kondo, 2005; Peschon et al., 1994).
Collectively, these data establish that IL-7R and Flt-3 ligand induced signals are essential
to mouse B lymphopoiesis.
Practical limitations of procuring healthy human bone marrow have made it
experimentally difficult to evaluate developing B cell precursors in their native
microenvironment. To address this limitation, in vitro models were developed by
culturing hematopoietic CD34+ progenitors on murine stromal cells lines (Barker &
Verfaillie, 2000; Fluckiger et al., 1998; Rawlings, Quan, Kato, & Witte, 1995). While
this model produces a substantial pool of B cell precursors, the effects of uncharacterized
murine proteins cannot be eliminated. To counter the effects of these as yet defined
factors, others evaluated the process of human B cell differentiation in stromal cell free
conditions (Kraus et al., 2014); on human bone marrow mesenchymal stem cells (MSC)
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(Briquet et al., 2010; Ichii et al., 2008) or in conditioned media from MSC (Ichii et al.,
2010), with or without the addition of exogenous cytokines. Another variable shown to
influence the in vitro models of lymphopoiesis is the lot of FSC or FBS selected for
media-supplementation (Ichii et al., 2010). By substituting human serum for FBS or FCS
in our selective cytokine cultures, we removed the influence of unknown growth factors
present in FCS while maintaining the stromal cell contact important for B cell
development (Torlakovic, Tenstad, Funderud, & Rian, 2005).
While in vitro models provide important information about B lymphopoiesis, they
are somewhat limiting, as they do not fully recapitulate the native, interactive multicellular bone marrow microenvironment. Humanized mouse models have been developed
to overcome this limitation, but there are considerations for their use/selection. Firstly,
the selected mouse strain matters, as each strain differs in its ability to engraft human
cells. NOD-SCID IL2RGnull (NSG) mice show increased engraftment of human cells
compared to other strains (Legrand, Weijer, & Spits, 2006; McDermott, Eppert,
Lechman, Doedens, & Dick, 2010). Secondly, the source of stem cells can affect
engraftment. HSCs from CB engraft at higher percentages compared to those from
mobilized PB (Lepus et al., 2009). Thirdly, some cytokines are species specific, e.g.
TSLP, IL-15 and BAFF. To overcome this limitation some have transgenically expressed
human cytokines in mice, for example, IL-15 (Huntington et al., 2009), which has been a
successful strategy. In our humanized model, based on injecting human stromal cells that
express human TSLP at concentrations similar to that observed in non-diseased children
(Lee et al., 2010), we saw functional effects of human TSLP on the differentiation of B
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cell precursors. The utility of this approach is reinforced by studies in mice where
systemic TSLP levels increased B cell production (Astrakhan et al., 2007).
Consistent with previous evaluations of fetal-derived and neonatal-derived HSCs
(S. E. Johnson et al., 2005; Pribyl & LeBien, 1996), we demonstrate that CB HSCs are
capable of IL-7R ligand independent B cell production in vitro. Unlike an earlier study
(Pribyl & LeBien, 1996), we found that in vitro supplementation with IL-7 consistently
augmented the number of B cell progenitors produced from HSC derived from CB.
TSLP, a known expander of B cells during fetal development in humans and mice
(Scheeren et al., 2010; Vosshenrich et al., 2003, 2004) also increased the production of B
cells from CB, but not postnatal sources in our selective cytokine culture model. In
stromal cell free conditions, Ichii et al, also found that TSLP was unable to expand
postnatal B cell production (Ichii et al., 2010).
Understanding the potential role of TSLP in human B cell production is important
because environmental pollutants, for example, diesel particles, can modulate TSLP
expression (Bleck, Tse, Gordon, Ahsan, & Reibman, 2010). Significantly higher TSLP
levels are seen in Th2-mediated inflammatory conditions like asthma (Ying et al., 2008)
and some (Lee et al., 2010) but not all (Nakamura, Tsuchida, Tsunemi, Saeki, & Tamaki,
2008) cases of atopic dermatitis. As an assessment of BM is not required for the
diagnosis of these conditions, it is not known if BM B cell progenitor numbers are
expanded in these patients in response to increased circulating TSLP. Neither have there
been reports of increased numbers of immature B cells in the circulation of patients with
these conditions. Higher TSLP concentrations are also found in the synovial fluid
(Koyama et al., 2007) and serum (Koyama, Ohba, Haro, & Nakao, 2015) of rheumatoid
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arthritis patients compared to healthy controls but did not correlate with disease severity.
Hence, a direct association of TSLP to the initiation or progression of atopic dermatitis
and rheumatoid arthritis requires further studies.
The persistence of normal to increased numbers of B cells with decreased T cells
in the peripheral blood of patients with SCID, due to mutations in either IL-7R or
common gamma chain, has contributed to the conclusion that IL-7 is dispensable for
human B lymphopoiesis (Giliani et al., 2005; Puel, Ziegler, Buckley, & Leonard, 1998).
These studies evaluated patients, who at the time of diagnosis were less than one year
old. In mice, HSCs switch from IL-7R independence to dependence one to two weeks
after birth (Kikuchi & Kondo, 2006), while the characteristics of human HSCs, change
between one to three years of age (Sidorov, Kimura, Yashin, & Aviv, 2009). It is
therefore conceivable that the HSCs evaluated in those SCID patients (Giliani et al.,
2005; Puel et al., 1998) were at a point in development where they did not require IL-7R
signals for B cell development.
TSLP or TSLPR signaling has been implicated in several cancers including
precursor B cell lymphoblastic leukemia (pre-B ALL). In an early study, TSLP increased
the proliferation of and protected primary pre-BALL cells from apoptosis (Brown et al.,
2007). Later studies identified aberrant expression of the TSLP receptor component,
CRLF2, in pre-B-ALL (Mullighan et al., 2009; Russell et al., 2009; Yoda et al., 2010).
Mutations in the tyrosine kinase, JAK2, were found to strongly associate with CRLF2
overexpression (Hertzberg et al., 2010). Not only do CRLF2 and mutant JAK2 interact
(Mullighan et al., 2009) but when expressed in BaF3 cells, together these aberrations
yielded phosphorylation of downstream kinases, in the absence of IL-7R and independent

209

of cytokine stimulation (Yoda et al., 2010), suggesting that the cytokine, TSLP, may not
be an important contributor to the initiation or progression of the disease. We compared
the gene expression profiles of cells from primary patients with those from PDX with or
without TSLP, and found that the gene expression profiles of cells expanded with TSLP
bore a profile more similar to primary patient cells than those expanded without. These
findings are important because they demonstrate that along with independent aberrant
CRLF2/JAK2 signaling, physiological concentrations of TSLP also modulate this
signaling axis. They further underscore the importance of including TSLP in the
development of treatments for pre-B ALL. A recent study demonstrated improved
survival of CRLF2-PDX mice treated with a JAK inhibitor (Wu et al., 2015). As these
PDX may not have been exposed to physiological concentrations of TSLP, an important
future consideration will be, does TSLP change the response of CRLF2-PDX to current
and future JAK inhibitors.
Transplantation of CB or BM-derived HSCs has been used in the treatment of
leukemia for many years. While both sources have proven beneficial, they also have
limitations. As compared to BM, transplantation with CB HSCs, results in a lower
incidence of graft-versus-host-disease (GvHD) (Broxmeyer, 2008); faster reconstitution
of B lymphocytes (Nakatani et al., 2014), although the frequency of memory B cells is
delayed (Charrier et al., 2013); and slower reconstitution of neutrophils and platelets
(Broxmeyer, 2008). While CB is more accessible, HSCs are present at a lower frequency
(Broxmeyer, 2008) and cell dose is an important factor in immune reconstitution after
transplantation (Rocha, Gluckman, Eurocord-Netcord, European, & Marrow Transplant,
2009). To address this limitation, some physicians have utilized the approach of
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transplanting more than one CB unit from different donors (Scaradavou et al., 2013). By
evaluating patient mortality and hematopoietic recovery i.e neutrophils and platelets, this
strategy proved to be just as successful as transplanting a single CB unit (Scaradavou et
al., 2013). Ex vivo expansion of IL-7R+ progenitors and co-transplantation with stem
cells may be an important future step, as a means of boosting lymphoid recovery after
BM transplantation.
Human and mouse studies reveal that with increasing age, B cell development is
impaired (Arakawa-Hoyt et al., 1999). Both cell intrinsic and micro-environmental
factors contribute to this decline. Micro-environmental changes in older mice include
decreased IL-7 secretion by BM stromal cells (Stephan, Reilly, & Witte, 1998; Tsuboi et
al., 2004) and decreased pro-B cell response to IL-7 (Stephan, Lill-Elghanian, & Witte,
1997); declining pre-B cell numbers in the bone marrow (Kline, Hayden, & Klinman,
1999) and increased inflammation (Riley, 2013).

Subsequent studies suggest that pre-B

cell numbers remain constant with age, but in older mice, pools of transitional and mature
B cells are not efficiently generated (K. M. Johnson, Owen, & Witte, 2002). Studies of
normal, BM B cell precursor subsets in elderly patients have been more limited. Our in
vivo model with selective TSLP or IL-7 may be an important tool to evaluate the
response of aging, human adult HSCs to the changing cytokine microenvironment in the
bone marrow.

211

References
Arakawa-Hoyt, J., Dao, M. A., Thiemann, F., Hao, Q. L., Ertl, D. C., Weinberg, K. I., . . .
Nolta, J. A. (1999). The number and generative capacity of human B lymphocyte
progenitors, measured in vitro and in vivo, is higher in umbilical cord blood than
in adult or pediatric bone marrow. Bone Marrow Transplant, 24(11), 1167-1176.
Astrakhan, A., Omori, M., Nguyen, T., Becker-Herman, S., Iseki, M., Aye, T., . . .
Rawlings, D. J. (2007). Local increase in thymic stromal lymphopoietin induces
systemic alterations in B cell development. Nat Immunol, 8(5), 522-531. doi:
ni1452 [pii]10.1038/ni1452
Barker, J., & Verfaillie, C. M. (2000). A novel in vitro model of early human adult B
lymphopoiesis that allows proliferation of pro-B cells and differentiation to
mature B lymphocytes. Leukemia, 14(9), 1614-1620.
Bleck, B., Tse, D. B., Gordon, T., Ahsan, M. R., & Reibman, J. (2010). Diesel exhaust
particle-treated human bronchial epithelial cells upregulate Jagged-1 and OX40
ligand in myeloid dendritic cells via thymic stromal lymphopoietin. J Immunol,
185(11), 6636-6645. doi: jimmunol.1000719 [pii]10.4049/jimmunol.1000719
Briquet, A., Dubois, S., Bekaert, S., Dolhet, M., Beguin, Y., & Gothot, A. (2010).
Prolonged ex vivo culture of human bone marrow mesenchymal stem cells
influences their supportive activity toward NOD/SCID-repopulating cells and
committed progenitor cells of B lymphoid and myeloid lineages. Haematologica,
95(1), 47-56. doi: 10.3324/haematol.2009.008524
Brown, V. I., Hulitt, J., Fish, J., Sheen, C., Bruno, M., Xu, Q., . . . Grupp, S. A. (2007).
Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia
and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha
signaling. Cancer Res, 67(20), 9963-9970. doi: 67/20/9963 [pii]10.1158/00085472.CAN-06-4704
Broxmeyer, H. E. (2008). Cord blood hematopoietic stem cell transplantation StemBook.
Cambridge (MA).
Carvalho, T. L., Mota-Santos, T., Cumano, A., Demengeot, J., & Vieira, P. (2001).
Arrested B lymphopoiesis and persistence of activated B cells in adult interleukin
7(-/)- mice. J Exp Med, 194(8), 1141-1150.
Charrier, E., Cordeiro, P., Brito, R. M., Mezziani, S., Herblot, S., Le Deist, F., & Duval,
M. (2013). Reconstitution of maturating and regulatory lymphocyte subsets after
cord blood and BMT in children. Bone Marrow Transplant, 48(3), 376-382. doi:
10.1038/bmt.2012.176
Fluckiger, A. C., Sanz, E., Garcia-Lloret, M., Su, T., Hao, Q. L., Kato, R., . . . Rawlings,
D. J. (1998). In vitro reconstitution of human B-cell ontogeny: from CD34(+)
multipotent progenitors to Ig-secreting cells. Blood, 92(12), 4509-4520.
212

Giliani, S., Mori, L., de Saint Basile, G., Le Deist, F., Rodriguez-Perez, C., Forino,
C., . . . Notarangelo, L. D. (2005). Interleukin-7 receptor alpha (IL-7Ralpha)
deficiency: cellular and molecular bases. Analysis of clinical, immunological, and
molecular features in 16 novel patients. Immunol Rev, 203, 110-126.
Hertzberg, L., Vendramini, E., Ganmore, I., Cazzaniga, G., Schmitz, M., Chalker, J., . . .
Izraeli, S. (2010). Down syndrome acute lymphoblastic leukemia, a highly
heterogeneous disease in which aberrant expression of CRLF2 is associated with
mutated JAK2: a report from the International BFM Study Group. Blood, 115(5),
1006-1017. doi: blood-2009-08-235408 [pii]10.1182/blood-2009-08-235408
Huntington, N. D., Legrand, N., Alves, N. L., Jaron, B., Weijer, K., Plet, A., . . . Di
Santo, J. P. (2009). IL-15 trans-presentation promotes human NK cell
development and differentiation in vivo. J Exp Med, 206(1), 25-34. doi:
10.1084/jem.20082013
Ichii, M., Oritani, K., Yokota, T., Nishida, M., Takahashi, I., Shirogane, T., . . .
Kanakura, Y. (2008). Regulation of human B lymphopoiesis by the transforming
growth factor-beta superfamily in a newly established coculture system using
human mesenchymal stem cells as a supportive microenvironment. Exp Hematol,
36(5), 587-597. doi: 10.1016/j.exphem.2007.12.013
Ichii, M., Oritani, K., Yokota, T., Schultz, D. C., Holter, J. L., Kanakura, Y., & Kincade,
P. W. (2010). Stromal cell-free conditions favorable for human B lymphopoiesis
in culture. J Immunol Methods, 359(1-2), 47-55. doi: S0022-1759(10)00167-5
[pii]10.1016/j.jim.2010.06.002
Jensen, C. T., Kharazi, S., Boiers, C., Cheng, M., Lubking, A., Sitnicka, E., & Jacobsen,
S. E. (2008). FLT3 ligand and not TSLP is the key regulator of IL-7-independent
B-1 and B-2 B lymphopoiesis. Blood, 112(6), 2297-2304. doi: blood-2008-04150508 [pii]10.1182/blood-2008-04-150508
Johnson, K. M., Owen, K., & Witte, P. L. (2002). Aging and developmental transitions in
the B cell lineage. Int Immunol, 14(11), 1313-1323.
Johnson, S. E., Shah, N., Panoskaltsis-Mortari, A., & LeBien, T. W. (2005). Murine and
human IL-7 activate STAT5 and induce proliferation of normal human pro-B
cells. J Immunol, 175(11), 7325-7331.
Kikuchi, K., & Kondo, M. (2006). Developmental switch of mouse hematopoietic stem
cells from fetal to adult type occurs in bone marrow after birth. Proc Natl Acad
Sci U S A, 103(47), 17852-17857. doi: 10.1073/pnas.0603368103
Kikuchi, K., Lai, A. Y., Hsu, C. L., & Kondo, M. (2005). IL-7 receptor signaling is
necessary for stage transition in adult B cell development through up-regulation
of EBF. J Exp Med, 201(8), 1197-1203. doi: jem.20050158
[pii]10.1084/jem.20050158

213

Kline, G. H., Hayden, T. A., & Klinman, N. R. (1999). B cell maintenance in aged mice
reflects both increased B cell longevity and decreased B cell generation. J
Immunol, 162(6), 3342-3349.
Koyama, K., Ohba, T., Haro, H., & Nakao, A. (2015). Positive association between
serum thymic stromal lymphopoietin and anti-citrullinated peptide antibodies in
patients with rheumatoid arthritis. Clin Exp Immunol, 181(2), 239-243. doi:
10.1111/cei.12632
Koyama, K., Ozawa, T., Hatsushika, K., Ando, T., Takano, S., Wako, M., . . . Nakao, A.
(2007). A possible role for TSLP in inflammatory arthritis. Biochem Biophys Res
Commun, 357(1), 99-104. doi: 10.1016/j.bbrc.2007.03.081
Kraus, H., Kaiser, S., Aumann, K., Bonelt, P., Salzer, U., Vestweber, D., . . . Rizzi, M.
(2014). A feeder-free differentiation system identifies autonomously proliferating
B cell precursors in human bone marrow. J Immunol, 192(3), 1044-1054. doi:
10.4049/jimmunol.1301815
Lee, E. B., Kim, K. W., Hong, J. Y., Jee, H. M., Sohn, M. H., & Kim, K. E. (2010).
Increased serum thymic stromal lymphopoietin in children with atopic dermatitis.
Pediatr Allergy Immunol, 21(2 Pt 2), e457-460. doi: PAI919 [pii]10.1111/j.13993038.2009.00919.x
Legrand, N., Weijer, K., & Spits, H. (2006). Experimental models to study development
and function of the human immune system in vivo. J Immunol, 176(4), 20532058.
Lepus, C. M., Gibson, T. F., Gerber, S. A., Kawikova, I., Szczepanik, M., Hossain, J., . . .
Harding, M. J. (2009). Comparison of human fetal liver, umbilical cord blood,
and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-,
Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum
Immunol, 70(10), 790-802. doi: 10.1016/j.humimm.2009.06.005
Malaspina, A., Moir, S., Chaitt, D. G., Rehm, C. A., Kottilil, S., Falloon, J., & Fauci, A.
S. (2006). Idiopathic CD4+ T lymphocytopenia is associated with increases in
immature/transitional B cells and serum levels of IL-7. Blood.
Malaspina, A., Moir, S., Ho, J., Wang, W., Howell, M. L., O'Shea, M. A., . . . Fauci, A.
S. (2006). Appearance of immature/transitional B cells in HIV-infected
individuals with advanced disease: correlation with increased IL-7. Proc Natl
Acad Sci U S A, 103(7), 2262-2267.
McDermott, S. P., Eppert, K., Lechman, E. R., Doedens, M., & Dick, J. E. (2010).
Comparison of human cord blood engraftment between immunocompromised
mouse strains. Blood, 116(2), 193-200. doi: 10.1182/blood-2010-02-271841
Mullighan, C. G., Collins-Underwood, J. R., Phillips, L. A., Loudin, M. G., Liu, W.,
Zhang, J., . . . Rabin, K. R. (2009). Rearrangement of CRLF2 in B-progenitor214

and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet, 41(11),
1243-1246. doi: ng.469 [pii]10.1038/ng.469
Nakamura, K., Tsuchida, T., Tsunemi, Y., Saeki, H., & Tamaki, K. (2008). Serum thymic
stromal lymphopoietin levels are not elevated in patients with atopic dermatitis. J
Dermatol, 35(8), 546-547. doi: JDE518 [pii]10.1111/j.1346-8138.2008.00518.x
Nakatani, K., Imai, K., Shigeno, M., Sato, H., Tezuka, M., Okawa, T., . . . Morio, T.
(2014). Cord blood transplantation is associated with rapid B-cell neogenesis
compared with BM transplantation. Bone Marrow Transplant, 49(9), 1155-1161.
doi: 10.1038/bmt.2014.123
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E.,
Gliniak, B. C., . . . et al. (1994). Early lymphocyte expansion is severely impaired
in interleukin 7 receptor-deficient mice. J Exp Med, 180(5), 1955-1960.
Pribyl, J. A., & LeBien, T. W. (1996). Interleukin 7 independent development of human
B cells. Proc Natl Acad Sci U S A, 93(19), 10348-10353.
Puel, A., Ziegler, S. F., Buckley, R. H., & Leonard, W. J. (1998). Defective IL7R
expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet,
20(4), 394-397.
Rawlings, D. J., Quan, S. G., Kato, R. M., & Witte, O. N. (1995). Long-term culture
system for selective growth of human B-cell progenitors. Proc Natl Acad Sci U S
A, 92(5), 1570-1574.
Riley, R. L. (2013). Impaired B lymphopoiesis in old age: a role for inflammatory B
cells? Immunol Res, 57(1-3), 361-369. doi: 10.1007/s12026-013-8444-5
Rocha, V., Gluckman, E., Eurocord-Netcord, r., European, B., & Marrow Transplant, g.
(2009). Improving outcomes of cord blood transplantation: HLA matching, cell
dose and other graft- and transplantation-related factors. Br J Haematol, 147(2),
262-274. doi: 10.1111/j.1365-2141.2009.07883.x
Russell, L. J., Capasso, M., Vater, I., Akasaka, T., Bernard, O. A., Calasanz, M. J., . . .
Harrison, C. J. (2009). Deregulated expression of cytokine receptor gene, CRLF2,
is involved in lymphoid transformation in B-cell precursor acute lymphoblastic
leukemia. Blood, 114(13), 2688-2698. doi: blood-2009-03-208397
[pii]10.1182/blood-2009-03-208397
Scaradavou, A., Brunstein, C. G., Eapen, M., Le-Rademacher, J., Barker, J. N., Chao,
N., . . . Shpall, E. J. (2013). Double unit grafts successfully extend the application
of umbilical cord blood transplantation in adults with acute leukemia. Blood,
121(5), 752-758. doi: 10.1182/blood-2012-08-449108

215

Scheeren, F. A., van Lent, A. U., Nagasawa, M., Weijer, K., Spits, H., Legrand, N., &
Blom, B. (2010). Thymic stromal lymphopoietin induces early human B-cell
proliferation and differentiation. Eur J Immunol. doi: 10.1002/eji.200939419
Sidorov, I., Kimura, M., Yashin, A., & Aviv, A. (2009). Leukocyte telomere dynamics
and human hematopoietic stem cell kinetics during somatic growth. Exp Hematol,
37(4), 514-524. doi: 10.1016/j.exphem.2008.11.009
Stephan, R. P., Lill-Elghanian, D. A., & Witte, P. L. (1997). Development of B cells in
aged mice: decline in the ability of pro-B cells to respond to IL-7 but not to other
growth factors. J Immunol, 158(4), 1598-1609.
Stephan, R. P., Reilly, C. R., & Witte, P. L. (1998). Impaired ability of bone marrow
stromal cells to support B-lymphopoiesis with age. Blood, 91(1), 75-88.
Thomas, X. (2015). Understanding leukemic hematopoiesis as a complex adaptive
system. World J Stem Cells, 7(9), 1145-1149. doi: 10.4252/wjsc.v7.i9.1145
Torlakovic, E., Tenstad, E., Funderud, S., & Rian, E. (2005). CD10+ stromal cells form
B-lymphocyte maturation niches in the human bone marrow. J Pathol, 205(3),
311-317.
Tsuboi, I., Morimoto, K., Hirabayashi, Y., Li, G. X., Aizawa, S., Mori, K. J., . . . Inoue,
T. (2004). Senescent B lymphopoiesis is balanced in suppressive homeostasis:
decrease in interleukin-7 and transforming growth factor-beta levels in stromal
cells of senescence-accelerated mice. Exp Biol Med (Maywood), 229(6), 494-502.
von Freeden-Jeffry, U., Vieira, P., Lucian, L. A., McNeil, T., Burdach, S. E., & Murray,
R. (1995). Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as
a nonredundant cytokine. J Exp Med, 181(4), 1519-1526.
Vosshenrich, C. A., Cumano, A., Muller, W., Di Santo, J. P., & Vieira, P. (2003). Thymic
stromal-derived lymphopoietin distinguishes fetal from adult B cell development.
Nat Immunol, 4(8), 773-779.
Vosshenrich, C. A., Cumano, A., Muller, W., Di Santo, J. P., & Vieira, P. (2004). Pre-B
cell receptor expression is necessary for thymic stromal lymphopoietin
responsiveness in the bone marrow but not in the liver environment. Proc Natl
Acad Sci U S A, 101(30), 11070-11075.
Wolf, M. L., Weng, W. K., Stieglbauer, K. T., Shah, N., & LeBien, T. W. (1993).
Functional effect of IL-7-enhanced CD19 expression on human B cell precursors.
J Immunol, 151(1), 138-148.
Wu, S. C., Li, L. S., Kopp, N., Montero, J., Chapuy, B., Yoda, A., . . . Weinstock, D. M.
(2015). Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute
Lymphoblastic Leukemia. Cancer Cell, 28(1), 29-41. doi:
10.1016/j.ccell.2015.06.005

216

Ying, S., O'Connor, B., Ratoff, J., Meng, Q., Fang, C., Cousins, D., . . . Corrigan, C. J.
(2008). Expression and cellular provenance of thymic stromal lymphopoietin and
chemokines in patients with severe asthma and chronic obstructive pulmonary
disease. J Immunol, 181(4), 2790-2798.
Yoda, A., Yoda, Y., Chiaretti, S., Bar-Natan, M., Mani, K., Rodig, S. J., . . . Weinstock,
D. M. (2010). Functional screening identifies CRLF2 in precursor B-cell acute
lymphoblastic leukemia. Proc Natl Acad Sci U S A, 107(1), 252-257. doi:
0911726107 [pii]10.1073/pnas.0911726107

217

